| 1 |
Carboplatin FDA Label
|
| 2 |
Cisplatin FDA Label
|
| 3 |
A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
|
| 4 |
Doxorubicin FDA Label
|
| 5 |
Paclitaxel FDA Label
|
| 6 |
Topotecan FDA Label
|
| 7 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 8 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 9 |
Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma.Biomed Res Int. 2013;2013:143202. doi: 10.1155/2013/143202. Epub 2013 Aug 19.
|
| 10 |
Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer.Oncol Rep. 2012 Apr;27(4):1156-62. doi: 10.3892/or.2012.1638. Epub 2012 Jan 16.
|
| 11 |
Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.Mol Carcinog. 2011 May;50(5):397-402. doi: 10.1002/mc.20714. Epub 2010 Dec 28.
|
| 12 |
Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival.Cancer Chemother Pharmacol. 2011 Nov;68(5):1273-83. doi: 10.1007/s00280-011-1595-y. Epub 2011 Mar 29.
|
| 13 |
Inhibition of the inflammatory cytokine TNF- increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.Mol Ther. 2011 Mar;19(3):490-9. doi: 10.1038/mt.2010.247. Epub 2010 Nov 16.
|
| 14 |
Identification of ovarian cancer associated genes using an integrated approach in a Boolean framework.BMC Syst Biol. 2013 Feb 6;7:12. doi: 10.1186/1752-0509-7-12.
|
| 15 |
Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell migration associated with upregulating integrin 51 and phosphorylating FAK and paxillin.J Exp Clin Cancer Res. 2012 Mar 9;31(1):19. doi: 10.1186/1756-9966-31-19.
|
| 16 |
Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer.J Cell Mol Med. 2012 Oct;16(10):2422-8. doi: 10.1111/j.1582-4934.2012.01559.x.
|
| 17 |
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011. Epub 2013 Oct 28.
|
| 18 |
Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma.Gynecol Oncol. 2014 Jun;133(3):575-83. doi: 10.1016/j.ygyno.2014.02.034. Epub 2014 Feb 28.
|
| 19 |
High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.Gynecol Oncol. 2010 Sep;118(3):244-50. doi: 10.1016/j.ygyno.2010.05.024. Epub 2010 Jun 17.
|
| 20 |
Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma.Diagn Pathol. 2013 Nov 19;8:190. doi: 10.1186/1746-1596-8-190.
|
| 21 |
Treatment of recurrent ovarian cancer.Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441.
|
| 22 |
AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells.Exp Cell Res. 2013 Oct 15;319(17):2627-36. doi: 10.1016/j.yexcr.2013.07.030. Epub 2013 Aug 13.
|
| 23 |
Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.Gynecol Oncol. 2012 Feb;124(2):325-34. doi: 10.1016/j.ygyno.2011.10.013. Epub 2011 Oct 15.
|
| 24 |
Increased expression of cysteine cathepsins in ovarian tissue from chickens with ovarian cancer.Reprod Biol Endocrinol. 2010 Aug 21;8:100. doi: 10.1186/1477-7827-8-100.
|
| 25 |
Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.J Pharm Sci. 2011 Oct;100(10):4205-9. doi: 10.1002/jps.22680. Epub 2011 Jun 23.
|
| 26 |
Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma.Carcinogenesis. 2012 Dec;33(12):2334-43. doi: 10.1093/carcin/bgs278. Epub 2012 Sep 10.
|
| 27 |
The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.Int J Oncol. 2012 Apr;40(4):1203-9. doi: 10.3892/ijo.2011.1293. Epub 2011 Dec 12.
|
| 28 |
Epiregulin as a marker for the initial steps of ovarian cancer development.Int J Oncol. 2011 Nov;39(5):1165-72. doi: 10.3892/ijo.2011.1123. Epub 2011 Jul 14.
|
| 29 |
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.Clin Exp Metastasis. 2004;21(3):191-9. doi: 10.1023/b:clin.0000037703.37275.35.
|
| 30 |
FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.J Clin Invest. 2013 Oct;123(10):4435-48. doi: 10.1172/JCI70625. Epub 2013 Sep 9.
|
| 31 |
FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome.Int J Oncol. 2013 Mar;42(3):912-20. doi: 10.3892/ijo.2013.1797. Epub 2013 Jan 23.
|
| 32 |
Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Cell Physiol Biochem. 2016;39(1):242-52.
|
| 33 |
No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk.Breast Cancer Res Treat. 2010 Jun;121(2):497-502. doi: 10.1007/s10549-009-0589-5. Epub 2009 Oct 27.
|
| 34 |
CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.Biosci Rep. 2017 Apr 10;37(2):BSR20160470. doi: 10.1042/BSR20160470. Print 2017 Apr 28.
|
| 35 |
GRP94/gp96 in Cancer: Biology, Structure, Immunology, and Drug Development.Adv Cancer Res. 2016;129:165-90. doi: 10.1016/bs.acr.2015.09.001. Epub 2015 Sep 28.
|
| 36 |
Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma.Clin Cancer Res. 2018 Nov 15;24(22):5685-5696. doi: 10.1158/1078-0432.CCR-18-0554. Epub 2018 Jul 31.
|
| 37 |
Interleukin 16 expression changes in association with ovarian malignant transformation.Am J Obstet Gynecol. 2014 Mar;210(3):272.e1-10. doi: 10.1016/j.ajog.2013.12.041. Epub 2013 Dec 28.
|
| 38 |
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.Hum Mol Genet. 2013 Aug 1;22(15):3038-47. doi: 10.1093/hmg/ddt160. Epub 2013 Apr 9.
|
| 39 |
Study of kallikrein-related peptidase 6 (KLK6) and its complex with 1-antitrypsin in biological fluids.Clin Chem Lab Med. 2017 Aug 28;55(9):1385-1396. doi: 10.1515/cclm-2017-0017.
|
| 40 |
A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer.Cancer Genet. 2012 Jul-Aug;205(7-8):373-6. doi: 10.1016/j.cancergen.2012.04.010.
|
| 41 |
Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery.Mol Cell Proteomics. 2013 Feb;12(2):356-68. doi: 10.1074/mcp.M112.019521. Epub 2012 Nov 19.
|
| 42 |
The relationship of haplotype in lactotransferrin and its expression levels in Chinese Han ovarian cancer.Acta Biochim Biophys Sin (Shanghai). 2011 Nov;43(11):884-90. doi: 10.1093/abbs/gmr089. Epub 2011 Sep 20.
|
| 43 |
The MAD1 1673 G ?A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer.Pharmacogenet Genomics. 2013 Apr;23(4):190-9. doi: 10.1097/FPC.0b013e32835ea08a.
|
| 44 |
Multiple steps of HLA-G in ovarian carcinoma metastasis: alter NK cytotoxicity and induce matrix metalloproteinase-15 (MMP-15) expression.Hum Immunol. 2013 Apr;74(4):439-46. doi: 10.1016/j.humimm.2012.11.021. Epub 2012 Dec 8.
|
| 45 |
Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma.PLoS One. 2013 Nov 13;8(11):e78783. doi: 10.1371/journal.pone.0078783. eCollection 2013.
|
| 46 |
Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.Clin Cancer Res. 2013 Jul 1;19(13):3577-90. doi: 10.1158/1078-0432.CCR-12-3212. Epub 2013 Apr 30.
|
| 47 |
TRIM52 plays an oncogenic role in ovarian cancer associated with NF-kB pathway.Cell Death Dis. 2018 Sep 5;9(9):908. doi: 10.1038/s41419-018-0881-6.
|
| 48 |
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.PLoS One. 2011 Mar 15;6(3):e17617. doi: 10.1371/journal.pone.0017617.
|
| 49 |
Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion.Int J Cancer. 2010 Jul 1;127(1):21-31. doi: 10.1002/ijc.25005.
|
| 50 |
p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18622-7. doi: 10.1073/pnas.0907481107. Epub 2010 Oct 6.
|
| 51 |
Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2018 Feb;28(2):323-331.
|
| 52 |
Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer.J Histochem Cytochem. 2013 Mar;61(3):206-17. doi: 10.1369/0022155413475452. Epub 2013 Jan 4.
|
| 53 |
Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.Cell Physiol Biochem. 2018;46(4):1716-1726. doi: 10.1159/000489586. Epub 2018 Apr 28.
|
| 54 |
Association between LMP2/LMP7 genetic variability and the metastasis risk of ovarian cancer in Chinese women in Beijing.Hum Immunol. 2014 Mar;75(3):239-44. doi: 10.1016/j.humimm.2013.12.006. Epub 2013 Dec 27.
|
| 55 |
Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells.Int J Oncol. 2013 Oct;43(4):1011-8. doi: 10.3892/ijo.2013.2021. Epub 2013 Jul 18.
|
| 56 |
PRL-3 suppresses c-Fos and integrin 2 expression in ovarian cancer cells.BMC Cancer. 2013 Feb 18;13:80. doi: 10.1186/1471-2407-13-80.
|
| 57 |
Silencing the receptor of activated C-kinase 1 (RACK1) suppresses tumorigenicity in epithelial ovarian cancer in vitro and in vivo.Int J Oncol. 2014 Apr;44(4):1252-8. doi: 10.3892/ijo.2014.2274. Epub 2014 Jan 23.
|
| 58 |
Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.Pathol Oncol Res. 2012 Apr;18(2):135-48. doi: 10.1007/s12253-011-9482-8. Epub 2011 Dec 9.
|
| 59 |
Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.Carcinogenesis. 2011 Oct;32(10):1540-9. doi: 10.1093/carcin/bgr140. Epub 2011 Aug 22.
|
| 60 |
Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer.Int J Oncol. 2012 Jun;40(6):1865-80. doi: 10.3892/ijo.2012.1371. Epub 2012 Feb 14.
|
| 61 |
ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).Anticancer Res. 2019 Mar;39(3):1267-1273. doi: 10.21873/anticanres.13237.
|
| 62 |
SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer.PLoS One. 2012;7(11):e49869. doi: 10.1371/journal.pone.0049869. Epub 2012 Nov 21.
|
| 63 |
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.Gynecol Oncol. 2011 Nov;123(2):314-9. doi: 10.1016/j.ygyno.2011.08.003. Epub 2011 Sep 8.
|
| 64 |
Relevance of the OCT1 transporter to the antineoplastic effect of biguanides.Biochem Biophys Res Commun. 2011 Nov 4;414(4):694-9. doi: 10.1016/j.bbrc.2011.09.134. Epub 2011 Oct 2.
|
| 65 |
Annexin A2 inhibition suppresses ovarian cancer progression via regulating -catenin/EMT. Oncol Rep. 2017 Jun;37(6):3643-3650.
|
| 66 |
Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT.Anticancer Res. 2011 Mar;31(3):897-906.
|
| 67 |
Sterol regulatory element-binding protein 1 is required for ovarian tumor growth.Oncol Rep. 2013 Sep;30(3):1346-54. doi: 10.3892/or.2013.2575. Epub 2013 Jun 28.
|
| 68 |
Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.Thromb Res. 2013 Nov;132(5):627-34. doi: 10.1016/j.thromres.2013.09.016. Epub 2013 Sep 21.
|
| 69 |
Tripartite Motif-Containing Protein 59 (TRIM59) Promotes Epithelial Ovarian Cancer Progression via the Focal Adhesion Kinase(FAK)/AKT/Matrix Metall... Med Sci Monit. 2019 May 7;25:3366-3373.
|
| 70 |
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.Hum Genet. 2014 May;133(5):481-97. doi: 10.1007/s00439-013-1383-3. Epub 2013 Nov 5.
|
| 71 |
Tumor suppressive effects of bromodomain-containing protein 7 (BRD7) in epithelial ovarian carcinoma.Clin Cancer Res. 2014 Feb 1;20(3):565-75. doi: 10.1158/1078-0432.CCR-13-1271. Epub 2013 Nov 6.
|
| 72 |
Citrate synthase expression affects tumor phenotype and drug resistance in human ovarian carcinoma.PLoS One. 2014 Dec 29;9(12):e115708. doi: 10.1371/journal.pone.0115708. eCollection 2014.
|
| 73 |
FoxM1 and -catenin predicts aggressiveness in Middle Eastern ovarian cancer and their co-targeting impairs the growth of ovarian cancer cells.Oncotarget. 2017 Dec 16;9(3):3590-3604. doi: 10.18632/oncotarget.23338. eCollection 2018 Jan 9.
|
| 74 |
Expression levels of MRP1, GST-, and GSK3 in ovarian cancer and the relationship with drug resistance and prognosis of patients.Oncol Lett. 2019 Jul;18(1):22-28. doi: 10.3892/ol.2019.10315. Epub 2019 May 6.
|
| 75 |
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.Elife. 2019 Sep 3;8:e47327. doi: 10.7554/eLife.47327.
|
| 76 |
FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway.Cell Death Dis. 2014 Jul 17;5(7):e1346. doi: 10.1038/cddis.2014.302.
|
| 77 |
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.J Ovarian Res. 2019 Nov 17;12(1):112. doi: 10.1186/s13048-019-0590-5.
|
| 78 |
Vascular marker expression during the development of various types of gynaecological malignancy.Tumour Biol. 2014 Nov;35(11):11229-35. doi: 10.1007/s13277-014-2447-2. Epub 2014 Aug 12.
|
| 79 |
Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.Clin Cancer Res. 2004 Jul 15;10(14):4761-8. doi: 10.1158/1078-0432.CCR-0204-03.
|
| 80 |
The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells.Mol Cancer Res. 2007 Dec;5(12):1246-53. doi: 10.1158/1541-7786.MCR-07-0060.
|
| 81 |
Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.Clin Cancer Res. 2009 Apr 1;15(7):2417-25. doi: 10.1158/1078-0432.CCR-08-1276. Epub 2009 Mar 24.
|
| 82 |
Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?.Anticancer Agents Med Chem. 2008 Feb;8(2):232-9. doi: 10.2174/187152008783497000.
|
| 83 |
Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma.J Cancer Res Clin Oncol. 2009 Jul;135(7):951-9. doi: 10.1007/s00432-008-0531-y. Epub 2009 Jan 13.
|
| 84 |
Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer.Acta Obstet Gynecol Scand. 2008;87(10):1060-70. doi: 10.1080/00016340802348286.
|
| 85 |
NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.Clin Cancer Res. 2007 Mar 1;13(5):1584-90. doi: 10.1158/1078-0432.CCR-06-1416.
|
| 86 |
Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.Biochem Pharmacol. 2004 Aug 15;68(4):601-9. doi: 10.1016/j.bcp.2004.05.007.
|
| 87 |
Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines.Int J Oncol. 2012 Sep;41(3):919-32. doi: 10.3892/ijo.2012.1522. Epub 2012 Jun 19.
|
| 88 |
Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression.J Biol Chem. 2008 Nov 7;283(45):31012-20. doi: 10.1074/jbc.M803547200. Epub 2008 Sep 7.
|
| 89 |
Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth.Cancer Res. 2005 Feb 1;65(3):925-32.
|
| 90 |
DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma.Clin Cancer Res. 2007 Oct 15;13(20):6153-61. doi: 10.1158/1078-0432.CCR-07-0671.
|
| 91 |
HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer.Int J Cancer. 2008 Aug 1;123(3):725-9. doi: 10.1002/ijc.23563.
|
| 92 |
HOXB13 promotes ovarian cancer progression.Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17093-8. doi: 10.1073/pnas.0707938104. Epub 2007 Oct 17.
|
| 93 |
Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.Int J Oncol. 2009 Feb;34(2):345-53.
|
| 94 |
Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma.Cancer Sci. 2007 Jun;98(6):844-9. doi: 10.1111/j.1349-7006.2007.00461.x. Epub 2007 Apr 5.
|
| 95 |
SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women.Fam Cancer. 2009;8(2):135-44. doi: 10.1007/s10689-008-9218-4. Epub 2008 Sep 27.
|
| 96 |
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.Nucleic Acids Res. 2006 Jan 23;34(2):555-63. doi: 10.1093/nar/gkj468. Print 2006.
|
| 97 |
Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.Cancer. 2006 Sep 15;107(6):1407-18. doi: 10.1002/cncr.22134.
|
| 98 |
Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer.Eur J Cancer. 2007 Jun;43(9):1452-9. doi: 10.1016/j.ejca.2007.03.004. Epub 2007 Apr 17.
|
| 99 |
Mannan-binding lectin (MBL) in women with tumours of the reproductive system.Cancer Immunol Immunother. 2007 Jul;56(7):959-71. doi: 10.1007/s00262-006-0250-7. Epub 2006 Nov 28.
|
| 100 |
VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion.Gynecol Oncol. 2009 Dec;115(3):414-23. doi: 10.1016/j.ygyno.2009.08.019. Epub 2009 Sep 18.
|
| 101 |
Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery.J Transl Med. 2008 Jul 24;6:41. doi: 10.1186/1479-5876-6-41.
|
| 102 |
Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1.J Clin Endocrinol Metab. 2008 May;93(5):1592-9. doi: 10.1210/jc.2007-2771. Epub 2008 Mar 4.
|
| 103 |
RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.Oncogene. 2007 Feb 1;26(5):683-700. doi: 10.1038/sj.onc.1209827. Epub 2006 Jul 31.
|
| 104 |
Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.PLoS One. 2009 Oct 30;4(10):e7670. doi: 10.1371/journal.pone.0007670.
|
| 105 |
Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer.Int J Gynecol Pathol. 2007 Jul;26(3):334-40. doi: 10.1097/01.pgp.0000236951.33914.1b.
|
| 106 |
Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.Gynecol Oncol. 2005 Jul;98(1):11-8. doi: 10.1016/j.ygyno.2005.03.043.
|
| 107 |
Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2557-65. doi: 10.1158/1055-9965.EPI-07-0542.
|
| 108 |
STEAP, a prostate tumor antigen, is a target of human CD8+ T cells.Cancer Immunol Immunother. 2006 Dec;55(12):1515-23. doi: 10.1007/s00262-006-0165-3. Epub 2006 Apr 19.
|
| 109 |
Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
|
| 110 |
BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):913-20. doi: 10.1158/1055-9965.EPI-07-0692.
|
| 111 |
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI.Mol Ther Oncolytics. 2018 Dec 8;12:9-15. doi: 10.1016/j.omto.2018.12.002. eCollection 2019 Mar 29.
|
| 112 |
ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.Cancer Lett. 2018 Jul 28;427:9-17. doi: 10.1016/j.canlet.2018.04.013. Epub 2018 Apr 13.
|
| 113 |
Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor in ovarian cancer.Mol Oncol. 2018 Oct;12(10):1689-1705. doi: 10.1002/1878-0261.12362. Epub 2018 Aug 23.
|
| 114 |
ACR Appropriateness Criteria() StagingandFollow-Up of Ovarian Cancer.J Am Coll Radiol. 2018 May;15(5S):S198-S207. doi: 10.1016/j.jacr.2018.03.015.
|
| 115 |
Breast and ovarian cancer referrals to the ACT Genetic Service: are we meeting guidelines?.Intern Med J. 2017 Mar;47(3):311-317. doi: 10.1111/imj.13357.
|
| 116 |
Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation.Sci Rep. 2019 Feb 21;9(1):2527. doi: 10.1038/s41598-019-38766-6.
|
| 117 |
ADAM17 inhibition enhances platinum efficiency in ovarian cancer.Oncotarget. 2018 Mar 23;9(22):16043-16058. doi: 10.18632/oncotarget.24682. eCollection 2018 Mar 23.
|
| 118 |
Adrenomedullin promotes angiogenesis in epithelial ovarian cancer through upregulating hypoxia-inducible factor-1 and vascular endothelial growth factor.Sci Rep. 2017 Jan 16;7:40524. doi: 10.1038/srep40524.
|
| 119 |
Overexpression of receptor for advanced glycation end products (RAGE) in ovarian cancer.Cancer Biomark. 2017;18(1):61-68. doi: 10.3233/CBM-160674.
|
| 120 |
Downregulation of AGR2, p21, and cyclin D and alterations in p53 function were associated with tumor progression and chemotherapy resistance in epithelial ovarian carcinoma.Cancer Med. 2018 Jul;7(7):3188-3199. doi: 10.1002/cam4.1530. Epub 2018 May 29.
|
| 121 |
Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress.J Exp Clin Cancer Res. 2019 Mar 7;38(1):116. doi: 10.1186/s13046-019-1127-x.
|
| 122 |
Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.J Cell Biochem. 2019 Mar;120(3):3091-3100. doi: 10.1002/jcb.27497. Epub 2018 Nov 28.
|
| 123 |
Identification of novel epithelial ovarian cancer loci in women of African ancestry.Int J Cancer. 2020 Jun 1;146(11):2987-2998. doi: 10.1002/ijc.32653. Epub 2019 Oct 8.
|
| 124 |
AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3/NF-B axis.Cell Signal. 2018 May;45:122-131. doi: 10.1016/j.cellsig.2018.01.021. Epub 2018 Jan 31.
|
| 125 |
MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3.Oncotarget. 2015 Dec 1;6(38):40799-814. doi: 10.18632/oncotarget.5695.
|
| 126 |
Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer.Cancer Biol Ther. 2017 Apr 3;18(4):245-251. doi: 10.1080/15384047.2017.1295175. Epub 2017 Mar 27.
|
| 127 |
ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2.J Exp Clin Cancer Res. 2019 Apr 15;38(1):163. doi: 10.1186/s13046-019-1159-2.
|
| 128 |
Expression of AMHR2 and C-KIT in cervical lesions in Uyghur Women of Xinjiang, China.Medicine (Baltimore). 2018 Jun;97(22):e10793. doi: 10.1097/MD.0000000000010793.
|
| 129 |
Angiogenic protein expression in advanced epithelial ovarian cancer.Clin Cancer Res. 1997 Sep;3(9):1579-86.
|
| 130 |
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.
|
| 131 |
Profiling of selected angiogenesis-related genes in serous ovarian cancer patients.Adv Med Sci. 2017 Mar;62(1):116-120. doi: 10.1016/j.advms.2016.11.005. Epub 2017 Feb 21.
|
| 132 |
A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer.Mol Cancer Res. 2020 Jan;18(1):79-90. doi: 10.1158/1541-7786.MCR-19-0691. Epub 2019 Oct 22.
|
| 133 |
Inhibition of Ca(2+) -activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling.Int J Cancer. 2019 May 1;144(9):2215-2226. doi: 10.1002/ijc.31887. Epub 2019 Feb 12.
|
| 134 |
Prognostic Significance of Increased Expression of Annexin A10 (ANXA10) in Serous Epithelial Ovarian Cancer.Med Sci Monit. 2019 Jul 31;25:5666-5673. doi: 10.12659/MSM.915911.
|
| 135 |
Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.J Exp Clin Cancer Res. 2019 Jan 8;38(1):10. doi: 10.1186/s13046-018-1017-7.
|
| 136 |
Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.J Transl Med. 2019 Sep 2;17(1):275. doi: 10.1186/s12967-019-2023-z.
|
| 137 |
Human APC2 localization and allelic imbalance.Cancer Res. 2001 Nov 1;61(21):7978-84.
|
| 138 |
Silencing of Apurinic/Apyrimidinic Endonuclease 1 Inhibits the Growth and Migration in Ovarian Cancer Cell via Activator-Protein-1 Signaling.Gynecol Obstet Invest. 2017;82(2):188-199. doi: 10.1159/000447261. Epub 2016 Aug 24.
|
| 139 |
Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis.Mol Cancer Res. 2019 Jun;17(6):1378-1390. doi: 10.1158/1541-7786.MCR-18-0989. Epub 2019 Mar 11.
|
| 140 |
APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.Clin Cancer Res. 2016 Sep 15;22(18):4746-55. doi: 10.1158/1078-0432.CCR-15-2910. Epub 2016 Mar 25.
|
| 141 |
Different Prognostic Implications of Aquaporin-1 and Aquaporin-5 Expression among Different Histological Types of Ovarian Carcinoma.Pathol Oncol Res. 2020 Jan;26(1):263-271. doi: 10.1007/s12253-018-0456-y. Epub 2018 Jul 19.
|
| 142 |
miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway.Oncogenesis. 2017 May 1;6(5):e326. doi: 10.1038/oncsis.2017.25.
|
| 143 |
Targeting Endothelin-1 Receptor/-Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach.Front Endocrinol (Lausanne). 2019 Sep 4;10:609. doi: 10.3389/fendo.2019.00609. eCollection 2019.
|
| 144 |
L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer.J Cell Mol Med. 2012 Oct;16(10):2369-78. doi: 10.1111/j.1582-4934.2012.01547.x.
|
| 145 |
ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.Int J Oncol. 2020 Jan;56(1):219-231. doi: 10.3892/ijo.2019.4913. Epub 2019 Nov 14.
|
| 146 |
Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):446-54. doi: 10.1158/1055-9965.EPI-15-0240. Epub 2016 Jan 8.
|
| 147 |
Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy.J BUON. 2018 Sep-Oct;23(5):1396-1401.
|
| 148 |
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.J Exp Clin Cancer Res. 2015 Jan 16;34(1):2. doi: 10.1186/s13046-015-0124-y.
|
| 149 |
LncRNA TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in epithelial ovarian cancer cells.Medicine (Baltimore). 2018 Sep;97(36):e12131. doi: 10.1097/MD.0000000000012131.
|
| 150 |
Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.J Mol Med (Berl). 2015 Apr;93(4):427-38. doi: 10.1007/s00109-014-1228-0. Epub 2014 Nov 21.
|
| 151 |
Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.Mol Cancer Ther. 2019 Feb;18(2):389-398. doi: 10.1158/1535-7163.MCT-18-0537. Epub 2018 Nov 26.
|
| 152 |
BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.Cancer Lett. 2019 Mar 31;445:45-56. doi: 10.1016/j.canlet.2019.01.003. Epub 2019 Jan 14.
|
| 153 |
Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer. 2010 Apr 27;10:163.
|
| 154 |
Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low-dose fraction radiation.Cancer Med. 2019 May;8(5):2442-2448. doi: 10.1002/cam4.2116. Epub 2019 Apr 2.
|
| 155 |
BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.Oncotarget. 2015 Oct 13;6(31):31522-43. doi: 10.18632/oncotarget.5159.
|
| 156 |
Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer.Cancer Sci. 2012 Feb;103(2):239-444. doi: 10.1111/j.1349-7006.2011.02156.x. Epub 2011 Dec 23.
|
| 157 |
Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3.Cell Death Dis. 2019 Feb 4;10(2):104. doi: 10.1038/s41419-018-1200-y.
|
| 158 |
Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing.J Ovarian Res. 2018 Apr 23;11(1):31. doi: 10.1186/s13048-018-0406-z.
|
| 159 |
Loss of BMP-10 is correlated with poor survival in ovarian cancer.Pathol Res Pract. 2019 Jan;215(1):121-126. doi: 10.1016/j.prp.2018.10.025. Epub 2018 Oct 28.
|
| 160 |
Expression Of BMP7 In Ovarian Cancer And Biological Effect Of BMP7 Knockdown On Ovarian Cancer Cells.Onco Targets Ther. 2019 Sep 26;12:7897-7909. doi: 10.2147/OTT.S217975. eCollection 2019.
|
| 161 |
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.
|
| 162 |
Altered uterine contractility in response to -adrenoceptor agonists in ovarian cancer.J Physiol Sci. 2017 Nov;67(6):711-722. doi: 10.1007/s12576-016-0500-1. Epub 2016 Nov 12.
|
| 163 |
Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.Mol Cancer Res. 2019 Aug;17(8):1721-1734. doi: 10.1158/1541-7786.MCR-18-1332. Epub 2019 May 1.
|
| 164 |
ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2(-/-) Ovarian Cancer Cells.Mol Cancer Ther. 2020 Jan;19(1):199-210. doi: 10.1158/1535-7163.MCT-19-0242. Epub 2019 Sep 18.
|
| 165 |
Coexpression of Lewisy antigen and CD147 inepithelial ovarian cancer is correlated with malignant progression and poor prognosis.Int J Mol Med. 2019 Apr;43(4):1687-1698. doi: 10.3892/ijmm.2019.4103. Epub 2019 Feb 20.
|
| 166 |
microRNA-27a-3p Down-regulation Inhibits Malignant Biological Behaviors of Ovarian Cancer by Targeting BTG1.Open Med (Wars). 2019 Jul 31;14:577-585. doi: 10.1515/med-2019-0065. eCollection 2019.
|
| 167 |
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19(high) B lymphocytes.J Immunother Cancer. 2019 Nov 21;7(1):313. doi: 10.1186/s40425-019-0744-4.
|
| 168 |
Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.Int J Cancer. 2020 May 1;146(9):2608-2618. doi: 10.1002/ijc.32676. Epub 2019 Nov 6.
|
| 169 |
Akt activation by Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells. J Biol Chem. 2017 Aug 25;292(34):14188-14204. doi: 10.1074/jbc.M117.778464. Epub 2017 Jun 20.
|
| 170 |
Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1.Exp Ther Med. 2017 Jul;14(1):499-506. doi: 10.3892/etm.2017.4546. Epub 2017 Jun 6.
|
| 171 |
CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.Nat Commun. 2018 Feb 12;9(1):631. doi: 10.1038/s41467-018-03031-3.
|
| 172 |
Inhibition of microRNA-383 has tumor suppressive effect in human epithelial ovarian cancer through the action on caspase-2 gene.Biomed Pharmacother. 2016 Oct;83:1286-1294. doi: 10.1016/j.biopha.2016.07.038. Epub 2016 Aug 25.
|
| 173 |
-NETA induces pyroptosis of epithelial ovarian cancer cells through the GSDMD/caspase-4 pathway.FASEB J. 2019 Nov;33(11):12760-12767. doi: 10.1096/fj.201900483RR. Epub 2019 Sep 6.
|
| 174 |
Costunolide Inhibits the Growth of OAW42-A Multidrug-Resistant Human Ovarian Cancer Cells by Activating Apoptotic and Autophagic Pathways, Production of Reactive Oxygen Species (ROS), Cleaved Caspase-3 and Cleaved Caspase-9.Med Sci Monit. 2019 May 2;25:3231-3237. doi: 10.12659/MSM.914029.
|
| 175 |
Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model.Mol Biol Rep. 2019 Oct;46(5):4685-4697. doi: 10.1007/s11033-019-04788-6. Epub 2019 Apr 25.
|
| 176 |
Targeting Glutathione and Cystathionine -Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation.Nutrients. 2019 Oct 19;11(10):2523. doi: 10.3390/nu11102523.
|
| 177 |
CCL20 Promotes Ovarian Cancer Chemotherapy Resistance by Regulating ABCB1 Expression.Cell Struct Funct. 2019;44(1):21-28. doi: 10.1247/csf.18029.
|
| 178 |
Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer.Immune Netw. 2018 Aug 13;18(4):e29. doi: 10.4110/in.2018.18.e29. eCollection 2018 Aug.
|
| 179 |
CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.BMC Cancer. 2019 Nov 25;19(1):1140. doi: 10.1186/s12885-019-6321-x.
|
| 180 |
Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysis.Mol Med Rep. 2017 Sep;16(3):3155-3160. doi: 10.3892/mmr.2017.7008. Epub 2017 Jul 15.
|
| 181 |
Migration deficit in monocyte-macrophages in human ovarian cancer.Cancer Immunol Immunother. 2008 May;57(5):635-45. doi: 10.1007/s00262-007-0401-5. Epub 2007 Oct 10.
|
| 182 |
Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas.Med Oncol. 2015 Mar;32(3):47. doi: 10.1007/s12032-015-0494-1. Epub 2015 Jan 31.
|
| 183 |
Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.Int J Oncol. 2011 Aug;39(2):373-81. doi: 10.3892/ijo.2011.1059. Epub 2011 May 31.
|
| 184 |
Anti-Inflammatory Drug Use and Ovarian Cancer Risk by COX1/COX2 Expression and Infiltration of Tumor-Associated Macrophages.Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1509-1517. doi: 10.1158/1055-9965.EPI-18-0346. Epub 2018 Oct 30.
|
| 185 |
Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells.Clin Transl Oncol. 2017 Dec;19(12):1489-1497. doi: 10.1007/s12094-017-1686-2. Epub 2017 Jun 6.
|
| 186 |
Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.Int J Mol Sci. 2019 Feb 3;20(3):660. doi: 10.3390/ijms20030660.
|
| 187 |
B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models.Nucl Med Biol. 2017 Apr;47:23-30. doi: 10.1016/j.nucmedbio.2017.01.003. Epub 2017 Jan 10.
|
| 188 |
The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.Oncoimmunology. 2018 May 31;7(8):e1465166. doi: 10.1080/2162402X.2018.1465166. eCollection 2018.
|
| 189 |
Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.J Clin Invest. 1998 Jun 1;101(11):2579-88. doi: 10.1172/JCI1518.
|
| 190 |
CD47 promotes cell growth and motility in epithelial ovarian cancer.Biomed Pharmacother. 2019 Nov;119:109105. doi: 10.1016/j.biopha.2019.109105. Epub 2019 Sep 4.
|
| 191 |
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.Clin Exp Metastasis. 2011 Oct;28(7):689-700. doi: 10.1007/s10585-011-9401-0. Epub 2011 Jul 2.
|
| 192 |
Differential expression of adhesion molecules (CD44, ICAM-1 and LFA-3) in cancer cells grown in monolayer or as multicellular spheroids.Anticancer Res. 1999 May-Jun;19(3A):1769-78.
|
| 193 |
Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide.Eur J Med Chem. 2019 Jan 1;161:594-606. doi: 10.1016/j.ejmech.2018.10.042. Epub 2018 Oct 23.
|
| 194 |
CDC25A Facilitates Chemo-resistance in Ovarian Cancer Multicellular Spheroids by Promoting E-cadherin Expression and Arresting Cell Cycles.J Cancer. 2019 Jun 2;10(13):2874-2884. doi: 10.7150/jca.31329. eCollection 2019.
|
| 195 |
Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.Front Oncol. 2019 Apr 8;9:236. doi: 10.3389/fonc.2019.00236. eCollection 2019.
|
| 196 |
High Resolution Based Quantitative Determination of Methylation Status of CDH1 and VIM Gene in Epithelial Ovarian Cancer.Asian Pac J Cancer Prev. 2019 Oct 1;20(10):2923-2928. doi: 10.31557/APJCP.2019.20.10.2923.
|
| 197 |
Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.Medicine (Baltimore). 2019 Nov;98(44):e17803. doi: 10.1097/MD.0000000000017803.
|
| 198 |
BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression.Cancer Res. 2001 Oct 1;61(19):6977-81.
|
| 199 |
Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.Cancer Res. 2016 Apr 1;76(7):1882-91. doi: 10.1158/0008-5472.CAN-15-2128. Epub 2016 Jan 19.
|
| 200 |
Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.Mol Cancer Ther. 2016 Jul;15(7):1691-701. doi: 10.1158/1535-7163.MCT-16-0032. Epub 2016 May 20.
|
| 201 |
Hypo/unmethylated promoter status of Cdk2 gene correlates with its over-expression in ovarian cancer in north Indian population.Cell Mol Biol (Noisy-le-grand). 2016 Jan 22;62(1):67-72.
|
| 202 |
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.Nat Commun. 2019 Feb 4;10(1):557. doi: 10.1038/s41467-019-08380-1.
|
| 203 |
CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.Gynecol Oncol. 2020 Jan;156(1):211-221. doi: 10.1016/j.ygyno.2019.11.004. Epub 2019 Nov 24.
|
| 204 |
The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.Br J Cancer. 2012 Jan 31;106(3):482-9. doi: 10.1038/bjc.2011.566. Epub 2012 Jan 10.
|
| 205 |
Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients.Dis Markers. 2018 Jun 28;2018:6714287. doi: 10.1155/2018/6714287. eCollection 2018.
|
| 206 |
An Improved Prediction Model for Ovarian Cancer Using Urinary Biomarkers and a Novel Validation Strategy.Int J Mol Sci. 2019 Oct 5;20(19):4938. doi: 10.3390/ijms20194938.
|
| 207 |
The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential.Gynecol Oncol. 2010 Jun;117(3):451-9. doi: 10.1016/j.ygyno.2010.02.024. Epub 2010 Mar 15.
|
| 208 |
Chemiluminescence noncompetitive immunoassay based on microchip electrophoresis for the determination of -subunit of human chorionic gonadotropin.J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 15;1053:42-47. doi: 10.1016/j.jchromb.2017.03.031. Epub 2017 Mar 29.
|
| 209 |
Directing the use of DDR kinase inhibitors in cancer treatment.Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355. doi: 10.1080/13543784.2017.1389895. Epub 2017 Oct 14.
|
| 210 |
One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer.Int J Mol Sci. 2018 Jul 19;19(7):2092. doi: 10.3390/ijms19072092.
|
| 211 |
Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer.Tumour Biol. 2015 Nov;36(11):9023-30. doi: 10.1007/s13277-015-3652-3. Epub 2015 Jun 18.
|
| 212 |
miR-23a promotes IKK expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.Br J Cancer. 2016 Sep 6;115(6):731-40. doi: 10.1038/bjc.2016.244. Epub 2016 Aug 18.
|
| 213 |
Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy.Oncoimmunology. 2018 Nov 11;8(2):e1528411. doi: 10.1080/2162402X.2018.1528411. eCollection 2019.
|
| 214 |
The Emerging Role of Calcium-activated Chloride Channel Regulator 1 in Cancer.Anticancer Res. 2019 Apr;39(4):1661-1666. doi: 10.21873/anticanres.13271.
|
| 215 |
CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer.Sci Rep. 2018 Oct 3;8(1):14725. doi: 10.1038/s41598-018-32885-2.
|
| 216 |
RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells.Mol Med Rep. 2015 Nov;12(5):6635-41. doi: 10.3892/mmr.2015.4238. Epub 2015 Aug 21.
|
| 217 |
Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities.Cancers (Basel). 2019 Sep 18;11(9):1389. doi: 10.3390/cancers11091389.
|
| 218 |
Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by siSAB1 in ovarian cancer.Oncol Rep. 2018 Nov;40(5):2788-2797. doi: 10.3892/or.2018.6658. Epub 2018 Aug 17.
|
| 219 |
Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.J Obstet Gynaecol Res. 2017 Dec;43(12):1870-1879. doi: 10.1111/jog.13466. Epub 2017 Oct 13.
|
| 220 |
Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor.Neoplasia. 2009 Feb;11(2):136-44. doi: 10.1593/neo.81150.
|
| 221 |
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.Genome Med. 2016 Oct 20;8(1):107. doi: 10.1186/s13073-016-0361-5.
|
| 222 |
Casein Kinase 1 Delta Regulates Cell Proliferation, Response to Chemotherapy and Migration in Human Ovarian Cancer Cells.Front Oncol. 2019 Nov 12;9:1211. doi: 10.3389/fonc.2019.01211. eCollection 2019.
|
| 223 |
TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2 as a therapeutic target.J Pathol. 2019 Jul;248(3):363-376. doi: 10.1002/path.5266. Epub 2019 Apr 23.
|
| 224 |
Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.Int J Cancer. 2018 Aug 1;143(3):515-526. doi: 10.1002/ijc.31335. Epub 2018 Mar 8.
|
| 225 |
Genome-wide bioinformatics analysis reveals CTCFL is upregulated in high-grade epithelial ovarian cancer.Oncol Lett. 2019 Oct;18(4):4030-4039. doi: 10.3892/ol.2019.10736. Epub 2019 Aug 8.
|
| 226 |
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.Cell Death Dis. 2014 Nov 6;5(11):e1510. doi: 10.1038/cddis.2014.468.
|
| 227 |
Cathepsin D non-proteolytically induces proliferation and migration in human omental microvascular endothelial cells via activation of the ERK1/2 and PI3K/AKT pathways.Biochim Biophys Acta Mol Cell Res. 2018 Jan;1865(1):25-33. doi: 10.1016/j.bbamcr.2017.10.005. Epub 2017 Oct 10.
|
| 228 |
Elevated Cathepsin K potentiates metastasis of epithelial ovarian cancer.Histol Histopathol. 2018 Jul;33(7):673-680. doi: 10.14670/HH-11-960. Epub 2018 Jan 5.
|
| 229 |
Cathepsin L Induces Proangiogenic Changes in Human Omental Microvascular Endothelial Cells via Activation of the ERK1/2 Pathway.Curr Cancer Drug Targets. 2019;19(3):231-242. doi: 10.2174/1568009618666180831123951.
|
| 230 |
Hypoxia-inducible factor-1 induces CX3CR1 expression and promotes the epithelial to mesenchymal transition (EMT) in ovarian cancer cells.J Ovarian Res. 2019 May 10;12(1):42. doi: 10.1186/s13048-019-0517-1.
|
| 231 |
A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.Int J Gynecol Cancer. 2018 Jan;28(1):51-58. doi: 10.1097/IGC.0000000000001141.
|
| 232 |
Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.Adv Med Sci. 2019 Sep;64(2):235-240. doi: 10.1016/j.advms.2018.12.007. Epub 2019 Feb 26.
|
| 233 |
CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer.Oncotarget. 2018 Jan 15;9(11):9751-9765. doi: 10.18632/oncotarget.24231. eCollection 2018 Feb 9.
|
| 234 |
Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case-control studies.Gene. 2013 Jul 25;524(2):168-74. doi: 10.1016/j.gene.2013.04.038. Epub 2013 Apr 26.
|
| 235 |
CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.Int J Mol Med. 2015 Feb;35(2):340-8. doi: 10.3892/ijmm.2014.2041. Epub 2014 Dec 16.
|
| 236 |
MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma.Int J Biochem Cell Biol. 2017 Apr;85:66-74. doi: 10.1016/j.biocel.2017.01.020. Epub 2017 Feb 2.
|
| 237 |
TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.Oncogene. 2018 Mar;37(13):1714-1729. doi: 10.1038/s41388-017-0043-9. Epub 2018 Jan 19.
|
| 238 |
High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.Int J Cancer. 2020 Apr 1;146(7):2007-2018. doi: 10.1002/ijc.32818. Epub 2019 Dec 19.
|
| 239 |
The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.Neoplasia. 2018 Dec;20(12):1209-1218. doi: 10.1016/j.neo.2018.10.005. Epub 2018 Nov 6.
|
| 240 |
Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry.Int J Mol Med. 2019 Jan;43(1):47-56. doi: 10.3892/ijmm.2018.3967. Epub 2018 Oct 31.
|
| 241 |
Dynamic contrast enhancedmagnetic resonance imaging for the early evaluation of the response to docetaxel in rats with epithelial ovarian cancer.Oncol Rep. 2019 Jun;41(6):3335-3346. doi: 10.3892/or.2019.7124. Epub 2019 Apr 17.
|
| 242 |
Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma.Tumour Biol. 2015 Jun;36(6):4157-65. doi: 10.1007/s13277-015-3050-x. Epub 2015 Jan 12.
|
| 243 |
An NF90/NF110-mediated feedback amplification loop regulates dicer expression and controls ovarian carcinoma progression.Cell Res. 2018 May;28(5):556-571. doi: 10.1038/s41422-018-0016-8. Epub 2018 Mar 21.
|
| 244 |
Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.Clin Biochem. 2013 Oct;46(15):1462-8. doi: 10.1016/j.clinbiochem.2013.03.010. Epub 2013 Mar 23.
|
| 245 |
Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.Oncogene. 2019 Apr;38(17):3201-3215. doi: 10.1038/s41388-018-0658-5. Epub 2019 Jan 9.
|
| 246 |
Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.Cancer Res. 2015 Oct 1;75(19):4086-96. doi: 10.1158/0008-5472.CAN-14-3773. Epub 2015 Sep 16.
|
| 247 |
miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells.Arch Biochem Biophys. 2019 Jan;661:1-9. doi: 10.1016/j.abb.2018.10.014. Epub 2018 Oct 23.
|
| 248 |
Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.Am J Transl Res. 2019 Feb 15;11(2):1145-1153. eCollection 2019.
|
| 249 |
Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma.Virchows Arch. 2019 Feb;474(2):177-185. doi: 10.1007/s00428-018-2487-x. Epub 2018 Nov 22.
|
| 250 |
Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.Mol Nutr Food Res. 2014 Oct;58(10):2023-35. doi: 10.1002/mnfr.201400068. Epub 2014 Jul 28.
|
| 251 |
Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1.Genomics. 1994 Sep 1;23(1):163-7. doi: 10.1006/geno.1994.1473.
|
| 252 |
E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer.Front Oncol. 2019 Mar 22;9:161. doi: 10.3389/fonc.2019.00161. eCollection 2019.
|
| 253 |
Targeting endothelin-1 receptor/-arrestin1 network for the treatment of ovarian cancer.Expert Opin Ther Targets. 2017 Oct;21(10):925-932. doi: 10.1080/14728222.2017.1361930. Epub 2017 Sep 5.
|
| 254 |
EGFL7 and RASSF1 promoter hypermethylation in epithelial ovarian cancer.Cancer Genet. 2018 Aug;224-225:37-40. doi: 10.1016/j.cancergen.2018.04.117. Epub 2018 Apr 17.
|
| 255 |
ERK Regulates HIF1-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer.Clin Cancer Res. 2019 Oct 1;25(19):5947-5960. doi: 10.1158/1078-0432.CCR-18-4145. Epub 2019 Jul 8.
|
| 256 |
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.Mol Cancer. 2014 Aug 12;13:189. doi: 10.1186/1476-4598-13-189.
|
| 257 |
Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.Biochem Biophys Res Commun. 2019 Mar 19;510(4):580-586. doi: 10.1016/j.bbrc.2019.01.117. Epub 2019 Feb 7.
|
| 258 |
EIF5A1 promotes epithelial ovarian cancer proliferation and progression.Biomed Pharmacother. 2018 Apr;100:168-175. doi: 10.1016/j.biopha.2018.02.016. Epub 2018 Feb 8.
|
| 259 |
Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma.Gynecol Oncol. 2009 Feb;112(2):314-8. doi: 10.1016/j.ygyno.2008.10.024. Epub 2008 Dec 2.
|
| 260 |
Human epithelial ovarian cancer cells expressing CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and drug resistance.Oncol Lett. 2019 Jun;17(6):5351-5360. doi: 10.3892/ol.2019.10221. Epub 2019 Apr 5.
|
| 261 |
Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer.Cancer Res. 2018 Apr 1;78(7):1779-1791. doi: 10.1158/0008-5472.CAN-17-2460. Epub 2018 Jan 26.
|
| 262 |
Knockdown of EPHA1 Using CRISPR/CAS9 Suppresses Aggressive Properties of Ovarian Cancer Cells.Anticancer Res. 2017 Aug;37(8):4415-4424. doi: 10.21873/anticanres.11836.
|
| 263 |
The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer.Gynecol Oncol. 2014 Mar;132(3):730-8. doi: 10.1016/j.ygyno.2014.01.047. Epub 2014 Feb 4.
|
| 264 |
Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6847-58. eCollection 2015.
|
| 265 |
IRE1-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.Nature. 2018 Oct;562(7727):423-428. doi: 10.1038/s41586-018-0597-x. Epub 2018 Oct 10.
|
| 266 |
Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells.Mol Ther. 2014 Apr;22(4):743-51. doi: 10.1038/mt.2014.1. Epub 2014 Jan 14.
|
| 267 |
ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.Cancer Lett. 2018 Feb 1;414:190-204. doi: 10.1016/j.canlet.2017.11.012. Epub 2017 Nov 22.
|
| 268 |
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma.PLoS One. 2016 Sep 13;11(9):e0162502. doi: 10.1371/journal.pone.0162502. eCollection 2016.
|
| 269 |
Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis.BMC Cancer. 2019 Nov 12;19(1):1095. doi: 10.1186/s12885-019-6176-1.
|
| 270 |
High expression of junctional adhesion molecule-A is associated with poor survival in patients with epithelial ovarian cancer.Int J Biol Markers. 2019 Sep;34(3):262-268. doi: 10.1177/1724600819850178. Epub 2019 Jun 13.
|
| 271 |
The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.Anticancer Res. 2018 Jun;38(6):3619-3625. doi: 10.21873/anticanres.12636.
|
| 272 |
Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.Gynecol Oncol. 2017 Apr;145(1):167-175. doi: 10.1016/j.ygyno.2017.01.022. Epub 2017 Jan 29.
|
| 273 |
Role of PAR-4 in ovarian cancer.Oncotarget. 2015 Sep 8;6(26):22641-52. doi: 10.18632/oncotarget.4010.
|
| 274 |
Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O?and Plasma Supply.Int J Mol Sci. 2017 Apr 12;18(4):809. doi: 10.3390/ijms18040809.
|
| 275 |
Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer.Mol Cancer Ther. 2018 Jan;17(1):39-49. doi: 10.1158/1535-7163.MCT-17-0574. Epub 2017 Nov 20.
|
| 276 |
IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment.Cancer Immunol Immunother. 2020 Jan;69(1):115-126. doi: 10.1007/s00262-019-02445-2. Epub 2019 Dec 4.
|
| 277 |
FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.Acta Biochim Biophys Sin (Shanghai). 2019 May 23;51(5):509-516. doi: 10.1093/abbs/gmz028.
|
| 278 |
Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.Carcinogenesis. 2015 Nov;36(11):1341-53. doi: 10.1093/carcin/bgv138. Epub 2015 Sep 29.
|
| 279 |
The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.Int J Cancer. 2018 Aug 15;143(4):992-1002. doi: 10.1002/ijc.31392. Epub 2018 Apr 1.
|
| 280 |
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).J Med Genet. 2019 Sep;56(9):574-580. doi: 10.1136/jmedgenet-2018-105930. Epub 2019 Apr 12.
|
| 281 |
Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling.Tumour Biol. 2017 Jul;39(7):1010428317712592. doi: 10.1177/1010428317712592.
|
| 282 |
Keratinocyte growth factor binding to fibroblast growth factor receptor 2-IIIb promotes epithelial ovarian cancer cell proliferation and invasion.J Cancer Res Ther. 2018 Jun;14(Supplement):S347-S353. doi: 10.4103/0973-1482.235353.
|
| 283 |
Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis.Int J Cancer. 2015 Oct 15;137(8):1806-17. doi: 10.1002/ijc.29197. Epub 2015 Jul 2.
|
| 284 |
Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.BMC Cancer. 2019 Jun 14;19(1):584. doi: 10.1186/s12885-019-5757-3.
|
| 285 |
VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.Neoplasia. 2014 Apr;16(4):343-53.e1-2. doi: 10.1016/j.neo.2014.04.003.
|
| 286 |
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous... Hum Pathol. 2009 Oct;40(10):1453-60.
|
| 287 |
Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers.J Ovarian Res. 2015 May 14;8:29. doi: 10.1186/s13048-015-0156-0.
|
| 288 |
lncRNA UCA1 Mediates Resistance to Cisplatin by Regulating the miR-143/FOSL2-Signaling Pathway in Ovarian Cancer.Mol Ther Nucleic Acids. 2019 Sep 6;17:92-101. doi: 10.1016/j.omtn.2019.05.007. Epub 2019 May 24.
|
| 289 |
MiR-27a promotes EMT in ovarian cancer through active Wnt/-catenin signalling by targeting FOXO1.Cancer Biomark. 2019;24(1):31-42. doi: 10.3233/CBM-181229.
|
| 290 |
MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.Exp Ther Med. 2018 Feb;15(2):1672-1679. doi: 10.3892/etm.2017.5529. Epub 2017 Nov 17.
|
| 291 |
MiR-342-3p inhibits cell migration and invasion through suppressing forkhead box protein Q1 in ovarian carcinoma.Anticancer Drugs. 2019 Oct;30(9):917-924. doi: 10.1097/CAD.0000000000000801.
|
| 292 |
Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.J Exp Clin Cancer Res. 2019 Nov 8;38(1):459. doi: 10.1186/s13046-019-1465-8.
|
| 293 |
Formyl peptide receptor2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.Oncol Rep. 2017 Dec;38(6):3297-3308. doi: 10.3892/or.2017.6034. Epub 2017 Oct 13.
|
| 294 |
Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.Gynecol Oncol. 2019 May;153(2):405-415. doi: 10.1016/j.ygyno.2019.01.020. Epub 2019 Feb 20.
|
| 295 |
BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.PLoS One. 2012;7(6):e37697. doi: 10.1371/journal.pone.0037697. Epub 2012 Jun 1.
|
| 296 |
N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance.Cancer Res. 2019 Jun 1;79(11):2812-2820. doi: 10.1158/0008-5472.CAN-18-3592. Epub 2019 Apr 9.
|
| 297 |
The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma.Mol Oncol. 2019 Apr;13(4):757-780. doi: 10.1002/1878-0261.12425. Epub 2019 Jan 19.
|
| 298 |
Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.Sci Rep. 2017 Oct 16;7(1):13244. doi: 10.1038/s41598-017-13802-5.
|
| 299 |
Association of metastin/a G-protein-coupled receptor signaling and Down syndrome critical region 1 in epithelial ovarian cancer.Anticancer Res. 2009 Feb;29(2):617-23.
|
| 300 |
Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.Cancer Res. 1995 Oct 1;55(19):4367-74.
|
| 301 |
GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2.J Exp Clin Cancer Res. 2018 Apr 10;37(1):80. doi: 10.1186/s13046-018-0744-0.
|
| 302 |
Epithelialmesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells.Mol Med Rep. 2019 Mar;19(3):1501-1508. doi: 10.3892/mmr.2019.9814. Epub 2019 Jan 3.
|
| 303 |
Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFRAkt pathway.Mol Med Rep. 2019 Mar;19(3):2287-2296. doi: 10.3892/mmr.2019.9876. Epub 2019 Jan 17.
|
| 304 |
Regulation of Survivin Isoform Expression by GLI Proteins in Ovarian Cancer.Cells. 2019 Feb 6;8(2):128. doi: 10.3390/cells8020128.
|
| 305 |
Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.J Int Med Res. 2018 Feb;46(2):723-731. doi: 10.1177/0300060517717625. Epub 2017 Sep 12.
|
| 306 |
GRP137 promotes cell proliferation and metastasis through regulation of the PI3K/AKT pathway in human ovarian cancer.Tumori. 2018 Oct;104(5):330-337. doi: 10.5301/tj.5000703. Epub 2018 May 9.
|
| 307 |
Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.Oncogene. 2016 Apr 28;35(17):2186-96. doi: 10.1038/onc.2015.279. Epub 2015 Jul 27.
|
| 308 |
Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.Cell Cycle. 2017 Apr 3;16(7):693-706. doi: 10.1080/15384101.2017.1295181. Epub 2017 Feb 22.
|
| 309 |
Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors.Med Oncol. 2019 Nov 12;37(1):4. doi: 10.1007/s12032-019-1326-5.
|
| 310 |
The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.Oncogene. 2020 Feb;39(7):1600-1616. doi: 10.1038/s41388-019-1087-9. Epub 2019 Nov 7.
|
| 311 |
Selection of suitable reference genes for gene expression studies in normal human ovarian tissues, borderline ovarian tumours and ovarian cancer.Mol Med Rep. 2016 Dec;14(6):5725-5731. doi: 10.3892/mmr.2016.5933. Epub 2016 Nov 8.
|
| 312 |
MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF.Tumour Biol. 2014 Dec;35(12):12427-34. doi: 10.1007/s13277-014-2560-2. Epub 2014 Sep 9.
|
| 313 |
HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.Cell Physiol Biochem. 2018;48(4):1505-1518. doi: 10.1159/000492260. Epub 2018 Aug 2.
|
| 314 |
HDAC10 as a potential therapeutic target in ovarian cancer.Gynecol Oncol. 2017 Mar;144(3):613-620. doi: 10.1016/j.ygyno.2017.01.009. Epub 2017 Jan 7.
|
| 315 |
Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1-mediated regulation of apoptosis and autophagy.Theranostics. 2019 Jan 30;9(4):1096-1114. doi: 10.7150/thno.29673. eCollection 2019.
|
| 316 |
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.Cancer Res. 2019 Nov 1;79(21):5482-5489. doi: 10.1158/0008-5472.CAN-19-1302. Epub 2019 Jul 16.
|
| 317 |
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.Oncogene. 2017 Mar 23;36(12):1707-1720. doi: 10.1038/onc.2016.337. Epub 2016 Oct 3.
|
| 318 |
MicroRNA?39 suppressed tumor cell proliferation, migration and invasion by directly targeting HDGF in epithelial ovarian cancer.Mol Med Rep. 2017 Sep;16(3):3379-3386. doi: 10.3892/mmr.2017.6956. Epub 2017 Jul 12.
|
| 319 |
MicroRNA let?d?p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1.Int J Oncol. 2019 May;54(5):1771-1784. doi: 10.3892/ijo.2019.4731. Epub 2019 Feb 27.
|
| 320 |
Quantitative analysis of the mitochondrial proteome in human ovarian carcinomas.Endocr Relat Cancer. 2018 Oct;25(10):909-931. doi: 10.1530/ERC-18-0243. Epub 2018 Jul 11.
|
| 321 |
Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5.Gynecol Oncol. 2018 Nov;151(2):345-355. doi: 10.1016/j.ygyno.2018.08.032. Epub 2018 Sep 7.
|
| 322 |
The effect of lncRNA HOTAIR on chemoresistance of ovarian cancer through regulation of HOXA7.Biol Chem. 2018 Apr 25;399(5):485-497. doi: 10.1515/hsz-2017-0274.
|
| 323 |
A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.
|
| 324 |
Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):115-28. doi: 10.1016/j.jsbmb.2007.10.004. Epub 2007 Nov 17.
|
| 325 |
Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma.Int J Cancer. 1993 May 8;54(2):220-5. doi: 10.1002/ijc.2910540210.
|
| 326 |
Targeting HSF1 leads to an antitumor effect in human epithelial ovarian cancer.Int J Mol Med. 2017 Jun;39(6):1564-1570. doi: 10.3892/ijmm.2017.2978. Epub 2017 May 8.
|
| 327 |
Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.Cancer Biol Ther. 2019;20(7):1035-1045. doi: 10.1080/15384047.2019.1595279. Epub 2019 Mar 30.
|
| 328 |
NF-B p65 promotes ovarian cancer cell proliferation and migration via regulating mortalin.J Cell Mol Med. 2019 Jun;23(6):4338-4348. doi: 10.1111/jcmm.14325. Epub 2019 Apr 14.
|
| 329 |
Long Non-Coding RNA NONHSAT076754 Promotes Invasion and Metastasis in Epithelial Ovarian Cancer.J Cancer. 2019 Apr 25;10(8):1930-1940. doi: 10.7150/jca.29057. eCollection 2019.
|
| 330 |
Correction to: HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.Diagn Pathol. 2018 Sep 17;13(1):75. doi: 10.1186/s13000-018-0748-2.
|
| 331 |
Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.Clin Cancer Res. 2003 Feb;9(2):779-85.
|
| 332 |
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.Radiol Oncol. 2018 Sep 11;52(3):307-319. doi: 10.2478/raon-2018-0030.
|
| 333 |
A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.Br J Cancer. 2017 Aug 22;117(5):666-674. doi: 10.1038/bjc.2017.199. Epub 2017 Jun 29.
|
| 334 |
The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesis.Sci Rep. 2016 Dec 23;6:39334. doi: 10.1038/srep39334.
|
| 335 |
Histone Deacetylase (HDAC) Inhibition Induces IB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.J Biol Chem. 2017 Mar 24;292(12):5043-5054. doi: 10.1074/jbc.M116.771014. Epub 2017 Feb 6.
|
| 336 |
Common Polymorphisms in IL-27 Genes May Contribute to Risk of Various Human Diseases in Asian Populations: A Meta-Analysis.Med Sci Monit. 2016 Mar 7;22:766-75. doi: 10.12659/msm.895558.
|
| 337 |
IL-21-secreting hUCMSCs combined with miR-200c inhibit tumor growth and metastasis via repression of Wnt/-catenin signaling and epithelial-mesenchymal transition in epithelial ovarian cancer.Onco Targets Ther. 2018 Apr 10;11:2037-2050. doi: 10.2147/OTT.S147855. eCollection 2018.
|
| 338 |
Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells.Oncotarget. 2016 Nov 15;7(46):76006-76020. doi: 10.18632/oncotarget.12579.
|
| 339 |
Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.J Ovarian Res. 2016 Jun 27;9(1):38. doi: 10.1186/s13048-016-0248-5.
|
| 340 |
Genetic Association of Interleukin-31 Gene Polymorphisms with Epithelial Ovarian Cancer in Chinese Population.Dis Markers. 2018 Feb 1;2018:3503858. doi: 10.1155/2018/3503858. eCollection 2018.
|
| 341 |
Dual-specificity phosphatase 5 suppresses ovarian cancer progression by inhibiting IL-33 signaling.Am J Transl Res. 2019 Feb 15;11(2):844-854. eCollection 2019.
|
| 342 |
Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.J Transl Med. 2018 Mar 20;16(1):73. doi: 10.1186/s12967-018-1432-8.
|
| 343 |
Effect of integrinlinked kinase gene silencing on microRNA expression in ovarian cancer.Mol Med Rep. 2017 Nov;16(5):7267-7276. doi: 10.3892/mmr.2017.7523. Epub 2017 Sep 19.
|
| 344 |
Targeting INHBA in Ovarian Cancer Cells Suppresses Cancer Xenograft Growth by Attenuating Stromal Fibroblast Activation.Dis Markers. 2019 Nov 11;2019:7275289. doi: 10.1155/2019/7275289. eCollection 2019.
|
| 345 |
miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin 5 expression.Am J Pathol. 2013 May;182(5):1876-89. doi: 10.1016/j.ajpath.2013.01.039. Epub 2013 Mar 15.
|
| 346 |
Expression of integrin -6 is associated with multi drug resistance and prognosis in ovarian cancer.Oncol Lett. 2019 Apr;17(4):3974-3980. doi: 10.3892/ol.2019.10056. Epub 2019 Feb 20.
|
| 347 |
Non-catalytic region of tyrosine kinase adaptor protein 2 (NCK2) pathways as factor promoting aggressiveness in ovarian cancer.Int J Biol Markers. 2018 Jan;33(1):124-131. doi: 10.5301/ijbm.5000264.
|
| 348 |
Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.Med Sci Monit. 2018 Dec 10;24:8933-8940. doi: 10.12659/MSM.911518.
|
| 349 |
Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression.Mol Cancer. 2017 Oct 17;16(1):163. doi: 10.1186/s12943-017-0732-6.
|
| 350 |
Calcium-activated potassium channels as potential early markers of human cervical cancer.Oncol Lett. 2018 May;15(5):7249-7254. doi: 10.3892/ol.2018.8187. Epub 2018 Mar 7.
|
| 351 |
Low expression of KCNN3 may affect drug resistance in ovarian cancer.Mol Med Rep. 2018 Aug;18(2):1377-1386. doi: 10.3892/mmr.2018.9107. Epub 2018 May 31.
|
| 352 |
Lysine demethylase2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelialmesenchymal transition.Oncol Rep. 2019 Feb;41(2):917-927. doi: 10.3892/or.2018.6888. Epub 2018 Nov 27.
|
| 353 |
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.Oncogene. 2017 Mar;36(11):1537-1545. doi: 10.1038/onc.2016.320. Epub 2016 Oct 3.
|
| 354 |
KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance.Mol Med Rep. 2017 Sep;16(3):3573-3580. doi: 10.3892/mmr.2017.6960. Epub 2017 Jul 12.
|
| 355 |
Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.Tumour Biol. 2015 Apr;36(4):2465-72. doi: 10.1007/s13277-014-2859-z. Epub 2015 Feb 8.
|
| 356 |
KDM6B promotes ovarian cancer cell migration and invasion by induced transforming growth factor-1 expression.J Cell Biochem. 2019 Jan;120(1):493-506. doi: 10.1002/jcb.27405. Epub 2018 Sep 11.
|
| 357 |
A comprehensive study on genome-wide coexpression network of KHDRBS1/Sam68 reveals its cancer and patient-specific association.Sci Rep. 2019 Jul 31;9(1):11083. doi: 10.1038/s41598-019-47558-x.
|
| 358 |
Upregulation of KIF26B, Cell Migration and Proliferation of Human Ovarian Cancer Cell Lines In Vitro, and Patient Outcomes from Human Bioinformatic Analysis.Med Sci Monit. 2018 Jun 8;24:3863-3872. doi: 10.12659/MSM.907889.
|
| 359 |
Long noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.Int J Cancer. 2020 May 1;146(9):2588-2598. doi: 10.1002/ijc.32692. Epub 2019 Dec 5.
|
| 360 |
Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.J Cancer Res Clin Oncol. 2018 Jun;144(6):1109-1118. doi: 10.1007/s00432-018-2623-7. Epub 2018 Mar 15.
|
| 361 |
Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarian cancer survival.Twin Res Hum Genet. 2011 Aug;14(4):323-7. doi: 10.1375/twin.14.4.323.
|
| 362 |
Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.BMC Cancer. 2019 Jul 15;19(1):696. doi: 10.1186/s12885-019-5901-0.
|
| 363 |
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.J Ovarian Res. 2014 Dec 5;7:109. doi: 10.1186/s13048-014-0109-z.
|
| 364 |
Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation.Oncoimmunology. 2017 Aug 21;6(9):e1339854. doi: 10.1080/2162402X.2017.1339854. eCollection 2017.
|
| 365 |
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7301-E7310. doi: 10.1073/pnas.1705441114. Epub 2017 Aug 15.
|
| 366 |
Overexpression of keratin 17 is associated with poor prognosis in epithelial ovarian cancer.Tumour Biol. 2013 Jun;34(3):1685-9. doi: 10.1007/s13277-013-0703-5. Epub 2013 Feb 21.
|
| 367 |
Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.Br J Cancer. 2018 Oct;119(7):1-9. doi: 10.1038/s41416-018-0260-1. Epub 2018 Oct 5.
|
| 368 |
A useful cell system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer.J Steroid Biochem Mol Biol. 2010 Oct;122(4):295-301. doi: 10.1016/j.jsbmb.2010.06.008. Epub 2010 Jun 17.
|
| 369 |
L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.Gynecol Oncol. 2017 Sep;146(3):615-622. doi: 10.1016/j.ygyno.2017.06.010. Epub 2017 Jun 16.
|
| 370 |
Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.Cancer Discov. 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. Epub 2016 Jul 17.
|
| 371 |
Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.Int J Gynecol Pathol. 2020 Nov;39(6):558-566. doi: 10.1097/PGP.0000000000000657.
|
| 372 |
Lentivirus-mediated RNA Interference Targeting LAPTM4B Inhibits Human Ovarian Cancer Cell Invasion In Vitro.Chem Biol Drug Des. 2016 Jan;87(1):121-30. doi: 10.1111/cbdd.12632. Epub 2015 Aug 31.
|
| 373 |
The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.Nucleic Acids Res. 2016 Feb 18;44(3):1227-46. doi: 10.1093/nar/gkv1515. Epub 2015 Dec 29.
|
| 374 |
Outcome in serous ovarian cancer is not associated with LATS expression.J Cancer Res Clin Oncol. 2019 Nov;145(11):2737-2749. doi: 10.1007/s00432-019-03037-4. Epub 2019 Oct 4.
|
| 375 |
Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.Cancer Immunol Immunother. 2019 Sep;68(9):1515-1526. doi: 10.1007/s00262-019-02385-x. Epub 2019 Sep 12.
|
| 376 |
Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway.Am J Transl Res. 2019 Jun 15;11(6):3862-3878. eCollection 2019.
|
| 377 |
Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function.J Toxicol Sci. 2019;44(1):47-56. doi: 10.2131/jts.44.47.
|
| 378 |
The expression of asparaginyl endopeptidase promotes growth potential in epithelial ovarian cancer.Cancer Biol Ther. 2017 Apr 3;18(4):222-228. doi: 10.1080/15384047.2017.1294290. Epub 2017 Mar 3.
|
| 379 |
LGR5 and LGR6 in stem cell biology and ovarian cancer.Oncotarget. 2017 Aug 11;9(1):1346-1355. doi: 10.18632/oncotarget.20178. eCollection 2018 Jan 2.
|
| 380 |
Expression of the luteinizing hormone receptor (LHR) in ovarian cancer.BMC Cancer. 2019 Nov 15;19(1):1114. doi: 10.1186/s12885-019-6153-8.
|
| 381 |
Endothelin A receptor drives invadopodia function and cell motility through the -arrestin/PDZ-RhoGEF pathway in ovarian carcinoma.Oncogene. 2016 Jun 30;35(26):3432-42. doi: 10.1038/onc.2015.403. Epub 2015 Nov 2.
|
| 382 |
The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer.Oncogene. 2019 Feb;38(9):1381-1397. doi: 10.1038/s41388-018-0512-9. Epub 2018 Sep 28.
|
| 383 |
Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update.Am J Surg Pathol. 2014 Sep;38(9):1227-34. doi: 10.1097/PAS.0000000000000268.
|
| 384 |
Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.Gynecol Oncol. 2017 Jul;146(1):170-178. doi: 10.1016/j.ygyno.2017.05.001. Epub 2017 May 9.
|
| 385 |
LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.BMC Cancer. 2016 Nov 4;16(1):846. doi: 10.1186/s12885-016-2865-1.
|
| 386 |
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.
|
| 387 |
Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.Biochim Biophys Acta. 2016 Feb;1863(2):236-43. doi: 10.1016/j.bbamcr.2015.11.011. Epub 2015 Nov 17.
|
| 388 |
The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.Oncotarget. 2016 Mar 22;7(12):14125-42. doi: 10.18632/oncotarget.7288.
|
| 389 |
Androgen receptor gene mutations do not occur in ovarian cancer.Anticancer Res. 2000 Mar-Apr;20(2A):815-9.
|
| 390 |
Overexpression of MAP3K3 promotes tumour growth through activation of the NF-B signalling pathway in ovarian carcinoma.Sci Rep. 2019 Jun 10;9(1):8401. doi: 10.1038/s41598-019-44835-7.
|
| 391 |
ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis.JCI Insight. 2017 Sep 21;2(18):e91828. doi: 10.1172/jci.insight.91828. eCollection 2017 Sep 21.
|
| 392 |
Expression of Syk and MAP4 proteins in ovarian cancer.J Cancer Res Clin Oncol. 2019 Apr;145(4):909-919. doi: 10.1007/s00432-019-02856-9. Epub 2019 Feb 8.
|
| 393 |
Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.Int J Mol Sci. 2017 Dec 23;19(1):41. doi: 10.3390/ijms19010041.
|
| 394 |
Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis.Oncotarget. 2017 Aug 24;8(43):74947-74961. doi: 10.18632/oncotarget.20471. eCollection 2017 Sep 26.
|
| 395 |
Clinical significance of melanoma cell adhesion molecule CD146 and VEGFA expression in epithelial ovarian cancer.Oncol Lett. 2019 Feb;17(2):2418-2424. doi: 10.3892/ol.2018.9840. Epub 2018 Dec 17.
|
| 396 |
MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966. doi: 10.1073/pnas.1814742116. Epub 2019 Feb 4.
|
| 397 |
Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16.
|
| 398 |
Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer.Onco Targets Ther. 2019 Nov 21;12:10057-10075. doi: 10.2147/OTT.S228678. eCollection 2019.
|
| 399 |
Association of MGMT promoter methylation with tumorigenesis features in patients with ovarian cancer: A systematic meta-analysis.Mol Genet Genomic Med. 2018 Jan;6(1):69-76. doi: 10.1002/mgg3.349. Epub 2017 Nov 30.
|
| 400 |
The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers.Transl Res. 2019 Apr;206:71-90. doi: 10.1016/j.trsl.2018.11.001. Epub 2018 Nov 20.
|
| 401 |
Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.Clin Transl Oncol. 2018 Mar;20(3):374-381. doi: 10.1007/s12094-017-1724-0. Epub 2017 Aug 1.
|
| 402 |
Primary Ovarian Tumors With Lymphogenic and Hematogenic Metastasis Express High MMP-14, Which Colocalizes With Highly Sulfated Chondroitin Sulfate in the Stroma.Int J Gynecol Pathol. 2020 Mar;39(2):184-192. doi: 10.1097/PGP.0000000000000587.
|
| 403 |
Aberrant Activation Of Hedgehog Signalling Promotes Cell Migration And Invasion Via Matrix Metalloproteinase-7 In Ovarian Cancer Cells.J Cancer. 2019 Jan 29;10(4):990-1003. doi: 10.7150/jca.26478. eCollection 2019.
|
| 404 |
Inhibition of RNA-Binding Protein Musashi-1 Suppresses Malignant Properties and Reverses Paclitaxel Resistance in Ovarian Carcinoma.J Cancer. 2019 Feb 26;10(6):1580-1592. doi: 10.7150/jca.27352. eCollection 2019.
|
| 405 |
Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.Int J Oncol. 2016 Nov;49(5):1945-1952. doi: 10.3892/ijo.2016.3683. Epub 2016 Sep 6.
|
| 406 |
PSP94, an upstream signaling mediator of prostasin found highly elevated in ovarian cancer.Cell Death Dis. 2014 Sep 4;5(9):e1407. doi: 10.1038/cddis.2014.374.
|
| 407 |
MicroRNA-30c inhibits metastasis of ovarian cancer by targeting metastasis-associated gene 1.J Cancer Res Ther. 2017;13(4):676-682. doi: 10.4103/jcrt.JCRT_132_17.
|
| 408 |
Nucleus accumbens-1/GADD45GIP1 axis mediates cisplatin resistance through cellular senescence in ovarian cancer.Oncol Lett. 2017 Jun;13(6):4713-4719. doi: 10.3892/ol.2017.6099. Epub 2017 Apr 26.
|
| 409 |
Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.Cancer Res. 2017 Jul 15;77(14):3857-3869. doi: 10.1158/0008-5472.CAN-16-3079. Epub 2017 May 15.
|
| 410 |
NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer.Biochem Biophys Res Commun. 2020 Feb 5;522(2):292-299. doi: 10.1016/j.bbrc.2019.11.014. Epub 2019 Nov 21.
|
| 411 |
Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis.Eur Rev Med Pharmacol Sci. 2018 Aug;22(16):5134-5139. doi: 10.26355/eurrev_201808_15708.
|
| 412 |
Activation of androgen receptor-associated protein 70 (ARA70) mRNA expression in ovarian cancer.Gynecol Oncol. 2001 Feb;80(2):132-8. doi: 10.1006/gyno.2000.6068.
|
| 413 |
Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.J Biol Chem. 2017 Apr 14;292(15):6339-6351. doi: 10.1074/jbc.M116.746859. Epub 2017 Feb 23.
|
| 414 |
NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice.Oncogene. 2018 Aug;37(35):4854-4870. doi: 10.1038/s41388-018-0296-y. Epub 2018 May 18.
|
| 415 |
PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8239-8248. doi: 10.26355/eurrev_201910_19133.
|
| 416 |
Emerging Role of Nestin as an Angiogenesis and Cancer Stem Cell Marker in Epithelial Ovarian Cancer: Immunohistochemical Study.Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):571-580. doi: 10.1097/PAI.0000000000000338.
|
| 417 |
Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway.Mol Cancer Ther. 2015 May;14(5):1202-12. doi: 10.1158/1535-7163.MCT-14-0911. Epub 2015 Feb 27.
|
| 418 |
Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer.Med Oncol. 2016 Oct;33(10):112. doi: 10.1007/s12032-016-0819-8. Epub 2016 Sep 1.
|
| 419 |
THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21.Am J Hum Genet. 1993 Apr;52(4):718-22.
|
| 420 |
Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.Cell Physiol Biochem. 2018;46(5):1971-1984. doi: 10.1159/000489418. Epub 2018 Apr 26.
|
| 421 |
Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.Onco Targets Ther. 2019 Sep 30;12:8015-8022. doi: 10.2147/OTT.S203550. eCollection 2019.
|
| 422 |
Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer.Arch Gynecol Obstet. 2019 Jun;299(6):1737-1746. doi: 10.1007/s00404-019-05139-3. Epub 2019 Apr 2.
|
| 423 |
The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis.Tumour Biol. 2017 May;39(5):1010428317705508. doi: 10.1177/1010428317705508.
|
| 424 |
Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer.Medicine (Baltimore). 2017 Jul;96(30):e7621. doi: 10.1097/MD.0000000000007621.
|
| 425 |
Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.J Pathol. 2019 Jul;248(3):352-362. doi: 10.1002/path.5264. Epub 2019 May 14.
|
| 426 |
Long noncoding RNA LINC00673 promotes the proliferation and metastasis of epithelial ovarian cancer by associating with opioid growth factor receptor.Onco Targets Ther. 2019 Aug 5;12:6145-6156. doi: 10.2147/OTT.S209784. eCollection 2019.
|
| 427 |
Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.Oncotarget. 2016 Mar 1;7(9):10594-605. doi: 10.18632/oncotarget.7236.
|
| 428 |
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study.Int J Gynecol Cancer. 2020 Feb;30(2):213-220. doi: 10.1136/ijgc-2019-000512. Epub 2019 Nov 27.
|
| 429 |
The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion.Tumour Biol. 2016 Apr;37(4):5375-83. doi: 10.1007/s13277-015-4363-5. Epub 2015 Nov 12.
|
| 430 |
Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.Oncogene. 2016 Apr 28;35(17):2178-85. doi: 10.1038/onc.2015.278. Epub 2015 Aug 10.
|
| 431 |
PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.Cell Death Dis. 2019 Feb 18;10(3):166. doi: 10.1038/s41419-019-1415-6.
|
| 432 |
Analysis of epigenetic alterations to proprotein convertase genes in disease.Methods Mol Biol. 2011;768:231-45. doi: 10.1007/978-1-61779-204-5_12.
|
| 433 |
Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer.Front Oncol. 2019 Oct 15;9:1015. doi: 10.3389/fonc.2019.01015. eCollection 2019.
|
| 434 |
Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.J Cell Physiol. 2019 May;234(5):6361-6370. doi: 10.1002/jcp.27369. Epub 2018 Sep 19.
|
| 435 |
Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites.Hum Gene Ther. 2001 Sep 20;12(14):1713-29. doi: 10.1089/104303401750476221.
|
| 436 |
Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.Tohoku J Exp Med. 2018 Apr;244(4):291-296. doi: 10.1620/tjem.244.291.
|
| 437 |
Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects.J Cell Physiol. 2019 Sep;234(9):15708-15716. doi: 10.1002/jcp.28224. Epub 2019 Jan 29.
|
| 438 |
Ginsenoside 20(S)-Rg3 Inhibits the Warburg Effect Via Modulating DNMT3A/ MiR-532-3p/HK2 Pathway in Ovarian Cancer Cells.Cell Physiol Biochem. 2018;45(6):2548-2559. doi: 10.1159/000488273. Epub 2018 Mar 16.
|
| 439 |
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.Cancer Res. 2010 Mar 1;70(5):2126-35. doi: 10.1158/0008-5472.CAN-09-3833. Epub 2010 Feb 23.
|
| 440 |
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells.Anticancer Res. 2015 Oct;35(10):5263-70.
|
| 441 |
Identification of clinical trait-related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer.EPMA J. 2019 Jul 19;10(3):273-290. doi: 10.1007/s13167-019-00175-0. eCollection 2019 Sep.
|
| 442 |
Plasminogen Activator Inhibitor Type 1 in Blood at Onset of Chemotherapy Unfavorably Affects Survival in Primary Ovarian Cancer.Adv Exp Med Biol. 2019;1153:47-54. doi: 10.1007/5584_2019_353.
|
| 443 |
Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.Clin Cancer Res. 2018 Sep 15;24(18):4588-4601. doi: 10.1158/1078-0432.CCR-17-2885. Epub 2018 Apr 13.
|
| 444 |
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.Oncotarget. 2012 Jan;3(1):78-83. doi: 10.18632/oncotarget.332.
|
| 445 |
High LIN28A and PLK4 coexpression is associated with poor prognosis in epithelial ovarian cancer.Mol Med Rep. 2018 Dec;18(6):5327-5336. doi: 10.3892/mmr.2018.9562. Epub 2018 Oct 16.
|
| 446 |
Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.Drug Deliv. 2018 Nov;25(1):1394-1402. doi: 10.1080/10717544.2018.1480672.
|
| 447 |
Association between newly identified variant form of DNA polymerase beta ( 208-304) and ovarian cancer.Cancer Biomark. 2012;11(4):155-60. doi: 10.3233/CBM-2012-00275.
|
| 448 |
Generation of a Fully Human scFv that binds Tumor-Specific Glycoforms.Sci Rep. 2019 Mar 25;9(1):5101. doi: 10.1038/s41598-019-41567-6.
|
| 449 |
Downregulation of miR-145-5p in cancer cellsand theirderived exosomes may contribute tothedevelopment of ovarian cancer by targeting CT.Int J Mol Med. 2019 Jan;43(1):256-266. doi: 10.3892/ijmm.2018.3958. Epub 2018 Oct 25.
|
| 450 |
BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.Mutat Res. 2016 Feb-Mar;784-785:8-15. doi: 10.1016/j.mrfmmm.2015.11.002. Epub 2015 Nov 28.
|
| 451 |
PKC regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.Oncogene. 2017 Jan 26;36(4):534-545. doi: 10.1038/onc.2016.224. Epub 2016 Jun 20.
|
| 452 |
The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.J Ovarian Res. 2016 Mar 31;9:20. doi: 10.1186/s13048-016-0228-9.
|
| 453 |
Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay.Acta Biochim Pol. 2000;47(1):157-64.
|
| 454 |
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.Oncotarget. 2016 Feb 9;7(6):6353-68. doi: 10.18632/oncotarget.7047.
|
| 455 |
Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor.BMC Cancer. 2018 Oct 19;18(1):999. doi: 10.1186/s12885-018-4918-0.
|
| 456 |
EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.J Cancer Res Clin Oncol. 2019 Oct;145(10):2519-2527. doi: 10.1007/s00432-019-03017-8. Epub 2019 Sep 4.
|
| 457 |
Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.ACS Omega. 2019 May 31;4(5):9251-9261. doi: 10.1021/acsomega.9b01093. Epub 2019 May 24.
|
| 458 |
PTN signaling: Components and mechanistic insights in human ovarian cancer.Mol Carcinog. 2015 Dec;54(12):1772-85. doi: 10.1002/mc.22249. Epub 2014 Nov 21.
|
| 459 |
High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome.Oncotarget. 2017 Sep 21;8(56):95662-95673. doi: 10.18632/oncotarget.21175. eCollection 2017 Nov 10.
|
| 460 |
Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer.Oncotarget. 2018 Jan 4;9(7):7522-7533. doi: 10.18632/oncotarget.23943. eCollection 2018 Jan 26.
|
| 461 |
LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer.Mol Med Rep. 2016 Sep;14(3):2465-72. doi: 10.3892/mmr.2016.5572. Epub 2016 Jul 28.
|
| 462 |
Dysregulation of micro-143-3p and BALBP1 contributes to the pathogenesis of the development of ovarian carcinoma.Oncol Rep. 2016 Dec;36(6):3605-3610. doi: 10.3892/or.2016.5148. Epub 2016 Oct 4.
|
| 463 |
Adipokine RBP4 drives ovarian cancer cell migration.J Ovarian Res. 2018 Apr 11;11(1):29. doi: 10.1186/s13048-018-0397-9.
|
| 464 |
Over-expression of nuclear NF-B1 and c-Rel correlates with chemoresistance and prognosis of serous epithelial ovarian cancer.Exp Mol Pathol. 2016 Feb;100(1):139-44. doi: 10.1016/j.yexmp.2015.11.030. Epub 2015 Dec 9.
|
| 465 |
RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.Gynecol Oncol. 2010 Mar;116(3):563-71. doi: 10.1016/j.ygyno.2009.11.015.
|
| 466 |
Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.J Immunol Res. 2019 Mar 17;2019:9394615. doi: 10.1155/2019/9394615. eCollection 2019.
|
| 467 |
Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.Transl Oncol. 2017 Jun;10(3):346-356. doi: 10.1016/j.tranon.2017.01.014. Epub 2017 Mar 23.
|
| 468 |
Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism.Oncotarget. 2016 Jan 5;7(1):712-28. doi: 10.18632/oncotarget.6412.
|
| 469 |
Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines.Med Oncol. 2016 Feb;33(2):11. doi: 10.1007/s12032-015-0724-6. Epub 2016 Jan 5.
|
| 470 |
MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1.Biochem Biophys Res Commun. 2013 Nov 29;441(4):693-700. doi: 10.1016/j.bbrc.2013.10.053. Epub 2013 Oct 21.
|
| 471 |
Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.J Ovarian Res. 2019 Nov 15;12(1):110. doi: 10.1186/s13048-019-0578-1.
|
| 472 |
RSF1 is a positive regulator of NF-B-induced gene expression required for ovarian cancer chemoresistance.Cancer Res. 2014 Apr 15;74(8):2258-69. doi: 10.1158/0008-5472.CAN-13-2459. Epub 2014 Feb 24.
|
| 473 |
The role of R-spondin 1 through activating Wnt/-catenin in the growth, survival and migration of ovarian cancer cells.Gene. 2019 Mar 20;689:124-130. doi: 10.1016/j.gene.2018.11.098. Epub 2018 Dec 17.
|
| 474 |
MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer.Gene. 2016 Jul 15;586(1):48-55. doi: 10.1016/j.gene.2016.04.001. Epub 2016 Apr 2.
|
| 475 |
Mammaglobin B expression in human endometrial cancer.Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1090-6. doi: 10.1111/j.1525-1438.2007.01137.x. Epub 2007 Nov 16.
|
| 476 |
Heterogeneity of the Mac-1 expression on peripheral blood neutrophils in patients with different types of epithelial ovarian cancer.Immunobiology. 2016 Feb;221(2):323-32. doi: 10.1016/j.imbio.2015.10.003. Epub 2015 Oct 29.
|
| 477 |
Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma.Int J Mol Med. 2015 May;35(5):1374-80. doi: 10.3892/ijmm.2015.2142. Epub 2015 Mar 17.
|
| 478 |
VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer.Cell Mol Biol Lett. 2018 Jan 3;23:2. doi: 10.1186/s11658-017-0058-9. eCollection 2018.
|
| 479 |
Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins.Oncotarget. 2019 Apr 26;10(31):2959-2972. doi: 10.18632/oncotarget.26836. eCollection 2019 Apr 26.
|
| 480 |
Levels of corticosteroid-binding globulin mRNA in human ovarian cancers.Tumour Biol. 1999 Sep-Oct;20(5):263-9. doi: 10.1159/000030073.
|
| 481 |
SERPIND1 Affects the Malignant Biological Behavior of Epithelial Ovarian Cancer via the PI3K/AKT Pathway: A Mechanistic Study.Front Oncol. 2019 Oct 4;9:954. doi: 10.3389/fonc.2019.00954. eCollection 2019.
|
| 482 |
Malignant ascites: a source of therapeutic protein against ovarian cancer?.Oncotarget. 2019 Oct 15;10(57):5894-5905. doi: 10.18632/oncotarget.27185. eCollection 2019 Oct 15.
|
| 483 |
The core genes involved in the promotion of depression in patients with ovarian cancer.Oncol Lett. 2019 Dec;18(6):5995-6007. doi: 10.3892/ol.2019.10934. Epub 2019 Sep 30.
|
| 484 |
Finding Novel Anti-carcinomas Compounds by Targeting SFRP4 Through Molecular Modeling, Docking and Dynamic Simulation Studies.Curr Comput Aided Drug Des. 2018;14(2):160-173. doi: 10.2174/1573409914666180112100122.
|
| 485 |
Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer.Front Oncol. 2019 Jul 9;9:542. doi: 10.3389/fonc.2019.00542. eCollection 2019.
|
| 486 |
SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1 pathway and Drp1-mediated mitochondrial fission in ovarian cancer.Cancer Lett. 2020 Jan 28;469:89-101. doi: 10.1016/j.canlet.2019.10.029. Epub 2019 Oct 19.
|
| 487 |
Downregulated Salt-inducible Kinase 3 Expression Promotes Chemoresistance in Serous Ovarian Cancer via the ATP-binding Cassette Protein ABCG2.J Cancer. 2019 Oct 15;10(24):6025-6036. doi: 10.7150/jca.34886. eCollection 2019.
|
| 488 |
Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression.Mol Med Rep. 2017 Apr;15(4):1638-1646. doi: 10.3892/mmr.2017.6183. Epub 2017 Feb 8.
|
| 489 |
Human Ovarian Cancer Tissue Exhibits Increase of Mitochondrial Biogenesis and Cristae Remodeling.Cancers (Basel). 2019 Sep 12;11(9):1350. doi: 10.3390/cancers11091350.
|
| 490 |
Comprehensive Analysis of Expression and Prognostic Value of Sirtuins in Ovarian Cancer.Front Genet. 2019 Sep 13;10:879. doi: 10.3389/fgene.2019.00879. eCollection 2019.
|
| 491 |
Mechanism of Low Expression of miR-30a-5p on Epithelial-Mesenchymal Transition and Metastasis in Ovarian Cancer.DNA Cell Biol. 2019 Apr;38(4):341-351. doi: 10.1089/dna.2018.4396. Epub 2019 Mar 6.
|
| 492 |
The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.J Trace Elem Med Biol. 2019 Dec;56:131-138. doi: 10.1016/j.jtemb.2019.07.008. Epub 2019 Aug 19.
|
| 493 |
Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.Gynecol Oncol. 2019 Oct;155(1):58-62. doi: 10.1016/j.ygyno.2019.08.004. Epub 2019 Aug 8.
|
| 494 |
Clinical associations between ASCT2 and pmTOR in the pathogenesis and prognosis of epithelial ovarian cancer.Oncol Rep. 2018 Dec;40(6):3725-3733. doi: 10.3892/or.2018.6729. Epub 2018 Sep 24.
|
| 495 |
Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates.Mol Cancer Ther. 2017 May;16(5):819-830. doi: 10.1158/1535-7163.MCT-16-0444. Epub 2017 Jan 30.
|
| 496 |
SLC6A1-miR133a-CDX2 loop regulates SK-OV-3 ovarian cancer cell proliferation, migration and invasion.Oncol Lett. 2018 Oct;16(4):4977-4983. doi: 10.3892/ol.2018.9273. Epub 2018 Aug 7.
|
| 497 |
Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer. Yonsei Med J. 2017 Jan;58(1):27-34.
|
| 498 |
Antisense lncRNA As-SLC7A11 suppresses epithelial ovarian cancer progression mainly by targeting SLC7A11.Pharmazie. 2017 Jul 3;72(7):402-407. doi: 10.1691/ph.2017.7449.
|
| 499 |
Increased expression of Na(+)/H(+) exchanger isoform 1 predicts tumor aggressiveness and unfavorable prognosis in epithelial ovarian cancer.Oncol Lett. 2018 Nov;16(5):6713-6720. doi: 10.3892/ol.2018.9500. Epub 2018 Sep 25.
|
| 500 |
Circular RNA circ-SMAD7 promoted ovarian cancer cell proliferation and metastasis by suppressing KLF6.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5603-5610. doi: 10.26355/eurrev_201907_18294.
|
| 501 |
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.Int J Cancer. 2020 Mar 15;146(6):1553-1567. doi: 10.1002/ijc.32673. Epub 2019 Oct 30.
|
| 502 |
Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1.Mol Cancer Ther. 2018 Sep;17(9):1941-1950. doi: 10.1158/1535-7163.MCT-17-0822. Epub 2018 Jun 11.
|
| 503 |
Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.Tumour Biol. 2016 Oct;37(10):14259-14269. doi: 10.1007/s13277-016-5290-9. Epub 2016 Aug 31.
|
| 504 |
Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC.Oncogene. 2019 May;38(22):4366-4383. doi: 10.1038/s41388-019-0728-3. Epub 2019 Feb 14.
|
| 505 |
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 Apr;17(4):870-881.
|
| 506 |
Loss of Sprouty2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion.FEBS Lett. 2015 Jan 30;589(3):302-9. doi: 10.1016/j.febslet.2014.12.012. Epub 2014 Dec 20.
|
| 507 |
Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.Gynecol Oncol. 2018 Jul;150(1):143-150. doi: 10.1016/j.ygyno.2018.04.557. Epub 2018 Apr 24.
|
| 508 |
Mining Featured Biomarkers Linked with Epithelial Ovarian CancerBased on Bioinformatics.Diagnostics (Basel). 2019 Apr 9;9(2):39. doi: 10.3390/diagnostics9020039.
|
| 509 |
Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer.Sci Rep. 2019 Sep 26;9(1):13924. doi: 10.1038/s41598-019-50436-1.
|
| 510 |
Decreasing the ratio of matriptase/HAI? by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer.Mol Med Rep. 2016 Aug;14(2):1465-74. doi: 10.3892/mmr.2016.5435. Epub 2016 Jun 23.
|
| 511 |
Stanniocalcin 1 in tumor microenvironment promotes metastasis of ovarian cancer.Onco Targets Ther. 2019 Apr 11;12:2789-2798. doi: 10.2147/OTT.S196150. eCollection 2019.
|
| 512 |
STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.Oncol Rep. 2015 Sep;34(3):1494-502. doi: 10.3892/or.2015.4120. Epub 2015 Jul 9.
|
| 513 |
Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.EMBO Mol Med. 2013 May;5(5):707-22. doi: 10.1002/emmm.201201504. Epub 2013 Apr 22.
|
| 514 |
Expression and clinical significance of SLP-2 in ovarian tumors.Oncol Lett. 2019 May;17(5):4626-4632. doi: 10.3892/ol.2019.10116. Epub 2019 Mar 5.
|
| 515 |
Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis.Cancers (Basel). 2019 Apr 2;11(4):463. doi: 10.3390/cancers11040463.
|
| 516 |
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.Cancer Cell. 2015 Jul 13;28(1):82-96. doi: 10.1016/j.ccell.2015.05.009. Epub 2015 Jun 18.
|
| 517 |
Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells.Exp Ther Med. 2017 Sep;14(3):1947-1952. doi: 10.3892/etm.2017.4788. Epub 2017 Jul 12.
|
| 518 |
Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.Tohoku J Exp Med. 2017 Mar;241(3):239-247. doi: 10.1620/tjem.241.239.
|
| 519 |
Higher Numbers of T-Bet+ Tumor-Infiltrating Lymphocytes Associate with Better Survival in Human Epithelial Ovarian Cancer.Cell Physiol Biochem. 2017;41(2):475-483. doi: 10.1159/000456600. Epub 2017 Jan 30.
|
| 520 |
Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome.J Cell Mol Med. 2017 Mar;21(3):510-518. doi: 10.1111/jcmm.12995. Epub 2016 Nov 7.
|
| 521 |
Screening the molecular targets of ovarian cancer based on bioinformatics analysis.Tumori. 2015 Jul-Aug;101(4):384-9. doi: 10.5301/tj.5000319. Epub 2015 Jul 2.
|
| 522 |
Transforming growth factor-beta isoform expression in human ovarian tumours.Eur J Cancer. 1997 Dec;33(14):2397-403. doi: 10.1016/s0959-8049(97)00304-3.
|
| 523 |
Physical interaction of STAT1 isoforms with TGF- receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer.J Exp Clin Cancer Res. 2018 May 11;37(1):103. doi: 10.1186/s13046-018-0773-8.
|
| 524 |
Extracellular tissue transglutaminase activates noncanonical NF-B signaling and promotes metastasis in ovarian cancer.Neoplasia. 2013 Jun;15(6):609-19. doi: 10.1593/neo.121878.
|
| 525 |
Thrombomodulin mediates the progression of epithelial ovarian cancer cells.Tumour Biol. 2013 Dec;34(6):3743-51. doi: 10.1007/s13277-013-0958-x. Epub 2013 Aug 6.
|
| 526 |
AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma.Cancer Gene Ther. 2020 May;27(5):356-367. doi: 10.1038/s41417-019-0108-8. Epub 2019 Jun 4.
|
| 527 |
Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.Sci Rep. 2018 Sep 4;8(1):13207. doi: 10.1038/s41598-018-31069-2.
|
| 528 |
Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4536-4541.
|
| 529 |
Prognostic values of transketolase family genes in ovarian cancer.Oncol Lett. 2019 Nov;18(5):4845-4857. doi: 10.3892/ol.2019.10818. Epub 2019 Sep 6.
|
| 530 |
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.Clin Cancer Res. 2017 Apr 15;23(8):1955-1966. doi: 10.1158/1078-0432.CCR-16-1453. Epub 2016 Oct 4.
|
| 531 |
Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers.Int J Cancer. 2012 Mar 15;130(6):1314-8. doi: 10.1002/ijc.26134. Epub 2011 May 30.
|
| 532 |
Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.J Exp Clin Cancer Res. 2019 Apr 25;38(1):176. doi: 10.1186/s13046-019-1171-6.
|
| 533 |
Molecular characterization of a novel human brain tumor-associated gene BR-3.Anticancer Res. 2002 May-Jun;22(3):1467-74.
|
| 534 |
Knockdown of HVEM, a Lymphocyte Regulator Gene, in Ovarian Cancer Cells Increases Sensitivity to Activated T Cells.Oncol Res. 2016;24(3):189-96. doi: 10.3727/096504016X14641336229602.
|
| 535 |
TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer.Clin Exp Med. 2018 Nov;18(4):547-554. doi: 10.1007/s10238-018-0508-3. Epub 2018 May 25.
|
| 536 |
High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy.BMC Cancer. 2018 Apr 16;18(1):425. doi: 10.1186/s12885-018-4339-0.
|
| 537 |
Pro-survival effects by NF-B, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.Biomed Pharmacother. 2016 Dec;84:1078-1087. doi: 10.1016/j.biopha.2016.10.028. Epub 2016 Oct 22.
|
| 538 |
TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA.Cancer Lett. 2017 May 1;393:60-67. doi: 10.1016/j.canlet.2017.02.009. Epub 2017 Feb 16.
|
| 539 |
Interferon- produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells.Angiogenesis. 2014 Jul;17(3):529-40. doi: 10.1007/s10456-013-9397-y. Epub 2013 Oct 20.
|
| 540 |
Tankyrase Promotes Aerobic Glycolysis and Proliferation of Ovarian Cancer through Activation of Wnt/-Catenin Signaling.Biomed Res Int. 2019 Feb 20;2019:2686340. doi: 10.1155/2019/2686340. eCollection 2019.
|
| 541 |
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.J Ovarian Res. 2019 Feb 13;12(1):17. doi: 10.1186/s13048-019-0492-6.
|
| 542 |
Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.J Ovarian Res. 2016 Jun 18;9(1):35. doi: 10.1186/s13048-016-0244-9.
|
| 543 |
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.
|
| 544 |
LncRNA TPT1-AS1 promotes tumorigenesis and metastasis in epithelial ovarian cancer by inducing TPT1 expression.Cancer Sci. 2019 May;110(5):1587-1598. doi: 10.1111/cas.14009. Epub 2019 Apr 29.
|
| 545 |
TPX2 gene silencing inhibits cell proliferation and promotes apoptosis through negative regulation of AKT signaling pathway in ovarian cancer.J Cell Biochem. 2018 Sep;119(9):7540-7555. doi: 10.1002/jcb.27065. Epub 2018 Jun 15.
|
| 546 |
Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27.Biomed Pharmacother. 2019 Jan;109:595-601. doi: 10.1016/j.biopha.2018.10.148. Epub 2018 Nov 3.
|
| 547 |
Knockdown of Tripartite Motif Containing 28 suppresses the migration, invasion and epithelial-mesenchymal transition in ovarian carcinoma cells through down-regulation of Wnt/-catenin signaling pathway.Neoplasma. 2017;64(6):893-900. doi: 10.4149/neo_2017_611.
|
| 548 |
Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.Int J Oncol. 2016 Jan;48(1):243-52. doi: 10.3892/ijo.2015.3254. Epub 2015 Nov 19.
|
| 549 |
FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.Endocr Relat Cancer. 2013 May 30;20(3):415-29. doi: 10.1530/ERC-12-0005. Print 2013 Jun.
|
| 550 |
TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.J Exp Clin Cancer Res. 2019 Feb 28;38(1):106. doi: 10.1186/s13046-019-1061-y.
|
| 551 |
Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model.J Cancer. 2018 Aug 6;9(17):3196-3207. doi: 10.7150/jca.20639. eCollection 2018.
|
| 552 |
Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses.Mol Cell Proteomics. 2007 Feb;6(2):294-304. doi: 10.1074/mcp.M600305-MCP200. Epub 2006 Nov 16.
|
| 553 |
MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2.Biol Res. 2019 Apr 3;52(1):18. doi: 10.1186/s40659-019-0219-6.
|
| 554 |
4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.J Ovarian Res. 2014 Oct 11;7:94. doi: 10.1186/s13048-014-0094-2.
|
| 555 |
Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.J Clin Invest. 2017 Dec 1;127(12):4554-4568. doi: 10.1172/JCI92914. Epub 2017 Nov 13.
|
| 556 |
UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-B pathway.Oncogene. 2020 Jan;39(2):322-333. doi: 10.1038/s41388-019-0987-z. Epub 2019 Sep 2.
|
| 557 |
The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948.
|
| 558 |
Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.Genet Mol Res. 2015 Jun 29;14(2):7241-7. doi: 10.4238/2015.June.29.17.
|
| 559 |
Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.PLoS One. 2019 May 15;14(5):e0216553. doi: 10.1371/journal.pone.0216553. eCollection 2019.
|
| 560 |
USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability.Sci Adv. 2019 May 8;5(5):eaav3235. doi: 10.1126/sciadv.aav3235. eCollection 2019 May.
|
| 561 |
Loss of Both USP10 and p14ARF Protein Expression Is an Independent Prognostic Biomarker for Poor Prognosis in Patients With Epithelial Ovarian Cancer.Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):553-562. doi: 10.21873/cgp.20157.
|
| 562 |
Amplification of USP13 drives ovarian cancer metabolism.Nat Commun. 2016 Nov 28;7:13525. doi: 10.1038/ncomms13525.
|
| 563 |
Inhibition of ubiquitinspecific protease14 promotes connexin32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells.Oncol Rep. 2019 Sep;42(3):1237-1247. doi: 10.3892/or.2019.7232. Epub 2019 Jul 15.
|
| 564 |
Ubiquitin specific peptidase 5 promotes ovarian cancer cell proliferation through deubiquitinating HDAC2.Aging (Albany NY). 2019 Nov 13;11(21):9778-9793. doi: 10.18632/aging.102425. Epub 2019 Nov 13.
|
| 565 |
Expression of USP7 and MARCH7 Is Correlated with Poor Prognosis in Epithelial Ovarian Cancer.Tohoku J Exp Med. 2016 Jul;239(3):165-75. doi: 10.1620/tjem.239.165.
|
| 566 |
HLA-G 3' untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer.Sci Rep. 2019 Apr 1;9(1):5407. doi: 10.1038/s41598-019-41900-z.
|
| 567 |
VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.Cancer Immunol Immunother. 2020 Jan;69(1):33-42. doi: 10.1007/s00262-019-02434-5. Epub 2019 Nov 28.
|
| 568 |
Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer.Oncoimmunology. 2019 Sep 30;8(12):e1665460. doi: 10.1080/2162402X.2019.1665460. eCollection 2019.
|
| 569 |
Clinical significance and expression of the PRSS3 and Wiskott-Aldrich syndrome protein family verprolin-homologous protein 1 for the early detection of epithelial ovarian cancer.Tumour Biol. 2016 May;37(5):6769-73. doi: 10.1007/s13277-015-4586-5. Epub 2015 Dec 10.
|
| 570 |
Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.Cancer Treat Rev. 2018 Dec;71:1-7. doi: 10.1016/j.ctrv.2018.09.003. Epub 2018 Sep 11.
|
| 571 |
The Role of Abnormal Methylation of Wnt5a Gene Promoter Regions in Human Epithelial Ovarian Cancer: A Clinical and Experimental Study.Anal Cell Pathol (Amst). 2018 Jul 16;2018:6567081. doi: 10.1155/2018/6567081. eCollection 2018.
|
| 572 |
An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.Oncogene. 2017 Jun 15;36(24):3384-3396. doi: 10.1038/onc.2016.487. Epub 2017 Jan 23.
|
| 573 |
FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.Biochem Pharmacol. 2018 Jan;147:93-103. doi: 10.1016/j.bcp.2017.11.009. Epub 2017 Nov 16.
|
| 574 |
TNFAIP8 promotes cell growth by regulating the Hippo pathway in epithelial ovarian cancer.Exp Ther Med. 2018 Dec;16(6):4975-4982. doi: 10.3892/etm.2018.6819. Epub 2018 Oct 2.
|
| 575 |
Title Prognosis Significance of ZEB2 and TGF-1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer.Int J Gynecol Cancer. 2017 Sep;27(7):1343-1349. doi: 10.1097/IGC.0000000000001037.
|
| 576 |
ZNF217 is associated with poor prognosis and enhances proliferation and metastasis in ovarian cancer.Int J Clin Exp Pathol. 2014 May 15;7(6):3038-47. eCollection 2014.
|
| 577 |
Identification of Potential Biomarkers in Association With Progression and Prognosis in Epithelial Ovarian Cancer by Integrated Bioinformatics Analysis.Front Genet. 2019 Oct 24;10:1031. doi: 10.3389/fgene.2019.01031. eCollection 2019.
|
| 578 |
MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer.Biochem Biophys Res Commun. 2019 Apr 30;512(2):331-337. doi: 10.1016/j.bbrc.2019.03.009. Epub 2019 Mar 16.
|
| 579 |
Co-expression of CD44/MyD88 is a poor prognostic factor in advanced epithelial ovarian cancer.Ann Transl Med. 2019 Mar;7(5):91. doi: 10.21037/atm.2019.01.28.
|
| 580 |
Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.Cancer Gene Ther. 2016 Jul;23(7):229-34. doi: 10.1038/cgt.2016.22. Epub 2016 May 27.
|
| 581 |
Constitutive expression of TGF-bta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma.Eur Cytokine Netw. 2003 Oct-Dec;14(4):246-55.
|
| 582 |
HOXA9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin.Mol Cancer. 2014 Jul 14;13:170. doi: 10.1186/1476-4598-13-170.
|
| 583 |
DLEU1 contributes to ovarian carcinoma tumourigenesis and development by interacting with miR-490-3p and altering CDK1 expression.J Cell Mol Med. 2017 Nov;21(11):3055-3065. doi: 10.1111/jcmm.13217. Epub 2017 Jun 9.
|
| 584 |
Overexpression of Growth-Related Oncogene- Is Associated with Tumorigenesis, Metastasis, and Poor Prognosis in Ovarian Cancer.Dis Markers. 2015;2015:387382. doi: 10.1155/2015/387382. Epub 2015 Apr 30.
|
| 585 |
Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis.Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5331-6. doi: 10.1073/pnas.1317242111. Epub 2014 Mar 24.
|
| 586 |
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.Clin Cancer Res. 2016 Apr 1;22(7):1713-24. doi: 10.1158/1078-0432.CCR-15-1275. Epub 2015 Nov 18.
|
| 587 |
Combined MEK and BCL-2/X(L) Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.Mol Cancer Ther. 2019 Mar;18(3):642-655. doi: 10.1158/1535-7163.MCT-18-0413. Epub 2019 Jan 24.
|
| 588 |
Over-expression of fibroblast activation protein alpha increases tumor growth in xenografts of ovarian cancer cells.Acta Biochim Biophys Sin (Shanghai). 2013 Nov;45(11):928-37. doi: 10.1093/abbs/gmt095. Epub 2013 Sep 12.
|
| 589 |
Genetic and molecular analyses reveal G6PC as a key element connecting glucose metabolism and cell cycle control in ovarian cancer.Tumour Biol. 2015 Sep;36(10):7649-58. doi: 10.1007/s13277-015-3463-6. Epub 2015 Apr 30.
|
| 590 |
Targeted Microbubbles for Ultrasound Mediated Short Hairpin RNA Plasmid Transfection to Inhibit Survivin Gene Expression and Induce Apoptosis of Ovarian Cancer A2780/DDP Cells.Mol Pharm. 2015 Sep 8;12(9):3137-45. doi: 10.1021/mp500835z. Epub 2015 Aug 3.
|
| 591 |
Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion.Mol Ther. 2013 Jan;21(1):78-90. doi: 10.1038/mt.2012.187. Epub 2012 Nov 20.
|
| 592 |
Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.Mol Cell Proteomics. 2014 Nov;13(11):3138-51. doi: 10.1074/mcp.M113.033217. Epub 2014 Aug 5.
|
| 593 |
Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system?.Oncotarget. 2017 Nov 11;8(63):107176-107187. doi: 10.18632/oncotarget.22412. eCollection 2017 Dec 5.
|
| 594 |
Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.Cytokine. 2008 Apr;42(1):77-84. doi: 10.1016/j.cyto.2008.01.011. Epub 2008 Mar 7.
|
| 595 |
PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.Cancer Immunol Res. 2015 Aug;3(8):926-35. doi: 10.1158/2326-6066.CIR-14-0239. Epub 2015 May 8.
|
| 596 |
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.J Cancer Res Clin Oncol. 2019 Apr;145(4):1063-1073. doi: 10.1007/s00432-019-02877-4. Epub 2019 Feb 27.
|
| 597 |
Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.Mol Oncol. 2011 Feb;5(1):48-60. doi: 10.1016/j.molonc.2010.08.002. Epub 2010 Aug 11.
|
| 598 |
Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.PLoS One. 2019 Feb 27;14(2):e0212968. doi: 10.1371/journal.pone.0212968. eCollection 2019.
|
| 599 |
Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.Thromb Haemost. 2009 Mar;101(3):541-6.
|
| 600 |
Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma.Hum Pathol. 2014 Jun;45(6):1285-93. doi: 10.1016/j.humpath.2014.02.008. Epub 2014 Feb 28.
|
| 601 |
Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.APMIS. 2013 Dec;121(12):1177-86. doi: 10.1111/apm.12071. Epub 2013 Apr 18.
|
| 602 |
Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer.Med Oncol. 2014 Aug;31(8):132. doi: 10.1007/s12032-014-0132-3. Epub 2014 Jul 18.
|
| 603 |
Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas.Am J Surg Pathol. 2019 May;43(5):591-600. doi: 10.1097/PAS.0000000000001220.
|
| 604 |
Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case-Control Study in Northern Sweden.Transl Oncol. 2020 Jan;13(1):86-91. doi: 10.1016/j.tranon.2019.09.007. Epub 2019 Dec 2.
|
| 605 |
Notch3 Targeting: A Novel Weapon against Ovarian Cancer Stem Cells.Stem Cells Int. 2019 Jan 6;2019:6264931. doi: 10.1155/2019/6264931. eCollection 2019.
|
| 606 |
NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis.Mol Med Rep. 2016 Jan;13(1):188-96. doi: 10.3892/mmr.2015.4556. Epub 2015 Nov 11.
|
| 607 |
Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer.Oncol Rep. 2015 Sep;34(3):1193-202. doi: 10.3892/or.2015.4113. Epub 2015 Jul 7.
|
| 608 |
Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.Oncotarget. 2016 May 3;7(18):25815-25. doi: 10.18632/oncotarget.8272.
|
| 609 |
Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1.Mol Cancer Res. 2020 Mar;18(3):436-447. doi: 10.1158/1541-7786.MCR-18-1369. Epub 2019 Nov 13.
|
| 610 |
Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.FASEB J. 2019 May;33(5):6596-6608. doi: 10.1096/fj.201802067RR. Epub 2019 Feb 25.
|
| 611 |
MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.Cancer Lett. 2020 Jan 28;469:54-67. doi: 10.1016/j.canlet.2019.10.021. Epub 2019 Oct 17.
|
| 612 |
Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells.Asian Pac J Cancer Prev. 2015;16(8):3325-31. doi: 10.7314/apjcp.2015.16.8.3325.
|
| 613 |
The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.BMC Cancer. 2015 Jun 16;15:471. doi: 10.1186/s12885-015-1435-2.
|
| 614 |
MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells.Oncol Rep. 2015 Jul;34(1):111-20. doi: 10.3892/or.2015.3952. Epub 2015 May 5.
|
| 615 |
Effects of shRNA-mediated knockdown of SPOCK1 on ovarian cancer growth and metastasis.Cell Mol Biol (Noisy-le-grand). 2015 Nov 30;61(7):102-9.
|
| 616 |
Variation in NF-B signaling pathways and survival in invasive epithelial ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1421-7. doi: 10.1158/1055-9965.EPI-13-0962. Epub 2014 Apr 16.
|
| 617 |
Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells.Dev Cell. 2014 May 27;29(4):421-36. doi: 10.1016/j.devcel.2014.03.024. Epub 2014 May 8.
|
| 618 |
Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer.PLoS Genet. 2014 Oct 30;10(10):e1004751. doi: 10.1371/journal.pgen.1004751. eCollection 2014 Oct.
|
| 619 |
The impact of microRNA expression on cellular proliferation.Hum Genet. 2014 Jul;133(7):931-8. doi: 10.1007/s00439-014-1434-4. Epub 2014 Mar 8.
|
| 620 |
GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer.Oncology. 2004;66(5):404-10. doi: 10.1159/000079489.
|
| 621 |
Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy.Gynecol Oncol. 2011 Aug;122(2):361-5. doi: 10.1016/j.ygyno.2011.04.025. Epub 2011 May 13.
|
| 622 |
Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614. doi: 10.1593/neo.09286.
|
| 623 |
Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma.Oncol Rep. 2016 Apr;35(4):2159-70. doi: 10.3892/or.2016.4599. Epub 2016 Jan 28.
|
| 624 |
ATP-binding cassette transporter A7 accelerates epithelial-to-mesenchymal transition in ovarian cancer cells by upregulating the transforming growth factor- signaling pathway.Oncol Lett. 2018 Nov;16(5):5868-5874. doi: 10.3892/ol.2018.9366. Epub 2018 Aug 24.
|
| 625 |
Association of ABC gene profiles with time to progression and resistance in ovarian cancer revealed by bioinformatics analyses.Cancer Med. 2019 Feb;8(2):606-616. doi: 10.1002/cam4.1964. Epub 2019 Jan 22.
|
| 626 |
ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer.Medicine (Baltimore). 2019 May;98(19):e15698. doi: 10.1097/MD.0000000000015698.
|
| 627 |
Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.Invest New Drugs. 2018 Apr;36(2):187-194. doi: 10.1007/s10637-017-0523-3. Epub 2017 Oct 30.
|
| 628 |
miR-139 Controls Viability Of Ovarian Cancer Cells Through Apoptosis Induction And Exosome Shedding Inhibition By Targeting ATP7A.Onco Targets Ther. 2019 Dec 6;12:10727-10737. doi: 10.2147/OTT.S221236. eCollection 2019.
|
| 629 |
A water-soluble polysaccharide from the roots of Polygala tenuifolia suppresses ovarian tumor growth and angiogenesis in vivo.Int J Biol Macromol. 2018 Feb;107(Pt A):713-718. doi: 10.1016/j.ijbiomac.2017.09.043. Epub 2017 Sep 15.
|
| 630 |
A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia.Sci Rep. 2016 Mar 10;6:22811. doi: 10.1038/srep22811.
|
| 631 |
SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer.Neoplasma. 2018 Nov 15;65(6):915-924. doi: 10.4149/neo_2018_180122N48. Epub 2018 Sep 4.
|
| 632 |
GLUT5 increases fructose utilization in ovarian cancer.Onco Targets Ther. 2019 Jul 8;12:5425-5436. doi: 10.2147/OTT.S205522. eCollection 2019.
|
| 633 |
MiRNA-8073 targets ZnT1 to inhibit malignant progression of ovarian cancer.Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6062-6069. doi: 10.26355/eurrev_201907_18419.
|
| 634 |
Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake.Mol Carcinog. 2019 May;58(5):794-807. doi: 10.1002/mc.22971. Epub 2019 Jan 21.
|
| 635 |
Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.J Genet Couns. 2017 Dec;26(6):1280-1291. doi: 10.1007/s10897-017-0108-5. Epub 2017 May 24.
|
| 636 |
Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells.PLoS One. 2018 Jun 21;13(6):e0197404. doi: 10.1371/journal.pone.0197404. eCollection 2018.
|
| 637 |
High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer. PLoS One. 2017 Nov 1;12(11):e0187385.
|
| 638 |
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk.PLoS One. 2015 Jun 19;10(6):e0128106. doi: 10.1371/journal.pone.0128106. eCollection 2015.
|
| 639 |
Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.Gynecol Oncol. 2005 Apr;97(1):110-7. doi: 10.1016/j.ygyno.2004.12.031.
|
| 640 |
Regulation of 3beta-hydroxysteroid dehydrogenase type 1 and type 2 gene expression and function in the human ovarian surface epithelium by cytokines.Mol Hum Reprod. 2009 Jun;15(6):379-92. doi: 10.1093/molehr/gap022.
|
| 641 |
Steroid-converting enzymes in human ovarian carcinomas.Mol Cell Endocrinol. 2009 Mar 25;301(1-2):51-8. doi: 10.1016/j.mce.2008.07.015. Epub 2008 Aug 3.
|
| 642 |
The ABO Blood Group is an Independent Prognostic Factor in Patients with Ovarian Cancer.J Cancer. 2019 Oct 22;10(26):6754-6760. doi: 10.7150/jca.36236. eCollection 2019.
|
| 643 |
ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer.Cancers (Basel). 2019 Oct 14;11(10):1553. doi: 10.3390/cancers11101553.
|
| 644 |
Asparagine Synthetase and Filamin A Have Different Roles in Ovarian Cancer.Front Oncol. 2019 Oct 18;9:1072. doi: 10.3389/fonc.2019.01072. eCollection 2019.
|
| 645 |
Association between EPHX1 polymorphism rs1051740 and the risk of ovarian cancer: a meta-analysis.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2338-2342. doi: 10.1080/21691401.2019.1622551.
|
| 646 |
Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of -catenin.Pathol Res Pract. 2019 Dec;215(12):152681. doi: 10.1016/j.prp.2019.152681. Epub 2019 Oct 3.
|
| 647 |
-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.Gynecol Oncol. 2018 Apr;149(1):163-172. doi: 10.1016/j.ygyno.2018.01.023. Epub 2018 Feb 9.
|
| 648 |
Identification of six new susceptibility loci for invasive epithelial ovarian cancer.Nat Genet. 2015 Feb;47(2):164-71. doi: 10.1038/ng.3185. Epub 2015 Jan 12.
|
| 649 |
The glutathione S-transferase M1 genotype in ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):587-90.
|
| 650 |
FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.Cancer Res. 2018 Mar 1;78(5):1184-1199. doi: 10.1158/0008-5472.CAN-17-2506. Epub 2017 Dec 19.
|
| 651 |
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.Oncology. 2018;94(4):233-242. doi: 10.1159/000485624. Epub 2018 Jan 12.
|
| 652 |
MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK.Oncol Lett. 2017 Jun;13(6):4039-4046. doi: 10.3892/ol.2017.5961. Epub 2017 Mar 31.
|
| 653 |
Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.Medicine (Baltimore). 2018 Apr;97(17):e0098. doi: 10.1097/MD.0000000000010098.
|
| 654 |
Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-beta signalling pathway in epithelial ovarian cancer. Cell Death Dis. 2017 Dec 13;8(12):3214.
|
| 655 |
Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer.Cell Death Dis. 2018 Mar 12;9(3):392. doi: 10.1038/s41419-018-0395-2.
|
| 656 |
Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3/-catenin signaling pathway.J Transl Med. 2019 Jun 6;17(1):190. doi: 10.1186/s12967-019-1932-1.
|
| 657 |
Expression of prostaglandin D synthase in ovarian cancer.Clin Chem Lab Med. 2001 Dec;39(12):1198-203. doi: 10.1515/CCLM.2001.190.
|
| 658 |
Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.Oncol Lett. 2017 Jun;13(6):4047-4054. doi: 10.3892/ol.2017.5969. Epub 2017 Apr 3.
|
| 659 |
Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.Oncotarget. 2017 Jul 18;8(29):46891-46899. doi: 10.18632/oncotarget.16781.
|
| 660 |
A novel p70 S6 kinase-microRNA biogenesis axis mediates multicellular spheroid formation in ovarian cancer progression.Oncotarget. 2016 Jun 21;7(25):38064-38077. doi: 10.18632/oncotarget.9345.
|
| 661 |
Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.Cancer Med. 2019 May;8(5):2503-2513. doi: 10.1002/cam4.1996. Epub 2019 Apr 18.
|
| 662 |
ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.J Pathol. 2020 Feb;250(2):159-169. doi: 10.1002/path.5356. Epub 2019 Dec 3.
|
| 663 |
Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):199-204. doi: 10.1111/j.1742-7843.2011.00802.x. Epub 2011 Oct 25.
|
| 664 |
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.PLoS One. 2016 May 12;11(5):e0155660. doi: 10.1371/journal.pone.0155660. eCollection 2016.
|
| 665 |
Frequent translocations of 11q13.2 and 19p13.2 in ovarian cancer.Genes Chromosomes Cancer. 2014 Jun;53(6):447-53. doi: 10.1002/gcc.22152. Epub 2014 Feb 24.
|
| 666 |
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.Hum Pathol. 2012 Nov;43(11):2062-9. doi: 10.1016/j.humpath.2012.02.016. Epub 2012 May 29.
|
| 667 |
Paradoxical expression of AHCYL1 affecting ovarian carcinogenesis between chickens and women.Exp Biol Med (Maywood). 2012 Jul;237(7):758-67. doi: 10.1258/ebm.2012.011433. Epub 2012 Jul 23.
|
| 668 |
Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer.Cancer Res. 2010 Feb 15;70(4):1616-24. doi: 10.1158/0008-5472.CAN-09-3215. Epub 2010 Jan 26.
|
| 669 |
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.Nat Commun. 2013;4:1627. doi: 10.1038/ncomms2613.
|
| 670 |
ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival.Br J Cancer. 2011 May 10;104(10):1602-10. doi: 10.1038/bjc.2011.117. Epub 2011 Apr 19.
|
| 671 |
ATP11B mediates platinum resistance in ovarian cancer.J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.
|
| 672 |
An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population.Mol Diagn Ther. 2014 Feb;18(1):85-91. doi: 10.1007/s40291-013-0059-y.
|
| 673 |
Common variants at 19p13 are associated with susceptibility to ovarian cancer.Nat Genet. 2010 Oct;42(10):880-4. doi: 10.1038/ng.666. Epub 2010 Sep 19.
|
| 674 |
Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):518-24. doi: 10.1097/PAI.0b013e318284a053.
|
| 675 |
BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment.Gynecol Oncol. 2010 May;117(2):189-97. doi: 10.1016/j.ygyno.2009.12.034. Epub 2010 Feb 26.
|
| 676 |
The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer.Int J Oncol. 2002 Nov;21(5):929-33.
|
| 677 |
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.J Natl Cancer Inst. 2011 Nov 2;103(21):1596-612. doi: 10.1093/jnci/djr372. Epub 2011 Sep 28.
|
| 678 |
Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues.Int J Oncol. 2013 Dec;43(6):1925-34. doi: 10.3892/ijo.2013.2124. Epub 2013 Oct 3.
|
| 679 |
BMPR1B up-regulation via a miRNA binding site variation defines endometriosis susceptibility and CA125 levels.PLoS One. 2013 Dec 5;8(12):e80630. doi: 10.1371/journal.pone.0080630. eCollection 2013.
|
| 680 |
Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence.Front Genet. 2016 Mar 22;7:37. doi: 10.3389/fgene.2016.00037. eCollection 2016.
|
| 681 |
CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.Oncotarget. 2010 Sep;1(5):329-38. doi: 10.18632/oncotarget.165.
|
| 682 |
Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk.Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1131-45. doi: 10.1158/1055-9965.EPI-10-1224. Epub 2011 Mar 29.
|
| 683 |
ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.PLoS Biol. 2011 Sep;9(9):e1001156. doi: 10.1371/journal.pbio.1001156. Epub 2011 Sep 20.
|
| 684 |
CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1/CXCR4 axis.Mol Cancer. 2013 Oct 5;12(1):115. doi: 10.1186/1476-4598-12-115.
|
| 685 |
Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer.Tumour Biol. 2013 Oct;34(5):2971-5. doi: 10.1007/s13277-013-0860-6. Epub 2013 May 28.
|
| 686 |
Human chorionic gonadotropin beta subunit genes CGB1 and CGB2 are transcriptionally active in ovarian cancer.Int J Mol Sci. 2013 Jun 17;14(6):12650-60. doi: 10.3390/ijms140612650.
|
| 687 |
Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.Br J Cancer. 2012 Jan 3;106(1):189-98. doi: 10.1038/bjc.2011.510. Epub 2011 Nov 22.
|
| 688 |
Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
|
| 689 |
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.Nat Genet. 2013 Apr;45(4):362-70, 370e1-2. doi: 10.1038/ng.2564.
|
| 690 |
CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.Tumour Biol. 2012 Dec;33(6):2299-306. doi: 10.1007/s13277-012-0492-2. Epub 2012 Aug 25.
|
| 691 |
Potential molecular signatures in epithelial ovarian cancer by genome wide expression profiling.Asia Pac J Clin Oncol. 2016 Jun;12(2):e259-68. doi: 10.1111/ajco.12182. Epub 2014 Mar 27.
|
| 692 |
Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers.PLoS One. 2011;6(9):e24987. doi: 10.1371/journal.pone.0024987. Epub 2011 Sep 15.
|
| 693 |
CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells.Eur J Pharmacol. 2011 Nov 16;670(1):96-104. doi: 10.1016/j.ejphar.2011.08.006. Epub 2011 Sep 3.
|
| 694 |
EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo.Cancer Sci. 2011 Mar;102(3):530-9. doi: 10.1111/j.1349-7006.2010.01836.x. Epub 2011 Jan 18.
|
| 695 |
Flaxseed enriched diet-mediated reduction in ovarian cancer severity is correlated to the reduction of prostaglandin E(2) in laying hen ovaries.Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):179-87. doi: 10.1016/j.plefa.2013.08.001. Epub 2013 Aug 14.
|
| 696 |
Expression and biological role of -catenin in human ovarian cancer.J Cancer Res Clin Oncol. 2012 Oct;138(10):1769-76. doi: 10.1007/s00432-012-1257-4. Epub 2012 Jun 15.
|
| 697 |
Cytotoxicity of Nubein6.8 peptide isolated from the snake venom of Naja nubiae on melanoma and ovarian carcinoma cell lines.Toxicon. 2019 Oct;168:22-31. doi: 10.1016/j.toxicon.2019.06.220. Epub 2019 Jun 21.
|
| 698 |
Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.Cancer Res. 2010 Nov 15;70(22):9197-206. doi: 10.1158/0008-5472.CAN-10-1568. Epub 2010 Nov 2.
|
| 699 |
Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis.Lab Invest. 2001 Jun;81(6):863-73. doi: 10.1038/labinvest.3780295.
|
| 700 |
Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.Gynecol Oncol. 2013 Aug;130(2):369-76. doi: 10.1016/j.ygyno.2013.05.002. Epub 2013 May 14.
|
| 701 |
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.Clin Cancer Res. 2011 Jun 15;17(12):4052-62. doi: 10.1158/1078-0432.CCR-10-3021. Epub 2011 Apr 1.
|
| 702 |
Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.Neoplasia. 2010 Jul;12(7):579-89. doi: 10.1593/neo.10340.
|
| 703 |
Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.Cancer Res. 2010 Dec 1;70(23):9979-90. doi: 10.1158/0008-5472.CAN-10-2394. Epub 2010 Nov 30.
|
| 704 |
Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization.Oncogene. 2011 Jun 23;30(25):2874-87. doi: 10.1038/onc.2011.11. Epub 2011 Feb 21.
|
| 705 |
Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours.Cancer Immunol Immunother. 2013 Aug;62(8):1411-9. doi: 10.1007/s00262-013-1445-3. Epub 2013 Jun 7.
|
| 706 |
C4orf7 contributes to ovarian cancer metastasis by promoting cancer cell migration and invasion.Oncol Rep. 2010 Oct;24(4):933-9.
|
| 707 |
Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.Biochem Biophys Res Commun. 2014 Mar 28;446(1):187-94. doi: 10.1016/j.bbrc.2014.02.087. Epub 2014 Feb 27.
|
| 708 |
Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer.Virchows Arch. 2011 Sep;459(3):255-63. doi: 10.1007/s00428-011-1135-5. Epub 2011 Aug 5.
|
| 709 |
Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):600-4. doi: 10.1158/1055-9965.EPI-09-0861.
|
| 710 |
Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA.Folia Biol (Praha). 2012;58(6):246-50.
|
| 711 |
High GMFG expression correlates with poor prognosis and promotes cell migration and invasion in epithelial ovarian cancer.Gynecol Oncol. 2014 Mar;132(3):745-51. doi: 10.1016/j.ygyno.2014.01.044. Epub 2014 Jan 31.
|
| 712 |
Suppression of GNAI2 message in ovarian cancer.J Ovarian Res. 2014 Jan 14;7:6. doi: 10.1186/1757-2215-7-6.
|
| 713 |
Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC).Curr Pharm Des. 2014;20(11):1904-16. doi: 10.2174/13816128113199990530.
|
| 714 |
Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism?.Med Hypotheses. 2013 Oct;81(4):515-20. doi: 10.1016/j.mehy.2013.06.009. Epub 2013 Jul 20.
|
| 715 |
Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma.Cancer Lett. 2013 Apr 28;330(2):123-9. doi: 10.1016/j.canlet.2012.07.001. Epub 2012 Jul 7.
|
| 716 |
Loss of HOXD10 expression induced by upregulation of miR-10b accelerates the migration and invasion activities of ovarian cancer cells.Int J Oncol. 2013 Jul;43(1):63-71. doi: 10.3892/ijo.2013.1935. Epub 2013 May 13.
|
| 717 |
Low penetrance alleles as risk modifiers in familial and sporadic breast cancer.Fam Cancer. 2012 Dec;11(4):629-36. doi: 10.1007/s10689-012-9563-1.
|
| 718 |
Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.PLoS One. 2011;6(6):e20705. doi: 10.1371/journal.pone.0020705. Epub 2011 Jun 10.
|
| 719 |
Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.PLoS One. 2011;6(12):e28141. doi: 10.1371/journal.pone.0028141. Epub 2011 Dec 7.
|
| 720 |
The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment.Clin Cancer Res. 2013 Sep 1;19(17):4611-20. doi: 10.1158/1078-0432.CCR-13-0568. Epub 2013 Jul 19.
|
| 721 |
Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.Int J Cancer. 2012 Apr 15;130(8):1787-97. doi: 10.1002/ijc.26190. Epub 2011 Aug 16.
|
| 722 |
Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.FASEB J. 2013 Oct;27(10):4244-53. doi: 10.1096/fj.13-230441. Epub 2013 Jul 3.
|
| 723 |
Transformation of human ovarian surface epithelial cells by Krppel-like factor 8.Oncogene. 2014 Jan 2;33(1):10-8. doi: 10.1038/onc.2012.545. Epub 2012 Dec 10.
|
| 724 |
Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.Arch Gynecol Obstet. 2014 Jul;290(1):149-54. doi: 10.1007/s00404-014-3177-9. Epub 2014 Feb 21.
|
| 725 |
Clinical significance of galectin-7 in epithelial ovarian cancer.Anticancer Res. 2013 Apr;33(4):1555-61.
|
| 726 |
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):745-50. doi: 10.1073/pnas.1016538108. Epub 2010 Dec 27.
|
| 727 |
Identification of LMX1B as a novel oncogene in human ovarian cancer.Oncogene. 2014 Aug 14;33(33):4226-35. doi: 10.1038/onc.2013.375. Epub 2013 Sep 23.
|
| 728 |
Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.Mol Cancer Ther. 2013 Jun;12(6):937-49. doi: 10.1158/1535-7163.MCT-12-1082. Epub 2013 Mar 27.
|
| 729 |
Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.Cancer Sci. 2014 May;105(5):545-52. doi: 10.1111/cas.12390. Epub 2014 Apr 7.
|
| 730 |
DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11.Epigenetics. 2013 Aug;8(8):849-63. doi: 10.4161/epi.25500. Epub 2013 Jul 9.
|
| 731 |
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.Int J Cancer. 2010 Mar 15;126(6):1378-89. doi: 10.1002/ijc.24797.
|
| 732 |
Knockdown of mediator complex subunit 19 inhibits the growth of ovarian cancer.Mol Med Rep. 2012 Nov;6(5):1050-6. doi: 10.3892/mmr.2012.1065. Epub 2012 Sep 5.
|
| 733 |
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.Gynecol Oncol. 2013 Aug;130(2):377-82. doi: 10.1016/j.ygyno.2013.04.054. Epub 2013 Apr 28.
|
| 734 |
Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.Mod Pathol. 2012 Dec;25(12):1644-53. doi: 10.1038/modpathol.2012.118. Epub 2012 Jul 13.
|
| 735 |
Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.Acta Pharmacol Sin. 2013 Apr;34(4):541-8. doi: 10.1038/aps.2012.197. Epub 2013 Mar 11.
|
| 736 |
NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.Mol Cancer Res. 2013 Apr;11(4):360-9. doi: 10.1158/1541-7786.MCR-12-0661. Epub 2013 Jan 29.
|
| 737 |
Common variation in Nemo-like kinase is associated with risk of ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):523-8. doi: 10.1158/1055-9965.EPI-11-0797. Epub 2012 Jan 17.
|
| 738 |
miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.Mol Cancer Res. 2013 Nov;11(11):1314-25. doi: 10.1158/1541-7786.MCR-13-0131. Epub 2013 Sep 17.
|
| 739 |
Expression and functional pathway analysis of nuclear receptor NR2F2 in ovarian cancer.J Clin Endocrinol Metab. 2013 Jul;98(7):E1152-62. doi: 10.1210/jc.2013-1081. Epub 2013 May 20.
|
| 740 |
Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment.Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16348-53. doi: 10.1073/pnas.1205226109. Epub 2012 Sep 17.
|
| 741 |
PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer.J Transl Med. 2012 Feb 27;10:31. doi: 10.1186/1479-5876-10-31.
|
| 742 |
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.Gynecol Oncol. 2011 Jan;120(1):113-20. doi: 10.1016/j.ygyno.2010.09.019. Epub 2010 Nov 6.
|
| 743 |
PES1 differentially regulates the expression of ER and ER in ovarian cancer.IUBMB Life. 2013 Dec;65(12):1017-25. doi: 10.1002/iub.1228. Epub 2013 Nov 24.
|
| 744 |
PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage.Cell Signal. 2013 Jan;25(1):74-84. doi: 10.1016/j.cellsig.2012.09.009. Epub 2012 Sep 11.
|
| 745 |
Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.BMC Cancer. 2010 Nov 8;10:611. doi: 10.1186/1471-2407-10-611.
|
| 746 |
Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer.BMC Cancer. 2011 Jun 25;11:270. doi: 10.1186/1471-2407-11-270.
|
| 747 |
iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.Clin Cancer Res. 2011 Nov 1;17(21):6924-33. doi: 10.1158/1078-0432.CCR-11-0588. Epub 2011 Sep 16.
|
| 748 |
Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.J Biol Chem. 2013 Nov 15;288(46):33387-97. doi: 10.1074/jbc.M113.485581. Epub 2013 Oct 4.
|
| 749 |
Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1-related epidermal growth factor signaling pathway.Cancer Sci. 2010 Jun;101(6):1454-62. doi: 10.1111/j.1349-7006.2010.01558.x. Epub 2010 Mar 10.
|
| 750 |
RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation.Mol Cancer Res. 2012 Sep;10(9):1169-77. doi: 10.1158/1541-7786.MCR-12-0331. Epub 2012 Jul 13.
|
| 751 |
Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways.PLoS One. 2013 Nov 11;8(11):e79117. doi: 10.1371/journal.pone.0079117. eCollection 2013.
|
| 752 |
Mutation analysis of the SHFM1 gene in breast/ovarian cancer families.J Cancer Res Clin Oncol. 2013 Mar;139(3):529-32. doi: 10.1007/s00432-013-1385-5. Epub 2013 Feb 1.
|
| 753 |
Smad4 deletion in blood vessel endothelial cells promotes ovarian cancer metastasis.Int J Oncol. 2017 May;50(5):1693-1700. doi: 10.3892/ijo.2017.3957. Epub 2017 Apr 7.
|
| 754 |
Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.Biochem Biophys Res Commun. 2013 Sep 20;439(2):187-90. doi: 10.1016/j.bbrc.2013.08.065. Epub 2013 Aug 29.
|
| 755 |
ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study.Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):245-50. doi: 10.1158/1055-9965.EPI-09-0729.
|
| 756 |
TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.Diagn Pathol. 2017 Feb 2;12(1):16. doi: 10.1186/s13000-017-0605-8.
|
| 757 |
Frequent hypermethylation and loss of heterozygosity of the testis derived transcript gene in ovarian cancer.Cancer Sci. 2010 May;101(5):1255-60. doi: 10.1111/j.1349-7006.2010.01497.x. Epub 2010 Jan 18.
|
| 758 |
Transcriptional regulation of hTREX84 in human cancer cells.PLoS One. 2012;7(8):e43610. doi: 10.1371/journal.pone.0043610. Epub 2012 Aug 27.
|
| 759 |
Inhibitory effect of soluble EP2 receptor on ovarian tumor growth in nude mice and utility of TMPRSS4 as a combinatorial molecular target.Int J Oncol. 2013 Aug;43(2):416-24. doi: 10.3892/ijo.2013.1957. Epub 2013 May 24.
|
| 760 |
Thymosin 10 expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production.PLoS One. 2012;7(5):e35399. doi: 10.1371/journal.pone.0035399. Epub 2012 May 18.
|
| 761 |
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.BMC Cancer. 2012 May 14;12:176. doi: 10.1186/1471-2407-12-176.
|
| 762 |
Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.Cancer Immunol Immunother. 2012 May;61(5):615-28. doi: 10.1007/s00262-011-1122-3. Epub 2011 Oct 22.
|
| 763 |
Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer.PLoS One. 2011;6(7):e21546. doi: 10.1371/journal.pone.0021546. Epub 2011 Jul 7.
|
| 764 |
STAMP alters the growth of transformed and ovarian cancer cells.BMC Cancer. 2010 Apr 7;10:128. doi: 10.1186/1471-2407-10-128.
|
| 765 |
Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women.Nat Commun. 2014 Aug 19;5:4682. doi: 10.1038/ncomms5682.
|
| 766 |
Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility.Tumour Biol. 2014 Apr;35(4):3385-9. doi: 10.1007/s13277-013-1446-z. Epub 2013 Nov 28.
|
| 767 |
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.Asian Pac J Cancer Prev. 2019 Oct 1;20(10):3001-3005. doi: 10.31557/APJCP.2019.20.10.3001.
|
| 768 |
Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer.Biomed Res Int. 2014;2014:159459. doi: 10.1155/2014/159459. Epub 2014 Jul 9.
|
| 769 |
Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer.BMC Cancer. 2014 Aug 27;14:620. doi: 10.1186/1471-2407-14-620.
|
| 770 |
OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer.Int J Oncol. 2006 Oct;29(4):903-10.
|
| 771 |
Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF-induced apoptosis of ovarian cancer cells OV-90.FEBS Lett. 2006 Jan 9;580(1):245-50. doi: 10.1016/j.febslet.2005.12.005. Epub 2005 Dec 12.
|
| 772 |
Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.Clin Cancer Res. 2007 Dec 15;13(24):7370-9. doi: 10.1158/1078-0432.CCR-07-0747.
|
| 773 |
A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer.Gynecol Oncol. 2005 Oct;99(1):183-8. doi: 10.1016/j.ygyno.2005.06.006.
|
| 774 |
Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.Cancer Res. 2008 Jul 1;68(13):5067-75. doi: 10.1158/0008-5472.CAN-08-0062.
|
| 775 |
p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance.Cancer Res. 2006 Dec 1;66(23):11432-40. doi: 10.1158/0008-5472.CAN-06-1867.
|
| 776 |
Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study.BMC Cancer. 2007 Apr 5;7:60. doi: 10.1186/1471-2407-7-60.
|
| 777 |
Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.Cancer Res. 2007 Jul 1;67(13):6100-5. doi: 10.1158/0008-5472.CAN-07-0369.
|
| 778 |
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct 1;17(19):6356-66. doi: 10.1158/1078-0432.CCR-11-0735. Epub 2011 Aug 17.
|
| 779 |
Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.Cancer. 2005 Dec 1;104(11):2417-29. doi: 10.1002/cncr.21538.
|
| 780 |
Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer.Oncogene. 2005 Jul 28;24(32):5089-100. doi: 10.1038/sj.onc.1208700.
|
| 781 |
BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer.J Cell Biochem. 2020 Mar;121(3):2643-2654. doi: 10.1002/jcb.29485. Epub 2019 Nov 6.
|
| 782 |
BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.Br J Cancer. 2009 Aug 4;101(3):504-10. doi: 10.1038/sj.bjc.6605161. Epub 2009 Jul 14.
|
| 783 |
Mechanisms of Cables 1 gene inactivation in human ovarian cancer development.Cancer Biol Ther. 2008 Feb;7(2):180-88. doi: 10.4161/cbt.7.2.5253. Epub 2007 Nov 15.
|
| 784 |
Distribution of microsatellite instability in Danish ovarian tumor patients and the prognostic value in ovarian cancer patients.Oncol Res. 2008;17(1):43-9. doi: 10.3727/096504008784046090.
|
| 785 |
Tumor-associated alterations in caspase-14 expression in epithelial malignancies.Clin Cancer Res. 2005 Aug 1;11(15):5462-71. doi: 10.1158/1078-0432.CCR-04-2527.
|
| 786 |
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.Cancer Cell. 2007 Jun;11(6):498-512. doi: 10.1016/j.ccr.2007.04.011.
|
| 787 |
Overexpression of CHP2 enhances tumor cell growth, invasion and metastasis in ovarian cancer.In Vivo. 2007 Jul-Aug;21(4):593-8.
|
| 788 |
Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer.Int J Gynecol Cancer. 2009 May;19(4):513-25. doi: 10.1111/IGC.0b013e3181a3cd38.
|
| 789 |
Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers.Cancer Biol Ther. 2005 Dec;4(12):1409-14. doi: 10.4161/cbt.4.12.2378. Epub 2005 Dec 5.
|
| 790 |
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
|
| 791 |
Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells.Clin Cancer Res. 2007 Oct 1;13(19):5889-96. doi: 10.1158/1078-0432.CCR-07-0703.
|
| 792 |
ERCC5 is a novel biomarker of ovarian cancer prognosis.J Clin Oncol. 2008 Jun 20;26(18):2952-8. doi: 10.1200/JCO.2007.13.5806.
|
| 793 |
Molecular pathogenesis of Fanconi anemia: recent progress.Blood. 2006 Jun 1;107(11):4223-33. doi: 10.1182/blood-2005-10-4240. Epub 2006 Feb 21.
|
| 794 |
From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer.Int J Cancer. 2006 Apr 1;118(7):1750-8. doi: 10.1002/ijc.21521.
|
| 795 |
Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer.Br J Cancer. 2009 Oct 20;101(8):1433-43. doi: 10.1038/sj.bjc.6605316. Epub 2009 Sep 15.
|
| 796 |
Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression.Med Mol Morphol. 2009 Jun;42(2):82-91. doi: 10.1007/s00795-008-0436-5. Epub 2009 Jun 18.
|
| 797 |
Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors.Int J Oncol. 2005 Jun;26(6):1621-7. doi: 10.3892/ijo.26.6.1621.
|
| 798 |
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.Cancer. 2009 Feb 15;115(4):800-11. doi: 10.1002/cncr.24048.
|
| 799 |
Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer.Clin Biochem. 2008 May;41(7-8):561-9. doi: 10.1016/j.clinbiochem.2008.01.004. Epub 2008 Jan 16.
|
| 800 |
Epigenetic and genetic alterations of p33ING1b in ovarian cancer.Carcinogenesis. 2005 Apr;26(4):855-63. doi: 10.1093/carcin/bgi011. Epub 2005 Jan 27.
|
| 801 |
Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro.J Exp Clin Cancer Res. 2008 Nov 27;27(1):77. doi: 10.1186/1756-9966-27-77.
|
| 802 |
Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.Int J Cancer. 2009 May 15;124(10):2353-60. doi: 10.1002/ijc.24214.
|
| 803 |
Mutation and expression analysis of LZTS1 in ovarian cancer.Cancer Lett. 2006 Feb 20;233(1):151-7. doi: 10.1016/j.canlet.2005.03.008.
|
| 804 |
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.Cancer Cell. 2009 Dec 8;16(6):521-32. doi: 10.1016/j.ccr.2009.10.018.
|
| 805 |
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.Hum Mol Genet. 2009 Jun 15;18(12):2297-304. doi: 10.1093/hmg/ddp138. Epub 2009 Mar 20.
|
| 806 |
The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO.Cancer Biol Ther. 2008 Sep;7(9):1460-7. doi: 10.4161/cbt.7.9.6427. Epub 2008 Sep 11.
|
| 807 |
Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.BMC Cancer. 2009 Jun 6;9:170. doi: 10.1186/1471-2407-9-170.
|
| 808 |
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.Br J Cancer. 2009 Mar 24;100(6):993-1001. doi: 10.1038/sj.bjc.6604947. Epub 2009 Feb 24.
|
| 809 |
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.Br J Cancer. 2005 Apr 25;92(8):1561-73. doi: 10.1038/sj.bjc.6602480.
|
| 810 |
PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival.Cancer Res. 2008 Nov 15;68(22):9302-10. doi: 10.1158/0008-5472.CAN-08-2592.
|
| 811 |
SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancer.Int J Cancer. 2005 Sep 10;116(4):547-54. doi: 10.1002/ijc.20912.
|
| 812 |
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.Br J Cancer. 2009 Oct 20;101(8):1461-8. doi: 10.1038/sj.bjc.6605284. Epub 2009 Sep 8.
|
| 813 |
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.Gynecol Oncol. 2009 Nov;115(2):193-8. doi: 10.1016/j.ygyno.2009.07.009. Epub 2009 Aug 21.
|
| 814 |
L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells.Gynecol Oncol. 2007 Feb;104(2):461-9. doi: 10.1016/j.ygyno.2006.08.038. Epub 2006 Oct 9.
|
| 815 |
Decreased expression of RIZ1 and its clinicopathological significance in epithelial ovarian carcinoma: correlation with epigenetic inactivation by aberrant DNA methylation.Pathol Int. 2007 Nov;57(11):725-33. doi: 10.1111/j.1440-1827.2007.02169.x.
|
| 816 |
Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.Clin Cancer Res. 2004 Jul 15;10(14):4652-60. doi: 10.1158/1078-0432.CCR-03-0439.
|
| 817 |
Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2.Mol Carcinog. 2005 Jul;43(3):141-54. doi: 10.1002/mc.20096.
|
| 818 |
Histone modifications silence the GATA transcription factor genes in ovarian cancer.Oncogene. 2006 Aug 31;25(39):5446-61. doi: 10.1038/sj.onc.1209533. Epub 2006 Apr 10.
|
| 819 |
The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D.Blood. 2009 Jul 9;114(2):310-7. doi: 10.1182/blood-2008-12-196287. Epub 2009 May 12.
|
| 820 |
Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer.Autophagy. 2008 Nov;4(8):1067-8. doi: 10.4161/auto.6827. Epub 2008 Nov 20.
|
| 821 |
Efficient antiproliferative and antiangiogenic effects on human ovarian cancer growth by gene transfer of attenuated mutants of Shiga-like toxin I.Int J Gynecol Cancer. 2008 Jul-Aug;18(4):677-91. doi: 10.1111/j.1525-1438.2007.01090.x. Epub 2007 Oct 18.
|
| 822 |
Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.J Physiol Pharmacol. 2008 Sep;59 Suppl 4:53-65.
|
| 823 |
Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer.Eur J Cancer. 2006 Oct;42(15):2647-52. doi: 10.1016/j.ejca.2006.05.030. Epub 2006 Aug 23.
|
| 824 |
Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.Int J Cancer. 2005 Dec 20;117(6):1049-54. doi: 10.1002/ijc.21250.
|
| 825 |
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16472-7. doi: 10.1073/pnas.0605752103. Epub 2006 Oct 23.
|
| 826 |
Circular RNA ABCB10 correlates with advanced clinicopathological features and unfavorable survival, and promotes cell proliferation while reduces cell apoptosis in epithelial ovarian cancer.Cancer Biomark. 2019;26(2):151-161. doi: 10.3233/CBM-190064.
|
| 827 |
lncRNA ABHD11-AS1, regulated by the EGFR pathway, contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2.Cancer Med. 2019 Nov;8(16):7074-7085. doi: 10.1002/cam4.2586. Epub 2019 Sep 30.
|
| 828 |
Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer.Oncotarget. 2016 Jul 26;7(30):47620-47636. doi: 10.18632/oncotarget.9951.
|
| 829 |
Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk.Cancer Res. 2019 Feb 1;79(3):505-517. doi: 10.1158/0008-5472.CAN-18-2726. Epub 2018 Dec 17.
|
| 830 |
Inhibitory short peptides targeting EPS8/ABI1/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells.BMC Cancer. 2019 Sep 5;19(1):878. doi: 10.1186/s12885-019-6087-1.
|
| 831 |
ACTL6A regulates follicle-stimulating hormone-driven glycolysis in ovarian cancer cells via PGK1.Cell Death Dis. 2019 Oct 24;10(11):811. doi: 10.1038/s41419-019-2050-y.
|
| 832 |
Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance.Mod Pathol. 2009 Apr;22(4):499-507. doi: 10.1038/modpathol.2008.234. Epub 2009 Jan 16.
|
| 833 |
MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci. 2011 Feb 1;124(Pt 3):359-68. doi: 10.1242/jcs.072223. Epub 2011 Jan 11.
|
| 834 |
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.Lab Invest. 2010 Mar;90(3):414-25. doi: 10.1038/labinvest.2009.138. Epub 2010 Jan 11.
|
| 835 |
Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival.Pathol Res Pract. 2018 Aug;214(8):1115-1122. doi: 10.1016/j.prp.2018.06.007. Epub 2018 Jun 12.
|
| 836 |
Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.Oncotarget. 2016 Nov 8;7(45):72381-72394. doi: 10.18632/oncotarget.10546.
|
| 837 |
MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.Neoplasia. 2019 Feb;21(2):206-215. doi: 10.1016/j.neo.2018.12.005. Epub 2019 Jan 9.
|
| 838 |
Expression of orphan GPR56 correlates with tumor progression in human epithelial ovarian cancer.Neoplasma. 2017;64(1):32-39. doi: 10.4149/neo_2017_104.
|
| 839 |
Expression of Adiponectin Receptor-1 and Prognosis of Epithelial Ovarian Cancer Patients.Med Sci Monit. 2017 Mar 30;23:1514-1521. doi: 10.12659/msm.899990.
|
| 840 |
Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.EBioMedicine. 2019 Dec;50:191-202. doi: 10.1016/j.ebiom.2019.11.009. Epub 2019 Nov 22.
|
| 841 |
EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.Cell Biochem Biophys. 2015 Jan;71(1):105-12. doi: 10.1007/s12013-014-0168-1.
|
| 842 |
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.J Ovarian Res. 2017 Aug 7;10(1):53. doi: 10.1186/s13048-017-0347-y.
|
| 843 |
AF6 gene on chromosome band 6q27 maps distal to the minimal region of deletion in epithelial ovarian cancer.Genes Chromosomes Cancer. 1995 Nov;14(3):220-2. doi: 10.1002/gcc.2870140311.
|
| 844 |
High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma.Oncol Lett. 2019 Nov;18(5):4900-4906. doi: 10.3892/ol.2019.10829. Epub 2019 Sep 9.
|
| 845 |
Autophagic degradation of SQSTM1 inhibits ovarian cancer motility by decreasing DICER1 and AGO2 to induce MIRLET7A-3P.Autophagy. 2018;14(12):2065-2082. doi: 10.1080/15548627.2018.1501135. Epub 2018 Aug 17.
|
| 846 |
Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.J Immunol Methods. 2012 Apr 30;378(1-2):20-32. doi: 10.1016/j.jim.2012.01.013. Epub 2012 Feb 15.
|
| 847 |
Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.J Proteome Res. 2015 Apr 3;14(4):1900-10. doi: 10.1021/pr5012894. Epub 2015 Mar 19.
|
| 848 |
Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.PLoS One. 2018 Jul 6;13(7):e0197561. doi: 10.1371/journal.pone.0197561. eCollection 2018.
|
| 849 |
Clinical and biological significance of an isozyme tumor marker--PLAP.Clin Biochem. 1987 Dec;20(6):387-92. doi: 10.1016/0009-9120(87)90003-8.
|
| 850 |
Ovarian cancer detection by DNA methylation in cervical scrapings.Clin Epigenetics. 2019 Nov 27;11(1):166. doi: 10.1186/s13148-019-0773-3.
|
| 851 |
Molecular cloning of differentially expressed genes in human epithelial ovarian cancer.Gynecol Oncol. 1994 Feb;52(2):247-52. doi: 10.1006/gyno.1994.1040.
|
| 852 |
Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.Int J Cancer. 2020 Apr 15;146(8):2147-2155. doi: 10.1002/ijc.32545. Epub 2019 Jul 16.
|
| 853 |
Upregulated Expression of Calcium-Dependent Annexin A6: A Potential Biomarker of Ovarian Carcinoma.Proteomics Clin Appl. 2020 Mar;14(2):e1900078. doi: 10.1002/prca.201900078. Epub 2020 Jan 9.
|
| 854 |
Luteolin promotes the sensitivity of cisplatin in ovarian cancer by decreasing PRPA1-medicated autophagy.Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):17-22.
|
| 855 |
APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.Gynecol Oncol. 2017 Dec;147(3):663-671. doi: 10.1016/j.ygyno.2017.10.016. Epub 2017 Oct 24.
|
| 856 |
APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.Histol Histopathol. 2019 Apr;34(4):405-417. doi: 10.14670/HH-18-050. Epub 2018 Oct 5.
|
| 857 |
CXCL12 promotes human ovarian cancer cell invasion through suppressing ARHGAP10 expression.Biochem Biophys Res Commun. 2019 Oct 20;518(3):416-422. doi: 10.1016/j.bbrc.2019.07.098. Epub 2019 Aug 22.
|
| 858 |
Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.Oncogene. 2019 Sep;38(36):6323-6337. doi: 10.1038/s41388-019-0881-8. Epub 2019 Jul 15.
|
| 859 |
ARID3B Directly Regulates Ovarian Cancer Promoting Genes.PLoS One. 2015 Jun 29;10(6):e0131961. doi: 10.1371/journal.pone.0131961. eCollection 2015.
|
| 860 |
Association of the ARLTS1 variants with familial ovarian cancer risk in China.Int J Gynecol Cancer. 2009 May;19(4):585-90. doi: 10.1111/IGC.0b013e3181a39d03.
|
| 861 |
Uterine and ovarian aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) mRNA expression in benign and malignant gynaecological conditions.Mol Hum Reprod. 2002 Jan;8(1):75-80. doi: 10.1093/molehr/8.1.75.
|
| 862 |
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.Int J Cancer. 2009 Sep 15;125(6):1454-63. doi: 10.1002/ijc.24546.
|
| 863 |
Rare ATAD5 missense variants in breast and ovarian cancer patients.Cancer Lett. 2016 Jun 28;376(1):173-7. doi: 10.1016/j.canlet.2016.03.048. Epub 2016 Apr 1.
|
| 864 |
Upregulation of the lncRNA Meg3 induces autophagy to inhibit tumorigenesis and progression of epithelial ovarian carcinoma by regulating activity of ATG3.Oncotarget. 2017 May 9;8(19):31714-31725. doi: 10.18632/oncotarget.15955.
|
| 865 |
Altered expression of different GalNActransferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.Int J Oncol. 2017 Dec;51(6):1887-1897. doi: 10.3892/ijo.2017.4147. Epub 2017 Oct 9.
|
| 866 |
Pharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort.Pharmacogenomics J. 2019 Feb;19(1):25-32. doi: 10.1038/s41397-018-0056-y. Epub 2018 Oct 5.
|
| 867 |
Downregulation of BAG3 attenuates cisplatin resistance by inhibiting autophagy in human epithelial ovarian cancer cells.Oncol Lett. 2019 Aug;18(2):1969-1978. doi: 10.3892/ol.2019.10494. Epub 2019 Jun 19.
|
| 868 |
MicroRNA-127-3p acts as a tumor suppressor in epithelial ovarian cancer by regulating the BAG5 gene.Oncol Rep. 2016 Nov;36(5):2563-2570. doi: 10.3892/or.2016.5055. Epub 2016 Aug 29.
|
| 869 |
LncRNA HAND2-AS1 exerts anti-oncogenic effects on ovarian cancer via restoration of BCL2L11 as a sponge of microRNA-340-5p.J Cell Physiol. 2019 Dec;234(12):23421-23436. doi: 10.1002/jcp.28911. Epub 2019 Jun 21.
|
| 870 |
The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.J Biol Chem. 2018 Oct 5;293(40):15483-15496. doi: 10.1074/jbc.RA118.004084. Epub 2018 Aug 22.
|
| 871 |
Low BCL7A expression predicts poor prognosis in ovarian cancer.J Ovarian Res. 2019 May 10;12(1):41. doi: 10.1186/s13048-019-0518-0.
|
| 872 |
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.Oncotarget. 2016 Nov 8;7(45):72654-72661. doi: 10.18632/oncotarget.12056.
|
| 873 |
A Dynamic Cis-Regulation Pattern Underlying Epithelial Ovarian Cancer Susceptibility.Cancer Res. 2019 Feb 1;79(3):439-440. doi: 10.1158/0008-5472.CAN-18-3938.
|
| 874 |
MiR-182-5p inhibited proliferation and migration of ovarian cancer cells by targeting BNIP3.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3270-3276. doi: 10.26355/eurrev_201904_17688.
|
| 875 |
Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.Br J Cancer. 2003 Jan 27;88(2):270-6. doi: 10.1038/sj.bjc.6600674.
|
| 876 |
Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer.J Ovarian Res. 2019 Apr 30;12(1):38. doi: 10.1186/s13048-019-0514-4.
|
| 877 |
Oncogene miR-934 promotes ovarian cancer cell proliferation and inhibits cell apoptosis through targeting BRMS1L.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5595-5602. doi: 10.26355/eurrev_201907_18293.
|
| 878 |
CD157: From immunoregulatory protein to potential therapeutic target.Immunol Lett. 2019 Jan;205:59-64. doi: 10.1016/j.imlet.2018.06.007. Epub 2018 Jun 21.
|
| 879 |
BTG3 Overexpression Suppresses the Proliferation and Invasion in Epithelial Ovarian Cancer Cell by Regulating AKT/GSK3/-Catenin Signaling.Reprod Sci. 2017 Oct;24(10):1462-1468. doi: 10.1177/1933719117691143. Epub 2017 Feb 9.
|
| 880 |
Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer.Cancer Res. 1999 Oct 15;59(20):5370-5.
|
| 881 |
The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.Oncogene. 2012 Apr 26;31(17):2175-86. doi: 10.1038/onc.2011.399. Epub 2011 Sep 19.
|
| 882 |
C1GALT1 Seems to Promote In Vitro Disease Progression in Ovarian Cancer.Int J Gynecol Cancer. 2017 Jun;27(5):863-871. doi: 10.1097/IGC.0000000000000965.
|
| 883 |
Knockdown of long non-coding RNA LINC00176 suppresses ovarian cancer progression by BCL3-mediated down-regulation of ceruloplasmin.J Cell Mol Med. 2020 Jan;24(1):202-213. doi: 10.1111/jcmm.14701. Epub 2019 Oct 30.
|
| 884 |
UPLC-MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4-binding protein.Biomed Chromatogr. 2018 May;32(5):e4180. doi: 10.1002/bmc.4180. Epub 2018 Jan 23.
|
| 885 |
It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.Br J Cancer. 2015 Jan 6;112(1):9-13. doi: 10.1038/bjc.2014.594. Epub 2014 Dec 9.
|
| 886 |
CALB1 enhances the interaction between p53 and MDM2, and inhibits the senescence of ovarian cancer cells.Mol Med Rep. 2019 Jun;19(6):5097-5104. doi: 10.3892/mmr.2019.10212. Epub 2019 Apr 30.
|
| 887 |
RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.Int J Cancer. 2016 Jan 1;138(1):217-28. doi: 10.1002/ijc.29690. Epub 2015 Jul 28.
|
| 888 |
L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.PLoS One. 2016 Jan 13;11(1):e0146885. doi: 10.1371/journal.pone.0146885. eCollection 2016.
|
| 889 |
CAP1 is overexpressed in human epithelial ovarian cancer and promotes cell proliferation.Int J Mol Med. 2015 Apr;35(4):941-9. doi: 10.3892/ijmm.2015.2089. Epub 2015 Feb 4.
|
| 890 |
Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.Genet Epidemiol. 2015 Dec;39(8):689-97. doi: 10.1002/gepi.21921. Epub 2015 Sep 24.
|
| 891 |
Capn4 overexpression indicates poor prognosis of ovarian cancer patients.J Cancer. 2018 Jan 1;9(2):304-309. doi: 10.7150/jca.22004. eCollection 2018.
|
| 892 |
A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer.Sci Rep. 2017 Oct 25;7(1):13998. doi: 10.1038/s41598-017-14571-x.
|
| 893 |
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.Expert Opin Biol Ther. 2018 Apr;18(4):359-367. doi: 10.1080/14712598.2018.1425679. Epub 2018 Jan 10.
|
| 894 |
Small molecule inhibition of the CBF/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.Gynecol Oncol. 2018 May;149(2):350-360. doi: 10.1016/j.ygyno.2018.03.005. Epub 2018 Mar 16.
|
| 895 |
CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer.Oncogenesis. 2018 Nov 26;7(11):92. doi: 10.1038/s41389-018-0103-1.
|
| 896 |
Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer.Front Oncol. 2019 Oct 1;9:986. doi: 10.3389/fonc.2019.00986. eCollection 2019.
|
| 897 |
Development of a M cell-targeted microparticulate platform, BSK02? for oral immunization against the ovarian cancer antigen, sperm protein 17.J Biomed Mater Res B Appl Biomater. 2019 Jan;107(1):29-36. doi: 10.1002/jbm.b.34092. Epub 2018 Mar 4.
|
| 898 |
Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.Genome Res. 2002 Jan;12(1):112-21. doi: 10.1101/gr.174202.
|
| 899 |
Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.Eur J Cancer. 2016 Nov;67:152-163. doi: 10.1016/j.ejca.2016.08.007. Epub 2016 Sep 24.
|
| 900 |
CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.Cancer Med. 2019 Jan;8(1):351-362. doi: 10.1002/cam4.1812. Epub 2018 Dec 18.
|
| 901 |
Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/-catenin signaling.Oncogene. 2016 Sep 8;35(36):4816-27. doi: 10.1038/onc.2016.15. Epub 2016 Feb 15.
|
| 902 |
Cyclin I mRNA expression correlates with kinase insert domain receptor expression in human epithelial ovarian cancer.Anticancer Res. 2015 Feb;35(2):1115-9.
|
| 903 |
APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study.Cancer Cell Int. 2018 May 29;18:78. doi: 10.1186/s12935-018-0572-5. eCollection 2018.
|
| 904 |
Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.Cell Rep. 2017 Mar 7;18(10):2343-2358. doi: 10.1016/j.celrep.2017.02.028.
|
| 905 |
Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.Tumour Biol. 2016 Apr;37(4):5455-66. doi: 10.1007/s13277-015-4313-2. Epub 2015 Nov 13.
|
| 906 |
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.Gynecol Oncol. 2019 May;153(2):217-222. doi: 10.1016/j.ygyno.2019.02.011. Epub 2019 Feb 23.
|
| 907 |
The expression of ubiquitin-conjugating enzyme E2C and KAI1 in ovarian carcinoma and their clinical significance.Medicine (Baltimore). 2019 Nov;98(46):e17896. doi: 10.1097/MD.0000000000017896.
|
| 908 |
Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression.Biochem Biophys Res Commun. 2019 Oct 22;518(4):698-705. doi: 10.1016/j.bbrc.2019.08.113. Epub 2019 Aug 28.
|
| 909 |
lncRNA UCA1-Mediated Cdc42 Signaling Promotes Oncolytic Vaccinia Virus Cell-to-Cell Spread in Ovarian Cancer.Mol Ther Oncolytics. 2019 Mar 26;13:35-48. doi: 10.1016/j.omto.2019.03.003. eCollection 2019 Jun 28.
|
| 910 |
Prediction of key genes in ovarian cancer treated with decitabine based on network strategy.Oncol Rep. 2016 Jun;35(6):3548-58. doi: 10.3892/or.2016.4697. Epub 2016 Mar 23.
|
| 911 |
The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy.Tumour Biol. 2016 Mar;37(3):2909-24. doi: 10.1007/s13277-015-4103-x. Epub 2015 Sep 26.
|
| 912 |
MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.Oncogene. 2019 Aug;38(32):6035-6050. doi: 10.1038/s41388-019-0860-0. Epub 2019 Jul 5.
|
| 913 |
MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer.Biomed Pharmacother. 2019 Feb;110:850-856. doi: 10.1016/j.biopha.2018.11.104. Epub 2018 Dec 14.
|
| 914 |
The long non-coding RNA ANRIL promotes proliferation and cell cycle progression and inhibits apoptosis and senescence in epithelial ovarian cancer.Oncotarget. 2016 May 31;7(22):32478-92. doi: 10.18632/oncotarget.8744.
|
| 915 |
CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer.Int J Clin Exp Pathol. 2015 May 1;8(5):4535-44. eCollection 2015.
|
| 916 |
Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer.Cancer Biomark. 2017 Dec 6;20(4):369-387. doi: 10.3233/CBM-170652.
|
| 917 |
CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway.Biomed Pharmacother. 2019 Jun;114:108787. doi: 10.1016/j.biopha.2019.108787. Epub 2019 Mar 27.
|
| 918 |
Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.Tumour Biol. 2016 May;37(5):6239-54. doi: 10.1007/s13277-015-4419-6. Epub 2015 Nov 28.
|
| 919 |
Over-expression of CHAF1A in Epithelial Ovarian Cancer can promote cell proliferation and inhibit cell apoptosis.Biochem Biophys Res Commun. 2017 Apr 22;486(1):191-197. doi: 10.1016/j.bbrc.2017.03.026. Epub 2017 Mar 9.
|
| 920 |
CircRNA UBAP2 promotes the progression of ovarian cancer by sponging microRNA-144.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7283-7294. doi: 10.26355/eurrev_201909_18833.
|
| 921 |
CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.Gynecol Obstet Invest. 2011;72(3):203-7. doi: 10.1159/000323883. Epub 2011 Aug 23.
|
| 922 |
The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.Cell Death Dis. 2018 Jan 24;9(2):93. doi: 10.1038/s41419-017-0137-x.
|
| 923 |
CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells.Endocr Relat Cancer. 2019 Jan 1;26(1):73-88. doi: 10.1530/ERC-18-0300.
|
| 924 |
The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.Cancer Gene Ther. 2012 Aug;19(8):588-91. doi: 10.1038/cgt.2012.33. Epub 2012 Jun 8.
|
| 925 |
CIB2 Negatively Regulates Oncogenic Signaling in Ovarian Cancer via Sphingosine Kinase 1.Cancer Res. 2017 Sep 15;77(18):4823-4834. doi: 10.1158/0008-5472.CAN-17-0025. Epub 2017 Jul 20.
|
| 926 |
MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the CIC transcriptional repressor.Pathol Res Pract. 2019 Oct;215(10):152606. doi: 10.1016/j.prp.2019.152606. Epub 2019 Aug 19.
|
| 927 |
Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.Oncol Rep. 2017 May;37(5):3084-3092. doi: 10.3892/or.2017.5534. Epub 2017 Mar 27.
|
| 928 |
Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis.Int J Biochem Cell Biol. 2013 May;45(5):979-86. doi: 10.1016/j.biocel.2013.02.003. Epub 2013 Feb 14.
|
| 929 |
CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3225-3234. doi: 10.26355/eurrev_201904_17681.
|
| 930 |
MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1.FEBS Lett. 2013 May 2;587(9):1434-9. doi: 10.1016/j.febslet.2013.03.023. Epub 2013 Mar 20.
|
| 931 |
Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element.Cancer Res. 2001 Feb 15;61(4):1291-5.
|
| 932 |
Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts.J Control Release. 2013 Dec 28;172(3):679-89. doi: 10.1016/j.jconrel.2013.10.015. Epub 2013 Oct 18.
|
| 933 |
An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.J Immunother Cancer. 2018 Apr 17;6(1):28. doi: 10.1186/s40425-018-0339-5.
|
| 934 |
Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer.Biol Reprod. 2000 Jun;62(6):1600-9. doi: 10.1095/biolreprod62.6.1600.
|
| 935 |
Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance.Int J Clin Oncol. 2017 Feb;22(1):107-117. doi: 10.1007/s10147-016-1033-6. Epub 2016 Aug 27.
|
| 936 |
Circadian Gene CLOCK Affects Drug-Resistant Gene Expression and Cell Proliferation in Ovarian Cancer SKOV3/DDP Cell Lines Through Autophagy.Cancer Biother Radiopharm. 2017 May;32(4):139-146. doi: 10.1089/cbr.2016.2153.
|
| 937 |
CNDP2 Acts as an Activator for Human Ovarian Cancer Growth and Metastasis via the PI3K/AKT Pathway.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819874773. doi: 10.1177/1533033819874773.
|
| 938 |
Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.Oncogene. 2018 Aug;37(35):4809-4820. doi: 10.1038/s41388-018-0297-x. Epub 2018 May 17.
|
| 939 |
Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2.Mol Cancer Res. 2015 Jan;13(1):78-85. doi: 10.1158/1541-7786.MCR-14-0334. Epub 2014 Aug 28.
|
| 940 |
Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.Oncol Rep. 2019 Jul;42(1):151-175. doi: 10.3892/or.2019.7147. Epub 2019 May 3.
|
| 941 |
Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.PLoS One. 2016 Oct 27;11(10):e0165385. doi: 10.1371/journal.pone.0165385. eCollection 2016.
|
| 942 |
Investigating key genes associated with ovarian cancer by integrating affinity propagation clustering and mutual information network analysis.Eur Rev Med Pharmacol Sci. 2016 Jun;20(12):2532-40.
|
| 943 |
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids.Oncoimmunology. 2019 Jun 4;8(9):e1614856. doi: 10.1080/2162402X.2019.1614856. eCollection 2019.
|
| 944 |
Long noncoding RNA DQ786243 interacts with miR-506 and promotes progression of ovarian cancer through targeting cAMP responsive element binding protein 1.J Cell Biochem. 2018 Dec;119(12):9764-9780. doi: 10.1002/jcb.27295. Epub 2018 Aug 13.
|
| 945 |
CREB5 promotes tumor cell invasion and correlates with poor prognosis in epithelial ovarian cancer.Oncol Lett. 2017 Dec;14(6):8156-8161. doi: 10.3892/ol.2017.7234. Epub 2017 Oct 20.
|
| 946 |
External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.Int J Gynecol Cancer. 2020 Jan;30(1):67-73. doi: 10.1136/ijgc-2019-000561. Epub 2019 Nov 21.
|
| 947 |
circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge.Biomed Pharmacother. 2019 Jun;114:108832. doi: 10.1016/j.biopha.2019.108832. Epub 2019 Apr 11.
|
| 948 |
Transforming growth factor?miR?43?p/cystatin B axis is a therapeutic target in human ovarian cancer.Int J Oncol. 2019 Jul;55(1):267-276. doi: 10.3892/ijo.2019.4815. Epub 2019 May 28.
|
| 949 |
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.
|
| 950 |
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.Gynecol Oncol. 2017 Jun;145(3):420-425. doi: 10.1016/j.ygyno.2017.03.509. Epub 2017 Apr 6.
|
| 951 |
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.Cancer Res. 2003 Sep 15;63(18):6076-83.
|
| 952 |
Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.Mol Pharmacol. 2019 Jul;96(1):99-108. doi: 10.1124/mol.118.114363. Epub 2019 Apr 29.
|
| 953 |
C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.Oncogene. 2013 Aug 15;32(33):3896-903. doi: 10.1038/onc.2012.380. Epub 2012 Sep 3.
|
| 954 |
CTCF promotes epithelial ovarian cancer metastasis by broadly controlling the expression of metastasis-associated genes.Oncotarget. 2017 Jul 10;8(37):62217-62230. doi: 10.18632/oncotarget.19216. eCollection 2017 Sep 22.
|
| 955 |
Correlation of Collagen Triple Helix Repeat Containing 1 Overexpression With Lymph Node and Peritoneal Metastasis in Epithelial Ovarian Cancer.Int J Gynecol Cancer. 2017 Jan;27(1):22-27. doi: 10.1097/IGC.0000000000000850.
|
| 956 |
Amazon Fruits Inhibit Growth and Promote Pro-apoptotic Effects on Human Ovarian Carcinoma Cell Lines.Biomolecules. 2019 Nov 6;9(11):707. doi: 10.3390/biom9110707.
|
| 957 |
Mllerian inhibiting substance inhibits an ovarian cancer cell line via -catenin interacting protein deregulation of the Wnt signal pathway.Int J Oncol. 2017 Mar;50(3):1022-1028. doi: 10.3892/ijo.2017.3874. Epub 2017 Feb 13.
|
| 958 |
Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer.Exp Cell Res. 2017 Aug 1;357(1):124-134. doi: 10.1016/j.yexcr.2017.05.008. Epub 2017 May 10.
|
| 959 |
MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research.BMC Cancer. 2019 Feb 22;19(1):171. doi: 10.1186/s12885-019-5371-4.
|
| 960 |
Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.Mol Oncol. 2013 Jun;7(3):419-27. doi: 10.1016/j.molonc.2012.11.005. Epub 2012 Dec 12.
|
| 961 |
miR?77 targets CUL4A and regulates metastatic capability in ovarian cancer.Int J Mol Med. 2018 Jun;41(6):3147-3156. doi: 10.3892/ijmm.2018.3540. Epub 2018 Mar 7.
|
| 962 |
Expression and biological role of cytoglobin in human ovarian cancer.Tumour Biol. 2014 Jul;35(7):6933-9. doi: 10.1007/s13277-014-1941-x. Epub 2014 Apr 17.
|
| 963 |
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.Eur J Hum Genet. 2017 Apr;25(4):432-438. doi: 10.1038/ejhg.2016.203. Epub 2017 Feb 1.
|
| 964 |
Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.Int J Oncol. 2015 Apr;46(4):1573-81. doi: 10.3892/ijo.2015.2858. Epub 2015 Jan 28.
|
| 965 |
DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p.Pathol Res Pract. 2019 Jul;215(7):152452. doi: 10.1016/j.prp.2019.152452. Epub 2019 May 14.
|
| 966 |
DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy.Sci Rep. 2017 Aug 24;7(1):9285. doi: 10.1038/s41598-017-08249-7.
|
| 967 |
DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway.J Ovarian Res. 2018 Oct 18;11(1):90. doi: 10.1186/s13048-018-0462-4.
|
| 968 |
Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.Eur J Immunol. 2003 Apr;33(4):1030-40. doi: 10.1002/eji.200323185.
|
| 969 |
Cell Cycle Regulator p27 Mediates Body Mass Index Effects in Ovarian Cancer in FIGO-stages I-II.Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):443-450. doi: 10.21873/cgp.20148.
|
| 970 |
DDA1 is induced by NR2F6 in ovarian cancer and predicts poor survival outcome.Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1206-1213.
|
| 971 |
DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1.Cell Death Dis. 2018 May 1;9(5):561. doi: 10.1038/s41419-018-0585-y.
|
| 972 |
Epigenetic down-regulated DDX10 promotes cell proliferation through Akt/NF-B pathway in ovarian cancer.Biochem Biophys Res Commun. 2016 Jan 22;469(4):1000-5. doi: 10.1016/j.bbrc.2015.12.069. Epub 2015 Dec 20.
|
| 973 |
Vitamin D and DDX4 regulate the proliferation and invasion of ovarian cancer cells.Oncol Lett. 2018 Jul;16(1):905-909. doi: 10.3892/ol.2018.8718. Epub 2018 May 16.
|
| 974 |
Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer.Oncol Rep. 2011 Sep;26(3):703-10. doi: 10.3892/or.2011.1337. Epub 2011 Jun 6.
|
| 975 |
Long noncoding RNA SNHG14 enhances migration and invasion of ovarian cancer by upregulating DGCR8.Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10226-10233. doi: 10.26355/eurrev_201912_19659.
|
| 976 |
Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.Epigenetics. 2020 Jan-Feb;15(1-2):122-133. doi: 10.1080/15592294.2019.1656155. Epub 2019 Sep 3.
|
| 977 |
An mDia2/ROCK signaling axis regulates invasive egress from epithelial ovarian cancer spheroids.PLoS One. 2014 Feb 28;9(2):e90371. doi: 10.1371/journal.pone.0090371. eCollection 2014.
|
| 978 |
The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts.Cancer. 2019 Apr 15;125(8):1267-1280. doi: 10.1002/cncr.31935. Epub 2019 Jan 8.
|
| 979 |
Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion.BMC Cancer. 2017 Jun 30;17(1):455. doi: 10.1186/s12885-017-3407-1.
|
| 980 |
Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.J Exp Clin Cancer Res. 2013 Aug 30;32(1):60. doi: 10.1186/1756-9966-32-60.
|
| 981 |
CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer.Epigenomics. 2018 Nov;10(11):1397-1413. doi: 10.2217/epi-2018-0035. Epub 2018 Oct 16.
|
| 982 |
MicroRNA-23a depletion promotes apoptosis of ovarian cancer stem cell and inhibits cell migration by targeting DLG2.Cancer Biol Ther. 2019;20(6):897-911. doi: 10.1080/15384047.2019.1579960. Epub 2019 Mar 12.
|
| 983 |
DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-/SMAD4 signaling.Oncogene. 2017 Mar;36(10):1404-1416. doi: 10.1038/onc.2016.307. Epub 2016 Sep 5.
|
| 984 |
Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers.Clin Cancer Res. 2004 Dec 15;10(24):8501-11. doi: 10.1158/1078-0432.CCR-04-1072.
|
| 985 |
Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.Mol Oncol. 2016 Jun;10(6):789-805. doi: 10.1016/j.molonc.2016.01.003. Epub 2016 Jan 29.
|
| 986 |
Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.Gynecol Oncol. 2005 Jun;97(3):898-903. doi: 10.1016/j.ygyno.2005.03.023.
|
| 987 |
Erratum: Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum].Onco Targets Ther. 2019 Nov 15;12:9793. doi: 10.2147/OTT.S236659. eCollection 2019.
|
| 988 |
Elmo1 helps dock180 to regulate Rac1 activity and cell migration of ovarian cancer.Int J Gynecol Cancer. 2014 Jun;24(5):844-50. doi: 10.1097/IGC.0000000000000137.
|
| 989 |
OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia.Oncol Lett. 2017 May;13(5):2929-2936. doi: 10.3892/ol.2017.5848. Epub 2017 Mar 13.
|
| 990 |
DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.Int J Mol Med. 2018 Dec;42(6):3065-3072. doi: 10.3892/ijmm.2018.3869. Epub 2018 Sep 11.
|
| 991 |
Desmocollin 3 mediates follicle stimulating hormone-induced ovarian epithelial cancer cell proliferation by activating the EGFR/Akt signaling pathway.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6716-23. eCollection 2015.
|
| 992 |
Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes.Oncotarget. 2019 May 21;10(36):3315-3327. eCollection 2019 May 21.
|
| 993 |
Effects of dynein light chain Tctex-type 3 on the biological behavior of ovarian cancer.Cancer Manag Res. 2019 Jul 1;11:5925-5938. doi: 10.2147/CMAR.S205158. eCollection 2019.
|
| 994 |
E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness.Cancer Sci. 2019 Mar;110(3):1085-1095. doi: 10.1111/cas.13920. Epub 2019 Jan 25.
|
| 995 |
Cytoplasmic and membranous receptor-binding cancer antigens expressed on SiSo cells (RCAS1) immunoreactivity in epithelial ovarian cancer cells represent differing biological function of RCAS1.Folia Histochem Cytobiol. 2019;57(3):116-126. doi: 10.5603/FHC.a2019.0012. Epub 2019 Aug 7.
|
| 996 |
The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women.Fam Cancer. 2009;8(4):399-402. doi: 10.1007/s10689-009-9255-7. Epub 2009 Jun 11.
|
| 997 |
Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells.Mol Carcinog. 2016 Jun;55(6):1048-59. doi: 10.1002/mc.22349. Epub 2015 Aug 10.
|
| 998 |
Increased HE4 mRNA Expression Correlates with High Level Of eIF3a mRNA And Better Survival in Women with Epithelial Ovarian Cancer.J Cancer. 2018 Feb 28;9(6):1088-1095. doi: 10.7150/jca.23639. eCollection 2018.
|
| 999 |
Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer.Cancer Res. 2001 May 1;61(9):3806-9.
|
| 1000 |
ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.Oncotarget. 2017 Mar 7;8(10):16951-16963. doi: 10.18632/oncotarget.15208.
|
| 1001 |
ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.Oncol Rep. 2017 Mar;37(3):1412-1418. doi: 10.3892/or.2017.5418. Epub 2017 Feb 2.
|
| 1002 |
NF-B1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.Oncotarget. 2017 Apr 11;8(15):24853-24868. doi: 10.18632/oncotarget.15267.
|
| 1003 |
TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer.Oncol Rep. 2016 Jan;35(1):359-65. doi: 10.3892/or.2015.4388. Epub 2015 Nov 3.
|
| 1004 |
Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.BMC Cancer. 2018 Oct 3;18(1):943. doi: 10.1186/s12885-018-4816-5.
|
| 1005 |
rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.Int J Mol Sci. 2018 Aug 21;19(9):2473. doi: 10.3390/ijms19092473.
|
| 1006 |
circEPSTI1 regulates ovarian cancer progression via decoying miR-942.J Cell Mol Med. 2019 May;23(5):3597-3602. doi: 10.1111/jcmm.14260. Epub 2019 Mar 19.
|
| 1007 |
Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial.Int J Gynecol Cancer. 2017 Jun;27(5):1046-1050. doi: 10.1097/IGC.0000000000000982.
|
| 1008 |
Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.Int J Cancer. 2007 Jan 1;120(1):81-90. doi: 10.1002/ijc.22256.
|
| 1009 |
ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells.Oncogenesis. 2017 Oct 9;6(10):e389. doi: 10.1038/oncsis.2017.87.
|
| 1010 |
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13.
|
| 1011 |
PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.Mol Cancer Res. 2007 May;5(5):413-21. doi: 10.1158/1541-7786.MCR-07-0019. Epub 2007 May 2.
|
| 1012 |
ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.Int J Cancer. 2012 Apr 1;130(7):1532-43. doi: 10.1002/ijc.26148. Epub 2011 Aug 12.
|
| 1013 |
LFG-500, a newly synthesized flavonoid, induces apoptosis in human ovarian carcinoma SKOV3 cells with involvement of the reactive oxygen species-mitochondria pathway.Exp Ther Med. 2017 Jun;13(6):2819-2827. doi: 10.3892/etm.2017.4343. Epub 2017 Apr 18.
|
| 1014 |
TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells.Oncol Lett. 2017 Mar;13(3):1398-1405. doi: 10.3892/ol.2016.5534. Epub 2016 Dec 27.
|
| 1015 |
Loss of the novel mitochondrial protein FAM210B promotes metastasis via PDK4-dependent metabolic reprogramming.Cell Death Dis. 2017 Jun 8;8(6):e2870. doi: 10.1038/cddis.2017.273.
|
| 1016 |
Upregulation of circular RNA circFAM53B predicts adverse prognosis and accelerates the progression of ovarian cancer via the miR?46/VAMP2 and miR?47/MDM2 signaling pathways.Oncol Rep. 2019 Dec;42(6):2728-2737. doi: 10.3892/or.2019.7366. Epub 2019 Oct 10.
|
| 1017 |
The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.Int J Cancer. 2019 Jun 1;144(11):2683-2694. doi: 10.1002/ijc.31992. Epub 2019 Jan 11.
|
| 1018 |
FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.BMC Med Genet. 2018 Jan 19;19(1):12. doi: 10.1186/s12881-018-0524-x.
|
| 1019 |
Dysregulation of fibulin-5 and matrix metalloproteases in epithelial ovarian cancer.Oncotarget. 2018 Feb 14;9(18):14251-14267. doi: 10.18632/oncotarget.24484. eCollection 2018 Mar 6.
|
| 1020 |
Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells.Oncol Rep. 2019 Apr;41(4):2321-2328. doi: 10.3892/or.2019.6986. Epub 2019 Jan 28.
|
| 1021 |
FBXW12, a novel F box protein-encoding gene, is deleted or methylated in some cases of epithelial ovarian cancer.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10192-203. eCollection 2015.
|
| 1022 |
FGF9-induced ovarian cancer cell invasion involves VEGF-A/VEGFR2 augmentation by virtue of ETS1 upregulation and metabolic reprogramming.J Cell Biochem. 2018 Nov;119(10):8174-8189. doi: 10.1002/jcb.26820. Epub 2018 Jun 15.
|
| 1023 |
FGFRL1 Promotes Ovarian Cancer Progression by Crosstalk with Hedgehog Signaling.J Immunol Res. 2018 Feb 20;2018:7438608. doi: 10.1155/2018/7438608. eCollection 2018.
|
| 1024 |
miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer.Cell Death Dis. 2019 May 8;10(5):372. doi: 10.1038/s41419-019-1604-3.
|
| 1025 |
Enhanced antitumor effect of biodegradable cationic heparin-polyethyleneimine nanogels delivering FILIP1LC103 gene combined with low-dose cisplatin on ovarian cancer.Oncotarget. 2017 Jul 22;8(44):76432-76442. doi: 10.18632/oncotarget.19464. eCollection 2017 Sep 29.
|
| 1026 |
Flotillin 1 is differentially expressed in human epithelial ovarian tumors.Neoplasma. 2018;65(4):561-571. doi: 10.4149/neo_2018_170714N483.
|
| 1027 |
Identification of six serum antigens and autoantibodies for the detection of early stage epithelial ovarian carcinoma by bioinformatics analysis and liquid chip analysis.Oncol Lett. 2018 Sep;16(3):3231-3240. doi: 10.3892/ol.2018.9027. Epub 2018 Jun 26.
|
| 1028 |
MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma.Cell Cycle. 2018;17(21-22):2474-2483. doi: 10.1080/15384101.2018.1542898. Epub 2018 Nov 18.
|
| 1029 |
Clinical significance and prognostic value of Forkhead box A1 expression in human epithelial ovarian cancer.Oncol Lett. 2018 Apr;15(4):4457-4462. doi: 10.3892/ol.2018.7899. Epub 2018 Jan 29.
|
| 1030 |
FOXK1 facilitates cell proliferation through regulating the expression of p21, and promotes metastasis in ovarian cancer.Oncotarget. 2017 Jul 31;8(41):70441-70451. doi: 10.18632/oncotarget.19713. eCollection 2017 Sep 19.
|
| 1031 |
The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.Mol Cancer Res. 2015 Mar;13(3):502-9. doi: 10.1158/1541-7786.MCR-14-0407. Epub 2014 Nov 3.
|
| 1032 |
MicroRNA-1 inhibits ovarian cancer cell proliferation and migration through c-Met pathway.Clin Chim Acta. 2017 Oct;473:237-244. doi: 10.1016/j.cca.2017.07.008. Epub 2017 Jul 8.
|
| 1033 |
Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin.Oncol Lett. 2017 Nov;14(5):5819-5824. doi: 10.3892/ol.2017.6978. Epub 2017 Sep 15.
|
| 1034 |
Alpha1,2-fucosyl transferase gene, the key enzyme of Lewis y synthesis, promotes Taxol resistance of ovarian carcinoma through apoptosis-related proteins.Neoplasma. 2018;65(4):515-522. doi: 10.4149/neo_2018_170823N552.
|
| 1035 |
A FXYD5/TGF?SMAD positive feedback loop drives epithelialtomesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.Int J Oncol. 2020 Jan;56(1):301-314. doi: 10.3892/ijo.2019.4911. Epub 2019 Nov 13.
|
| 1036 |
HOXD-AS1 promotes cell proliferation, migration and invasion through miR-608/FZD4 axis in ovarian cancer.Am J Cancer Res. 2018 Jan 1;8(1):170-182. eCollection 2018.
|
| 1037 |
Elevated expression of Gab1 promotes breast cancer metastasis by dissociating the PAR complex.J Exp Clin Cancer Res. 2019 Jan 21;38(1):27. doi: 10.1186/s13046-019-1025-2.
|
| 1038 |
Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.Am J Cancer Res. 2019 Jan 1;9(1):145-159. eCollection 2019.
|
| 1039 |
The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.PLoS One. 2015 Sep 30;10(9):e0138692. doi: 10.1371/journal.pone.0138692. eCollection 2015.
|
| 1040 |
The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.Int J Mol Sci. 2019 May 8;20(9):2264. doi: 10.3390/ijms20092264.
|
| 1041 |
GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.Oncotarget. 2017 Jun 27;8(26):42588-42601. doi: 10.18632/oncotarget.16585.
|
| 1042 |
Multiple roles and regulatory mechanisms of the transcription factor GATA6 in human cancers.Clin Genet. 2020 Jan;97(1):64-72. doi: 10.1111/cge.13630. Epub 2019 Aug 28.
|
| 1043 |
The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.Sci Rep. 2018 May 31;8(1):8485. doi: 10.1038/s41598-018-26468-4.
|
| 1044 |
MicroRNA-16 inhibits migration and invasion via regulation of the Wnt/-catenin signaling pathway in ovarian cancer.Oncol Lett. 2019 Mar;17(3):2631-2638. doi: 10.3892/ol.2019.9923. Epub 2019 Jan 14.
|
| 1045 |
GEN-1 immunotherapy for the treatment of ovarian cancer.Future Oncol. 2019 Feb;15(4):421-438. doi: 10.2217/fon-2018-0423. Epub 2018 Oct 16.
|
| 1046 |
ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer.Gynecol Oncol. 2017 Nov;147(2):418-425. doi: 10.1016/j.ygyno.2017.08.025. Epub 2017 Aug 31.
|
| 1047 |
Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.Horm Metab Res. 2011 Oct;43(11):816-20. doi: 10.1055/s-0031-1287766. Epub 2011 Oct 18.
|
| 1048 |
Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.J Ovarian Res. 2019 Nov 8;12(1):106. doi: 10.1186/s13048-019-0580-7.
|
| 1049 |
Therapeutic implications of GIPC1 silencing in cancer.PLoS One. 2010 Dec 30;5(12):e15581. doi: 10.1371/journal.pone.0015581.
|
| 1050 |
Evaluation of core serous epithelial ovarian cancer genes as potential prognostic markers and indicators of the underlying molecular mechanisms using an integrated bioinformatics analysis.Oncol Lett. 2019 Nov;18(5):5508-5522. doi: 10.3892/ol.2019.10884. Epub 2019 Sep 19.
|
| 1051 |
The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-B signaling pathway.J Exp Clin Cancer Res. 2017 Oct 4;36(1):137. doi: 10.1186/s13046-017-0607-0.
|
| 1052 |
Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells.PLoS One. 2019 Nov 26;14(11):e0225450. doi: 10.1371/journal.pone.0225450. eCollection 2019.
|
| 1053 |
Grb7 gene amplification and protein expression by FISH and IHC in ovarian cancer.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11296-304. eCollection 2015.
|
| 1054 |
GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer.Oncogene. 2018 Nov;37(44):5873-5886. doi: 10.1038/s41388-018-0377-y. Epub 2018 Jul 4.
|
| 1055 |
Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis.Tumour Biol. 2013 Dec;34(6):4059-63. doi: 10.1007/s13277-013-0995-5. Epub 2013 Jul 25.
|
| 1056 |
Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1.Cancer Lett. 2018 Oct 1;433:242-251. doi: 10.1016/j.canlet.2018.06.030. Epub 2018 Jun 28.
|
| 1057 |
Bi-directional Mendelian randomization of epithelial ovarian cancer and schizophrenia and uni-directional Mendelian randomization of schizophrenia on circulating 1- or 2-glycerophosphocholine metabolites.Mol Genet Metab Rep. 2019 Nov 6;21:100539. doi: 10.1016/j.ymgmr.2019.100539. eCollection 2019 Dec.
|
| 1058 |
A natural entkaurane diterpenoid induces antiproliferation in ovarian cancer cells via ERK1/2 regulation and inhibition of cellular migration and invasion.Mol Med Rep. 2018 Oct;18(4):3898-3906. doi: 10.3892/mmr.2018.9377. Epub 2018 Aug 9.
|
| 1059 |
Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.Oncol Lett. 2018 May;15(5):6457-6468. doi: 10.3892/ol.2018.8101. Epub 2018 Feb 21.
|
| 1060 |
HPIP Silencing Prevents Epithelial-Mesenchymal Transition Induced by TGF-1 in Human Ovarian Cancer Cells.Oncol Res. 2016;24(1):33-9. doi: 10.3727/096504016X14575597858654.
|
| 1061 |
Hematopoietic lineage cell-specific protein 1 immunoreactivity indicates an increased risk of poor overall survival in patients with ovarian carcinoma.Oncol Lett. 2018 Jun;15(6):9406-9412. doi: 10.3892/ol.2018.8493. Epub 2018 Apr 13.
|
| 1062 |
AIB1 regulates the ovarian cancer cell cycle through TUG1.Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5610-5617. doi: 10.26355/eurrev_201712_14002.
|
| 1063 |
Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.Cancer Lett. 2017 Dec 28;411:65-73. doi: 10.1016/j.canlet.2017.09.048. Epub 2017 Oct 6.
|
| 1064 |
Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.Gynecol Oncol. 2018 May;149(2):341-349. doi: 10.1016/j.ygyno.2018.03.006. Epub 2018 Mar 21.
|
| 1065 |
LINC01342 promotes the progression of ovarian cancer by absorbing microRNA-30c-2-3p to upregulate HIF3A.J Cell Physiol. 2020 Apr;235(4):3939-3949. doi: 10.1002/jcp.29289. Epub 2019 Oct 9.
|
| 1066 |
T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.Clin Cancer Res. 2018 Nov 15;24(22):5562-5573. doi: 10.1158/1078-0432.CCR-18-0573. Epub 2018 May 31.
|
| 1067 |
Clinicopathologic significance of HLA-G and HLA-E molecules in Tunisian patients with ovarian carcinoma.Hum Immunol. 2018 Jun;79(6):463-470. doi: 10.1016/j.humimm.2018.02.012. Epub 2018 Mar 2.
|
| 1068 |
Humoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer.J Immunol Res. 2014;2014:326593. doi: 10.1155/2014/326593. Epub 2014 Apr 27.
|
| 1069 |
Low expression level of HMBOX1 in high-grade serous ovarian cancer accelerates cell proliferation by inhibiting cell apoptosis.Biochem Biophys Res Commun. 2018 Jun 22;501(2):380-386. doi: 10.1016/j.bbrc.2018.04.203. Epub 2018 May 10.
|
| 1070 |
SRPX and HMCN1 regulate cancerassociated fibroblasts to promote the invasiveness of ovarian carcinoma.Oncol Rep. 2019 Dec;42(6):2706-2715. doi: 10.3892/or.2019.7379. Epub 2019 Oct 17.
|
| 1071 |
Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin.Cancer Res. 2019 Jul 1;79(13):3185-3191. doi: 10.1158/0008-5472.CAN-19-0542. Epub 2019 May 6.
|
| 1072 |
Increased RHAMM expression relates to ovarian cancer progression.J Ovarian Res. 2017 Sep 27;10(1):66. doi: 10.1186/s13048-017-0360-1.
|
| 1073 |
Sohlh2 alleviates malignancy of EOC cells under hypoxia via inhibiting the HIF1/CA9 signaling pathway.Biol Chem. 2020 Feb 25;401(2):263-271. doi: 10.1515/hsz-2019-0119.
|
| 1074 |
MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4663-4672. doi: 10.26355/eurrev_201906_18046.
|
| 1075 |
HOXA4, down-regulated in lung cancer, inhibits the growth, motility and invasion of lung cancer cells.Cell Death Dis. 2018 May 1;9(5):465. doi: 10.1038/s41419-018-0497-x.
|
| 1076 |
Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.Cancer Genomics Proteomics. 2017 Mar-Apr;14(2):137-141. doi: 10.21873/cgp.20026.
|
| 1077 |
Ovarian cancer variant rs2072590 is associated with HOXD1 and HOXD3 gene expression.Oncotarget. 2017 Oct 13;8(61):103410-103414. doi: 10.18632/oncotarget.21902. eCollection 2017 Nov 28.
|
| 1078 |
Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer.Sci Rep. 2018 Sep 7;8(1):13483. doi: 10.1038/s41598-018-31030-3.
|
| 1079 |
Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.Anticancer Drugs. 2019 Feb;30(2):117-127. doi: 10.1097/CAD.0000000000000696.
|
| 1080 |
Epigenetic loss of heparan sulfate 3-O-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis.Int J Cancer. 2018 Oct 15;143(8):1943-1953. doi: 10.1002/ijc.31580. Epub 2018 Aug 9.
|
| 1081 |
Role of Hydroxysteroid Dehydrogenase-Like 2 (HSDL2) in Human Ovarian Cancer.Med Sci Monit. 2018 Jun 12;24:3997-4008. doi: 10.12659/MSM.909418.
|
| 1082 |
HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer.Sci Rep. 2019 Sep 2;9(1):12628. doi: 10.1038/s41598-019-48992-7.
|
| 1083 |
Secretion of cytokines and heat shock protein (HspA1A) by ovarian cancer cells depending on the tumor type and stage of disease.Cytokine. 2017 Jan;89:136-142. doi: 10.1016/j.cyto.2016.01.017. Epub 2016 Feb 8.
|
| 1084 |
Heat shock protein 70-2 (HSP70-2) a novel cancer testis antigen that promotes growth of ovarian cancer.Am J Cancer Res. 2017 Jun 1;7(6):1252-1269. eCollection 2017.
|
| 1085 |
High-temperature requirement factor A3 (Htra3): a novel serine protease and its potential role in ovarian function and ovarian cancers.Mol Cell Endocrinol. 2010 Oct 7;327(1-2):13-8. doi: 10.1016/j.mce.2010.06.001. Epub 2010 Jun 9.
|
| 1086 |
Huwe1 Sustains Normal Ovarian Epithelial Cell Transformation and Tumor Growth through the Histone H1.3-H19 Cascade.Cancer Res. 2017 Sep 15;77(18):4773-4784. doi: 10.1158/0008-5472.CAN-16-2597. Epub 2017 Jul 7.
|
| 1087 |
HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis.Eur Rev Med Pharmacol Sci. 2019 Jan;23(10):4126-4135. doi: 10.26355/eurrev_201901_17914.
|
| 1088 |
Isoprenylcysteine carboxylmethyltransferase regulates ovarian cancer cell response to chemotherapy and Ras activation.Biochem Biophys Res Commun. 2018 Jun 22;501(2):556-562. doi: 10.1016/j.bbrc.2018.05.038. Epub 2018 May 11.
|
| 1089 |
Significance of blood and salivary IEX-1 expression in diagnosis of epithelial ovarian carcinoma.J Obstet Gynaecol Res. 2018 Apr;44(4):764-771. doi: 10.1111/jog.13576. Epub 2018 Feb 12.
|
| 1090 |
Overexpression of MEF2D contributes to oncogenic malignancy and chemotherapeutic resistance in ovarian carcinoma.Am J Cancer Res. 2019 May 1;9(5):887-905. eCollection 2019.
|
| 1091 |
IL-36 suppresses proliferation of ovarian cancer cells.Tumour Biol. 2017 Jun;39(6):1010428317706918. doi: 10.1177/1010428317706918.
|
| 1092 |
MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma.Oncotarget. 2019 Aug 6;10(47):4880-4893. doi: 10.18632/oncotarget.27117. eCollection 2019 Aug 6.
|
| 1093 |
MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.J Ovarian Res. 2017 Jan 11;10(1):1. doi: 10.1186/s13048-016-0301-4.
|
| 1094 |
Molecular analysis of inhibin A and activin A subunit gene loci in epithelial ovarian cancer.Int J Gynecol Cancer. 2002 Sep-Oct;12(5):443-7. doi: 10.1046/j.1525-1438.2002.01143.x.
|
| 1095 |
Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.Oncotarget. 2015 Apr 30;6(12):10548-62. doi: 10.18632/oncotarget.3307.
|
| 1096 |
Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction.Cancer. 1995 Apr 15;75(8):2139-46. doi: 10.1002/1097-0142(19950415)75:8<2139::aid-cncr2820750817>3.0.co;2-6.
|
| 1097 |
Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/-catenin signaling.Int J Oncol. 2016 Jan;48(1):153-60. doi: 10.3892/ijo.2015.3228. Epub 2015 Nov 4.
|
| 1098 |
Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.Cancer Biomark. 2020;27(1):51-61. doi: 10.3233/CBM-190460.
|
| 1099 |
Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.Gynecol Oncol. 2016 Mar;140(3):545-53. doi: 10.1016/j.ygyno.2015.12.006. Epub 2015 Dec 12.
|
| 1100 |
Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer.J Cell Mol Med. 2019 Jun;23(6):4005-4018. doi: 10.1111/jcmm.14286. Epub 2019 Apr 16.
|
| 1101 |
Knockdown of JARID2 inhibits the proliferation and invasion of ovarian cancer through the PI3K/Akt signaling pathway.Mol Med Rep. 2017 Sep;16(3):3600-3605. doi: 10.3892/mmr.2017.7024. Epub 2017 Jul 17.
|
| 1102 |
Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer.Signal Transduct Target Ther. 2019 Jul 26;4:24. doi: 10.1038/s41392-019-0055-8. eCollection 2019.
|
| 1103 |
JRK is a positive regulator of -catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer.Oncogene. 2016 Jun 2;35(22):2834-41. doi: 10.1038/onc.2015.347. Epub 2015 Oct 12.
|
| 1104 |
GCN-5/PGC-1 signaling is activated and associated with metabolism in cyclin E1-driven ovarian cancer.Aging (Albany NY). 2019 Jul 17;11(14):4890-4899. doi: 10.18632/aging.102082.
|
| 1105 |
HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells.Nanomedicine. 2019 Apr;17:254-265. doi: 10.1016/j.nano.2019.01.017. Epub 2019 Feb 10.
|
| 1106 |
Expression of hMOF in different ovarian tissues and its effects on ovarian cancer prognosis.Oncol Rep. 2015 Feb;33(2):685-92. doi: 10.3892/or.2014.3649. Epub 2014 Dec 5.
|
| 1107 |
Clinical relevance of cytoskeleton associated proteins for ovarian cancer.J Cancer Res Clin Oncol. 2018 Nov;144(11):2195-2205. doi: 10.1007/s00432-018-2710-9. Epub 2018 Aug 9.
|
| 1108 |
The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.Oncogene. 2019 Feb;38(7):1080-1092. doi: 10.1038/s41388-018-0490-y. Epub 2018 Sep 11.
|
| 1109 |
miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.Cell Death Dis. 2018 Nov 8;9(11):1123. doi: 10.1038/s41419-018-1093-9.
|
| 1110 |
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.Oncogene. 2017 May 4;36(18):2565-2576. doi: 10.1038/onc.2016.412. Epub 2016 Nov 21.
|
| 1111 |
Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women.Tumour Biol. 2015 Sep;36(9):6919-27. doi: 10.1007/s13277-015-3394-2. Epub 2015 Apr 9.
|
| 1112 |
Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer.Cancer Manag Res. 2018 Sep 12;10:3433-3450. doi: 10.2147/CMAR.S169214. eCollection 2018.
|
| 1113 |
Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23.Cell Cycle. 2019 Jul;18(14):1601-1618. doi: 10.1080/15384101.2019.1624112. Epub 2019 Jun 9.
|
| 1114 |
Overexpression of KIF2A is Suppressed by miR-206 and Associated with Poor Prognosis in Ovarian Cancer.Cell Physiol Biochem. 2018;50(3):810-822. doi: 10.1159/000494467. Epub 2018 Oct 23.
|
| 1115 |
Low expression of KIF7 indicates poor prognosis in epithelial ovarian cancer.Cancer Biomark. 2019;26(4):481-489. doi: 10.3233/CBM-190328.
|
| 1116 |
A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas.J Ovarian Res. 2016 Mar 18;9:17. doi: 10.1186/s13048-016-0224-0.
|
| 1117 |
LINC00702 accelerates the progression of ovarian cancer through interacting with EZH2 to inhibit the transcription of KLF2.Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):201-208. doi: 10.26355/eurrev_201908_18648.
|
| 1118 |
Long non-coding RNA OR3A4 promotes metastasis of ovarian cancer via inhibiting KLF6.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2360-2365. doi: 10.26355/eurrev_201903_17380.
|
| 1119 |
Lentivirus-mediated knockdown of Krppel-like factor 9 inhibits the growth of ovarian cancer.Arch Gynecol Obstet. 2015 Feb;291(2):377-82. doi: 10.1007/s00404-014-3405-3. Epub 2014 Sep 13.
|
| 1120 |
Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer.Clin Cancer Res. 2004 Apr 15;10(8):2766-70. doi: 10.1158/1078-0432.ccr-03-0269.
|
| 1121 |
A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.BMC Cancer. 2011 Apr 1;11:119. doi: 10.1186/1471-2407-11-119.
|
| 1122 |
Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.PLoS One. 2017 Nov 2;12(11):e0186847. doi: 10.1371/journal.pone.0186847. eCollection 2017.
|
| 1123 |
KPNA2 promotes migration and invasion in epithelial ovarian cancer cells by inducing epithelial-mesenchymal transition via Akt/GSK-3/Snail activation.J Cancer. 2018 Jan 1;9(1):157-165. doi: 10.7150/jca.20879. eCollection 2018.
|
| 1124 |
Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk.Hum Mol Genet. 2016 Aug 15;25(16):3600-3612. doi: 10.1093/hmg/ddw196. Epub 2016 Jul 4.
|
| 1125 |
Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.Oncotarget. 2017 Mar 14;8(11):17819-17832. doi: 10.18632/oncotarget.14867.
|
| 1126 |
Epidermolytic palmoplantar keratoderma cosegregates with a keratin 9 mutation in a pedigree with breast and ovarian cancer.Nat Genet. 1994 Jan;6(1):106-10. doi: 10.1038/ng0194-106.
|
| 1127 |
Correlation of LAMA3 with onset and prognosis of ovarian cancer.Oncol Lett. 2019 Sep;18(3):2813-2818. doi: 10.3892/ol.2019.10600. Epub 2019 Jul 10.
|
| 1128 |
LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.Tumour Biol. 2017 Mar;39(3):1010428317695014. doi: 10.1177/1010428317695014.
|
| 1129 |
La-Related Protein 4 as a Suppressor for Motility of Ovarian Cancer Cells.Tohoku J Exp Med. 2019 Jan;247(1):59-67. doi: 10.1620/tjem.247.59.
|
| 1130 |
Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.Arch Pharm Res. 2004 Jun;27(6):633-9. doi: 10.1007/BF02980163.
|
| 1131 |
Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/-Catenin Signaling in Ovarian Cancer.Mol Ther Oncolytics. 2019 Apr 19;14:94-106. doi: 10.1016/j.omto.2019.04.002. eCollection 2019 Sep 27.
|
| 1132 |
Inhibition of miR-214-3p Aids in Preventing Epithelial Ovarian Cancer Malignancy by Increasing the Expression of LHX6.Cancers (Basel). 2019 Dec 2;11(12):1917. doi: 10.3390/cancers11121917.
|
| 1133 |
Epithelial protein lost in neoplasm- (EPLIN-) is a potential prognostic marker for the progression of epithelial ovarian cancer.Int J Oncol. 2016 Jun;48(6):2488-96. doi: 10.3892/ijo.2016.3462. Epub 2016 Mar 29.
|
| 1134 |
Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling.Oncotarget. 2016 Jan 12;7(2):1408-20. doi: 10.18632/oncotarget.6368.
|
| 1135 |
RNA-binding protein LIN28B inhibits apoptosis through regulation of the AKT2/FOXO3A/BIM axis in ovarian cancer cells.Signal Transduct Target Ther. 2018 Aug 31;3:23. doi: 10.1038/s41392-018-0026-5. eCollection 2018.
|
| 1136 |
Long noncoding RNA CASC9 promotes LIN7A expression via miR-758-3p to facilitate the malignancy of ovarian cancer.J Cell Physiol. 2019 Jul;234(7):10800-10808. doi: 10.1002/jcp.27903. Epub 2018 Dec 7.
|
| 1137 |
LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer.Gynecol Oncol. 2013 Mar;128(3):475-82. doi: 10.1016/j.ygyno.2012.12.018. Epub 2012 Dec 24.
|
| 1138 |
Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.J Clin Invest. 2018 Feb 1;128(2):589-606. doi: 10.1172/JCI95200. Epub 2017 Dec 18.
|
| 1139 |
Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome.Arch Pathol Lab Med. 1988 Feb;112(2):151-4.
|
| 1140 |
A multiple mixed TiO(2) mesocrystal junction based PEC-colorimetric immunoassay for specific recognition of lipolysis stimulated lipoprotein receptor.Biosens Bioelectron. 2020 Jan 15;148:111809. doi: 10.1016/j.bios.2019.111809. Epub 2019 Oct 26.
|
| 1141 |
Identification of key genes associated with the effect of estrogen on ovarian cancer using microarray analysis.Arch Gynecol Obstet. 2016 Feb;293(2):421-7. doi: 10.1007/s00404-015-3833-8. Epub 2015 Aug 12.
|
| 1142 |
The significance of lumican expression in ovarian cancer drug-resistant cell lines.Oncotarget. 2017 Aug 10;8(43):74466-74478. doi: 10.18632/oncotarget.20169. eCollection 2017 Sep 26.
|
| 1143 |
Cancer mortality in relatives of women with breast cancer: the OPCS Study. Office of Population Censuses and Surveys.Int J Cancer. 1996 Jan 26;65(3):275-83. doi: 10.1002/(SICI)1097-0215(19960126)65:3<275::AID-IJC1>3.0.CO;2-X.
|
| 1144 |
Down-regulation of miR-338-3p and Up-regulation of MACC1 Indicated Poor Prognosis of Epithelial Ovarian Cancer Patients.J Cancer. 2019 Feb 23;10(6):1385-1392. doi: 10.7150/jca.29502. eCollection 2019.
|
| 1145 |
BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.Int J Gynecol Cancer. 2018 Mar;28(3):472-478. doi: 10.1097/IGC.0000000000001214.
|
| 1146 |
The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.J Gynecol Oncol. 2018 Jan;29(1):e17. doi: 10.3802/jgo.2018.29.e17.
|
| 1147 |
Variants in Notch signalling pathway genes, PSEN1 and MAML2, predict overall survival in Chinese patients with epithelial ovarian cancer.J Cell Mol Med. 2018 Oct;22(10):4975-4984. doi: 10.1111/jcmm.13764. Epub 2018 Jul 28.
|
| 1148 |
Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.Br J Cancer. 2019 Nov;121(11):944-953. doi: 10.1038/s41416-019-0607-2. Epub 2019 Oct 29.
|
| 1149 |
Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer.Sci Rep. 2017 Feb 7;7:41977. doi: 10.1038/srep41977.
|
| 1150 |
MAP2K6-FP Enhances the Sensitiveness of Paclitaxel for Ovarian Cancer via Inducing Autophagy.Int J Gynecol Cancer. 2017 Jul;27(6):1082-1087. doi: 10.1097/IGC.0000000000001003.
|
| 1151 |
MARCH5 RNA promotes autophagy, migration, and invasion of ovarian cancer cells.Autophagy. 2017 Feb;13(2):333-344. doi: 10.1080/15548627.2016.1256520. Epub 2016 Nov 22.
|
| 1152 |
Interaction of E3 Ubiquitin Ligase MARCH7 with Long Noncoding RNA MALAT1 and Autophagy-Related Protein ATG7 Promotes Autophagy and Invasion in Ovarian Cancer.Cell Physiol Biochem. 2018;47(2):654-666. doi: 10.1159/000490020. Epub 2018 May 22.
|
| 1153 |
MIR-92 stimulates VEGF by inhibiting von Hippel-Lindau gene product in epithelial ovarian cancer.J Biol Regul Homeost Agents. 2017 Jul-Sep,;31(3):615-624.
|
| 1154 |
Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.Oncol Rep. 2018 Apr;39(4):1747-1756. doi: 10.3892/or.2018.6229. Epub 2018 Jan 22.
|
| 1155 |
Expression analysis of the MCPH1/BRIT1 and BRCA1 tumor suppressor genes and telomerase splice variants in epithelial ovarian cancer.Gene. 2018 Sep 25;672:34-44. doi: 10.1016/j.gene.2018.05.113. Epub 2018 May 31.
|
| 1156 |
MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition.Tumour Biol. 2015 Jun;36(6):4261-9. doi: 10.1007/s13277-015-3063-5. Epub 2015 Jan 16.
|
| 1157 |
Loss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR.Cancer Res. 2018 Jul 1;78(13):3532-3543. doi: 10.1158/0008-5472.CAN-18-0134. Epub 2018 May 7.
|
| 1158 |
Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.Reproduction. 2017 Mar;153(3):277-284. doi: 10.1530/REP-16-0265. Epub 2016 Dec 13.
|
| 1159 |
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.Gynecol Oncol. 2018 Nov;151(2):356-365. doi: 10.1016/j.ygyno.2018.09.015. Epub 2018 Sep 21.
|
| 1160 |
The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer.J Biol Chem. 2017 Sep 29;292(39):16351-16359. doi: 10.1074/jbc.M117.783936. Epub 2017 Aug 23.
|
| 1161 |
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.Cancer Immunol Immunother. 2012 Aug;61(8):1243-53. doi: 10.1007/s00262-012-1201-0. Epub 2012 Jan 19.
|
| 1162 |
Silencing of MICAL-L2 suppresses malignancy of ovarian cancer by inducing mesenchymal-epithelial transition.Cancer Lett. 2015 Jul 10;363(1):71-82. doi: 10.1016/j.canlet.2015.04.002. Epub 2015 Apr 9.
|
| 1163 |
MICU1 drives glycolysis and chemoresistance in ovarian cancer.Nat Commun. 2017 May 22;8:14634. doi: 10.1038/ncomms14634.
|
| 1164 |
Involvement of AF1q/MLLT11 in the progression of ovarian cancer.Oncotarget. 2017 Apr 4;8(14):23246-23264. doi: 10.18632/oncotarget.15574.
|
| 1165 |
Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome.Sci Rep. 2019 Aug 12;9(1):11677. doi: 10.1038/s41598-019-47871-5.
|
| 1166 |
Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.Oncogene. 2017 Mar 23;36(12):1698-1706. doi: 10.1038/onc.2016.336. Epub 2016 Oct 10.
|
| 1167 |
MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.Oncol Rep. 2019 Aug;42(2):679-687. doi: 10.3892/or.2019.7199. Epub 2019 Jun 12.
|
| 1168 |
Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.BMC Cancer. 2017 Jan 10;17(1):44. doi: 10.1186/s12885-016-3026-2.
|
| 1169 |
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.Oncogene. 2019 Feb;38(9):1576-1584. doi: 10.1038/s41388-018-0523-6. Epub 2018 Oct 10.
|
| 1170 |
Prevalence and molecular characteristics of defective mismatch repair epithelial ovarian cancer in a Japanese hospital-based population.Jpn J Clin Oncol. 2018 Aug 1;48(8):728-735. doi: 10.1093/jjco/hyy081.
|
| 1171 |
Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.Clin Cancer Res. 2016 Jun 15;22(12):3097-3104. doi: 10.1158/1078-0432.CCR-15-1669. Epub 2016 Jan 13.
|
| 1172 |
Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells.Yonsei Med J. 2014 Sep;55(5):1206-13. doi: 10.3349/ymj.2014.55.5.1206.
|
| 1173 |
MUC20 promotes aggressive phenotypes of epithelial ovarian cancer cells via activation of the integrin 1 pathway.Gynecol Oncol. 2016 Jan;140(1):131-7. doi: 10.1016/j.ygyno.2015.11.025. Epub 2015 Nov 23.
|
| 1174 |
MUS81 Inhibition Increases the Sensitivity to Therapy Effect in Epithelial Ovarian Cancer via Regulating CyclinB Pathway.J Cancer. 2019 May 21;10(10):2276-2287. doi: 10.7150/jca.30818. eCollection 2019.
|
| 1175 |
Diverse functions of myosin VI elucidated by an isoform-specific -helix domain.Nat Struct Mol Biol. 2016 Apr;23(4):300-308. doi: 10.1038/nsmb.3187. Epub 2016 Mar 7.
|
| 1176 |
MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer.Oncol Lett. 2019 Aug;18(2):1049-1056. doi: 10.3892/ol.2019.10406. Epub 2019 May 27.
|
| 1177 |
Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.Br J Cancer. 2017 May 9;116(10):1287-1293. doi: 10.1038/bjc.2017.83. Epub 2017 Mar 28.
|
| 1178 |
Cloning and expression of functional cDNA genes of a mouse/human chimeric antibody rcM4.Tumori. 1994 Dec 31;80(6):473-9. doi: 10.1177/030089169408000613.
|
| 1179 |
[Corrigendum] miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1.Int J Oncol. 2017 Jun;50(6):2236. doi: 10.3892/ijo.2017.3977. Epub 2017 Apr 27.
|
| 1180 |
New insight into NANOG: A novel therapeutic target for ovarian cancer (OC).Eur J Pharmacol. 2019 Jun 5;852:51-57. doi: 10.1016/j.ejphar.2019.03.003. Epub 2019 Mar 2.
|
| 1181 |
Napsin-A, a Possible Diagnostic Marker for Differentiating Clear Cell Ovarian Carcinoma From Other High-grade Ovarian Carcinomas.Appl Immunohistochem Mol Morphol. 2018 Sep;26(8):605-610. doi: 10.1097/PAI.0000000000000510.
|
| 1182 |
Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family.Hum Mutat. 2003 Jun;21(6):654. doi: 10.1002/humu.9148.
|
| 1183 |
High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.J Transl Med. 2019 May 20;17(1):166. doi: 10.1186/s12967-019-1904-5.
|
| 1184 |
HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab Invest. 2011 Jan;91(1):124-37. doi: 10.1038/labinvest.2010.136. Epub 2010 Jul 26.
|
| 1185 |
NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.Oncotarget. 2016 Jan 19;7(3):3018-32. doi: 10.18632/oncotarget.6576.
|
| 1186 |
Nectin-2 in ovarian cancer: How is it expressed and what might be its functional role?.Cancer Sci. 2019 Jun;110(6):1872-1882. doi: 10.1111/cas.13992. Epub 2019 May 2.
|
| 1187 |
Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells.Biomed Pharmacother. 2019 Feb;110:139-144. doi: 10.1016/j.biopha.2018.11.020. Epub 2018 Nov 20.
|
| 1188 |
Deregulation of sialidases in human normal and tumor tissues.Cancer Biomark. 2018 Feb 14;21(3):591-601. doi: 10.3233/CBM-170548.
|
| 1189 |
The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma.Int J Oncol. 2016 Apr;48(4):1457-66. doi: 10.3892/ijo.2016.3355. Epub 2016 Jan 25.
|
| 1190 |
Nrf2 induces cisplatin resistance via suppressing the iron export related gene SLC40A1 in ovarian cancer cells.Oncotarget. 2017 Jul 25;8(55):93502-93515. doi: 10.18632/oncotarget.19548. eCollection 2017 Nov 7.
|
| 1191 |
The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer.Oncogenesis. 2019 Aug 12;8(8):41. doi: 10.1038/s41389-019-0150-2.
|
| 1192 |
NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells.Oncotarget. 2017 May 16;8(20):33110-33121. doi: 10.18632/oncotarget.16145.
|
| 1193 |
Evaluation of Serum Nidogen-2 as a Screening and Diagnostic Tool for Ovarian Cancer.Gynecol Obstet Invest. 2018;83(5):461-465. doi: 10.1159/000481798. Epub 2017 Nov 7.
|
| 1194 |
Diagnostic Utility of Thyroid Transcription Factor-1 in Ovarian Carcinoma and Its Relationship With Clinicopathologic Prognostic Parameters.Appl Immunohistochem Mol Morphol. 2017 Apr;25(4):237-243. doi: 10.1097/PAI.0000000000000301.
|
| 1195 |
NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer.EBioMedicine. 2019 May;43:238-252. doi: 10.1016/j.ebiom.2019.04.041. Epub 2019 Apr 29.
|
| 1196 |
Nucleoside Diphosphate Kinase-3 (NME3) Enhances TLR5-Induced NFB Activation.Mol Cancer Res. 2018 Jun;16(6):986-999. doi: 10.1158/1541-7786.MCR-17-0603. Epub 2018 Mar 9.
|
| 1197 |
Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.Int J Cancer. 2019 Oct 1;145(7):1921-1934. doi: 10.1002/ijc.32293. Epub 2019 Apr 4.
|
| 1198 |
Clinicopathological significance of steroidogenic factor-1 expression in ovarian cancer versus ovarian sex cord stromal tumor.Tumour Biol. 2015 Mar;36(3):1429-35. doi: 10.1007/s13277-014-2187-3. Epub 2015 Jan 22.
|
| 1199 |
Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.Biomed Pharmacother. 2017 Jan;85:248-255. doi: 10.1016/j.biopha.2016.11.012. Epub 2016 Nov 28.
|
| 1200 |
E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival.Eur Rev Med Pharmacol Sci. 2017 May;21(9):2150-2156.
|
| 1201 |
Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival.Future Oncol. 2017 Sep;13(22):1981-1990. doi: 10.2217/fon-2017-0084. Epub 2017 Aug 22.
|
| 1202 |
NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.Tumour Biol. 2017 Sep;39(9):1010428317714631. doi: 10.1177/1010428317714631.
|
| 1203 |
Single nucleotide variant in Nucleoporin 107 may be predictive of sensitivity to chemotherapy in patients with ovarian cancer.Pharmacogenet Genomics. 2017 Jul;27(7):264-269. doi: 10.1097/FPC.0000000000000288.
|
| 1204 |
Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.Gynecol Oncol. 2017 Nov;147(2):465-480. doi: 10.1016/j.ygyno.2017.07.138. Epub 2017 Aug 8.
|
| 1205 |
Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.J Biol Chem. 2016 Sep 2;291(36):18897-914. doi: 10.1074/jbc.M116.734533. Epub 2016 Jul 11.
|
| 1206 |
Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer.Oncol Lett. 2017 Jul;14(1):217-223. doi: 10.3892/ol.2017.6111. Epub 2017 May 3.
|
| 1207 |
The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001 Apr;7(4):806-11.
|
| 1208 |
The non-coding RNA OTUB1-isoform2 promotes ovarian tumour progression and predicts poor prognosis.J Cell Mol Med. 2018 Oct;22(10):4794-4806. doi: 10.1111/jcmm.13733. Epub 2018 Jul 25.
|
| 1209 |
Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.Drug Deliv. 2018 Nov;25(1):995-1003. doi: 10.1080/10717544.2018.1461956.
|
| 1210 |
hPaf1/PD2 interacts with OCT3/4 to promote self-renewal of ovarian cancer stem cells.Oncotarget. 2017 Feb 28;8(9):14806-14820. doi: 10.18632/oncotarget.14775.
|
| 1211 |
miR-193b-3p possesses anti-tumor activity in ovarian carcinoma cells by targeting p21-activated kinase 3.Biomed Pharmacother. 2017 Dec;96:1275-1282. doi: 10.1016/j.biopha.2017.11.086. Epub 2017 Nov 21.
|
| 1212 |
PAK5 Induces EMT and Promotes Cell Migration and Invasion by Activating the PI3K/AKT Pathway in Ovarian Cancer.Anal Cell Pathol (Amst). 2018 Sep 2;2018:8073124. doi: 10.1155/2018/8073124. eCollection 2018.
|
| 1213 |
AKAP2 is upregulated in ovarian cancer, and promotes growth and migration of cancer cells.Mol Med Rep. 2017 Oct;16(4):5151-5156. doi: 10.3892/mmr.2017.7286. Epub 2017 Aug 18.
|
| 1214 |
Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.PLoS One. 2019 Nov 21;14(11):e0224564. doi: 10.1371/journal.pone.0224564. eCollection 2019.
|
| 1215 |
The promising role of PAX1 (aliases: HUP48, OFC2) gene methylation in cancer screening.Mol Genet Genomic Med. 2019 Mar;7(3):e506. doi: 10.1002/mgg3.506. Epub 2019 Jan 12.
|
| 1216 |
UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer.Cancers (Basel). 2018 Aug 8;10(8):262. doi: 10.3390/cancers10080262.
|
| 1217 |
PBOV1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells.Oncol Rep. 2016 Jan;35(1):488-96. doi: 10.3892/or.2015.4396. Epub 2015 Nov 4.
|
| 1218 |
Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1.Cancer Res. 2016 Nov 1;76(21):6351-6361. doi: 10.1158/0008-5472.CAN-16-0980. Epub 2016 Sep 2.
|
| 1219 |
Aberrant methylation of PCDH17 gene in high-grade serous ovarian carcinoma.Cancer Biomark. 2018;23(1):125-133. doi: 10.3233/CBM-181493.
|
| 1220 |
Low Expression of Protocadherin-8 Promotes the Progression of Ovarian Cancer.Int J Gynecol Cancer. 2018 Feb;28(2):346-354. doi: 10.1097/IGC.0000000000001169.
|
| 1221 |
MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9.Onco Targets Ther. 2019 Oct 8;12:8329-8338. doi: 10.2147/OTT.S220339. eCollection 2019.
|
| 1222 |
PCNA-associated factor P15(PAF) , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.Int J Cancer. 2018 Dec 1;143(11):2973-2984. doi: 10.1002/ijc.31800. Epub 2018 Oct 4.
|
| 1223 |
Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.Oncogene. 2015 Apr 16;34(16):2125-37. doi: 10.1038/onc.2014.117. Epub 2014 Jun 9.
|
| 1224 |
Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis.Nanoscale. 2017 Sep 14;9(35):13142-13152. doi: 10.1039/c7nr04473a.
|
| 1225 |
Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.Acta Biochim Biophys Sin (Shanghai). 2013 Sep;45(9):756-62. doi: 10.1093/abbs/gmt075. Epub 2013 Jul 3.
|
| 1226 |
ERp57small interfering RNA silencing can enhance the sensitivity of drugresistant human ovarian cancer cells to paclitaxel.Int J Oncol. 2019 Jan;54(1):249-260. doi: 10.3892/ijo.2018.4628. Epub 2018 Nov 7.
|
| 1227 |
Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.J Cell Biochem. 2019 Apr;120(4):6057-6070. doi: 10.1002/jcb.27892. Epub 2018 Oct 18.
|
| 1228 |
Overexpression of PDK4 is associated with cell proliferation, drug resistance and poor prognosis in ovarian cancer.Cancer Manag Res. 2018 Dec 24;11:251-262. doi: 10.2147/CMAR.S185015. eCollection 2019.
|
| 1229 |
PDZ and LIM domain protein 4 suppresses the growth and invasion of ovarian cancer cells via inactivation of STAT3 signaling.Life Sci. 2019 Sep 15;233:116715. doi: 10.1016/j.lfs.2019.116715. Epub 2019 Jul 31.
|
| 1230 |
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.Clin Cancer Res. 2011 Apr 15;17(8):2250-9. doi: 10.1158/1078-0432.CCR-10-2718. Epub 2011 Mar 18.
|
| 1231 |
miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma.FASEB J. 2018 Jun 6:fj201800495RR. doi: 10.1096/fj.201800495RR. Online ahead of print.
|
| 1232 |
Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.Oncogene. 2015 Jan 15;34(3):373-83. doi: 10.1038/onc.2013.562. Epub 2014 Jan 27.
|
| 1233 |
HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3.J Exp Clin Cancer Res. 2019 Mar 1;38(1):110. doi: 10.1186/s13046-019-1103-5.
|
| 1234 |
Invasion of ovarian cancer cells is induced byPITX2-mediated activation of TGF- and Activin-A.Mol Cancer. 2015 Aug 23;14:162. doi: 10.1186/s12943-015-0433-y.
|
| 1235 |
Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers.PLoS One. 2018 Jan 10;13(1):e0190485. doi: 10.1371/journal.pone.0190485. eCollection 2018.
|
| 1236 |
PKP3 interactions with MAPK-JNK-ERK1/2-mTOR pathway regulates autophagy and invasion in ovarian cancer.Biochem Biophys Res Commun. 2019 Jan 8;508(2):646-653. doi: 10.1016/j.bbrc.2018.11.163. Epub 2018 Dec 4.
|
| 1237 |
Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.Gynecol Oncol. 2004 Dec;95(3):449-55. doi: 10.1016/j.ygyno.2004.08.051.
|
| 1238 |
Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth.J Exp Clin Cancer Res. 2018 Jul 11;37(1):146. doi: 10.1186/s13046-018-0796-1.
|
| 1239 |
Identification of proteins associated with paclitaxel resistance of epithelial ovarian cancer using iTRAQ-based proteomics.Oncol Lett. 2018 Jun;15(6):9793-9801. doi: 10.3892/ol.2018.8600. Epub 2018 Apr 27.
|
| 1240 |
MiR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2.Reprod Biol. 2018 Sep;18(3):218-224. doi: 10.1016/j.repbio.2018.07.005. Epub 2018 Jul 24.
|
| 1241 |
EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer.Mol Carcinog. 2003 Dec;38(4):188-200. doi: 10.1002/mc.10162.
|
| 1242 |
PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.Mol Genet Genomic Med. 2019 Jun;7(6):e721. doi: 10.1002/mgg3.721. Epub 2019 May 5.
|
| 1243 |
The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.Gynecol Endocrinol. 2009 Feb;25(2):104-9. doi: 10.1080/09513590802549841.
|
| 1244 |
Identification of potential prognostic TF-associated lncRNAs for predicting survival in ovarian cancer.J Cell Mol Med. 2019 Mar;23(3):1840-1851. doi: 10.1111/jcmm.14084. Epub 2018 Dec 13.
|
| 1245 |
Epigenetic activation of POTE genes in ovarian cancer.Epigenetics. 2019 Feb;14(2):185-197. doi: 10.1080/15592294.2019.1581590. Epub 2019 Mar 4.
|
| 1246 |
MicroRNA-299-3p regulates proliferation, migration and invasion of human ovarian cancer cells by modulating the expression of OCT4.Arch Biochem Biophys. 2018 Aug 1;651:21-27. doi: 10.1016/j.abb.2018.05.007. Epub 2018 May 31.
|
| 1247 |
Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer.Tohoku J Exp Med. 2017 Feb;241(2):165-173. doi: 10.1620/tjem.241.165.
|
| 1248 |
The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity.Cell Tissue Res. 2018 Dec;374(3):577-585. doi: 10.1007/s00441-018-2906-y. Epub 2018 Sep 4.
|
| 1249 |
Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.Mol Med Rep. 2013 Jun;7(6):1826-30. doi: 10.3892/mmr.2013.1416. Epub 2013 Apr 9.
|
| 1250 |
Upregulation of miR-614 promotes proliferation and inhibits apoptosis in ovarian cancer by suppressing PPP2R2A expression.Mol Med Rep. 2018 May;17(5):6285-6292. doi: 10.3892/mmr.2018.8714. Epub 2018 Mar 9.
|
| 1251 |
MiR-572 prompted cell proliferation of human ovarian cancer cells by suppressing PPP2R2C expression. Biomed Pharmacother. 2016 Feb;77:92-7.
|
| 1252 |
Age is associated with prognosis in serous ovarian carcinoma.J Ovarian Res. 2017 Jun 12;10(1):36. doi: 10.1186/s13048-017-0331-6.
|
| 1253 |
Frequent loss of pRb2/p130 in human ovarian carcinoma.Clin Cancer Res. 2004 May 1;10(9):3098-103. doi: 10.1158/1078-0432.ccr-03-0524.
|
| 1254 |
Molecular bases of aberrant miR-182 expression in ovarian cancer.Genes Chromosomes Cancer. 2016 Nov;55(11):877-89. doi: 10.1002/gcc.22387. Epub 2016 Jul 12.
|
| 1255 |
Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer.Ann Agric Environ Med. 2019 Sep 19;26(3):415-419. doi: 10.26444/aaem/105899. Epub 2019 Apr 1.
|
| 1256 |
PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.Oncol Rep. 2016 May;35(5):2543-52. doi: 10.3892/or.2016.4653. Epub 2016 Mar 3.
|
| 1257 |
Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance.Biochem Biophys Res Commun. 2019 Feb 5;509(2):373-378. doi: 10.1016/j.bbrc.2018.12.127. Epub 2018 Dec 25.
|
| 1258 |
PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.Mol Cancer Ther. 2019 Jan;18(1):162-172. doi: 10.1158/1535-7163.MCT-17-1050. Epub 2018 Oct 10.
|
| 1259 |
Long non-coding RNA RP11-552M11.4 favors tumorigenesis and development of cervical cancer via modulating miR-3941/ATF1 signaling.Int J Biol Macromol. 2019 Jun 1;130:24-33. doi: 10.1016/j.ijbiomac.2019.02.083. Epub 2019 Feb 18.
|
| 1260 |
PRR11 Overexpression Facilitates Ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/-Catenin Pathway.Cell Physiol Biochem. 2018;49(2):696-705. doi: 10.1159/000493034. Epub 2018 Aug 30.
|
| 1261 |
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.Pharmacogenomics J. 2017 Dec;17(6):506-514. doi: 10.1038/tpj.2016.63. Epub 2016 Oct 25.
|
| 1262 |
PRSS21/testisin inhibits ovarian tumor metastasis and antagonizes proangiogenic angiopoietins ANG2 and ANGPTL4.J Mol Med (Berl). 2019 May;97(5):691-709. doi: 10.1007/s00109-019-01763-3. Epub 2019 Mar 25.
|
| 1263 |
PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis.Arch Gynecol Obstet. 2016 Jun;293(6):1297-307. doi: 10.1007/s00404-015-3904-x. Epub 2015 Oct 6.
|
| 1264 |
The Effect of PTCH1 on Ovarian Cancer Cell Proliferation and Apoptosis.Cancer Biother Radiopharm. 2019 Mar;34(2):103-109. doi: 10.1089/cbr.2018.2626. Epub 2018 Dec 6.
|
| 1265 |
Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.Tumour Biol. 2015 Jan;36(1):453-8. doi: 10.1007/s13277-014-2662-x. Epub 2014 Oct 1.
|
| 1266 |
PTTG1: a Unique Regulator of Stem/Cancer Stem Cells in the Ovary and Ovarian Cancer.Stem Cell Rev Rep. 2019 Dec;15(6):866-879. doi: 10.1007/s12015-019-09911-5.
|
| 1267 |
circPUM1 Promotes Tumorigenesis and Progression of Ovarian Cancer by Sponging miR-615-5p and miR-6753-5p.Mol Ther Nucleic Acids. 2019 Dec 6;18:882-892. doi: 10.1016/j.omtn.2019.09.032. Epub 2019 Oct 23.
|
| 1268 |
High expression of PXDN is associated with poor prognosis and promotes proliferation, invasion as well as migration in ovarian cancer.Ann Diagn Pathol. 2018 Jun;34:161-165. doi: 10.1016/j.anndiagpath.2018.03.002. Epub 2018 Mar 14.
|
| 1269 |
Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway.Oncol Lett. 2018 Apr;15(4):5155-5160. doi: 10.3892/ol.2018.7949. Epub 2018 Feb 5.
|
| 1270 |
Rab25 is responsible for phosphoinositide 3-kinase/AKTmediated cisplatin resistance in human epithelial ovarian cancer cells.Mol Med Rep. 2015 Mar;11(3):2173-8. doi: 10.3892/mmr.2014.2963. Epub 2014 Nov 17.
|
| 1271 |
Rac GTPase activating protein 1 promotes oncogenic progression of epithelial ovarian cancer.Cancer Sci. 2018 Jan;109(1):84-93. doi: 10.1111/cas.13434. Epub 2017 Nov 22.
|
| 1272 |
Upregulation of Circular RNA VPS13C-has-circ-001567 Promotes Ovarian Cancer Cell Proliferation and Invasion.Cancer Biother Radiopharm. 2019 Mar;34(2):110-118. doi: 10.1089/cbr.2018.2641. Epub 2018 Oct 30.
|
| 1273 |
Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B.Nat Commun. 2015 Jan 8;6:5917. doi: 10.1038/ncomms6917.
|
| 1274 |
The HRAS1 minisatellite locus and risk of ovarian cancer.Cancer Res. 2000 Jan 15;60(2):259-61.
|
| 1275 |
Suppression of FIP200 and autophagy by tumor-derived lactate promotes nave T cell apoptosis and affects tumor immunity.Sci Immunol. 2017 Nov 17;2(17):eaan4631. doi: 10.1126/sciimmunol.aan4631.
|
| 1276 |
The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing.Mol Carcinog. 2019 Feb;58(2):196-205. doi: 10.1002/mc.22919. Epub 2018 Oct 28.
|
| 1277 |
High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer.Med Sci Monit. 2017 Dec 21;23:6033-6041. doi: 10.12659/msm.905314.
|
| 1278 |
Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/-catenin/CBP signaling.Clin Cancer Res. 2019 Feb 1;25(3):1022-1035. doi: 10.1158/1078-0432.CCR-18-2554. Epub 2018 Oct 2.
|
| 1279 |
CRBP-1 over-expression is associated with poor prognosis in tongue squamous cell carcinoma.BMC Cancer. 2018 May 2;18(1):514. doi: 10.1186/s12885-018-4249-1.
|
| 1280 |
RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.FASEB J. 2019 Apr;33(4):5350-5365. doi: 10.1096/fj.201801529RR. Epub 2019 Feb 15.
|
| 1281 |
Knockdown of NRSF inhibits cell proliferation of ovarian cancer via activating Hippo pathway.Life Sci. 2018 Dec 15;215:73-79. doi: 10.1016/j.lfs.2018.10.070. Epub 2018 Nov 2.
|
| 1282 |
Novel oncogenic and chemoresistance-inducing functions of resistin in ovarian cancer cells require miRNAs-mediated induction of epithelial-to-mesenchymal transition.Sci Rep. 2018 Aug 21;8(1):12522. doi: 10.1038/s41598-018-30978-6.
|
| 1283 |
Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.PLoS One. 2014 Jan 27;9(1):e87455. doi: 10.1371/journal.pone.0087455. eCollection 2014.
|
| 1284 |
Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.PLoS One. 2015 May 1;10(5):e0125714. doi: 10.1371/journal.pone.0125714. eCollection 2015.
|
| 1285 |
Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses: A Systematic Review and Meta-Analysis.Gynecol Obstet Invest. 2019;84(6):591-598. doi: 10.1159/000501681. Epub 2019 Jul 16.
|
| 1286 |
Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.Int J Cancer. 2006 Mar 15;118(6):1565-71. doi: 10.1002/ijc.21520.
|
| 1287 |
A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling.Cancers (Basel). 2019 Feb 22;11(2):255. doi: 10.3390/cancers11020255.
|
| 1288 |
Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.Am J Physiol Cell Physiol. 2018 Aug 1;315(2):C225-C235. doi: 10.1152/ajpcell.00283.2017. Epub 2018 May 2.
|
| 1289 |
Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.Cancer Res. 2019 Feb 15;79(4):760-772. doi: 10.1158/0008-5472.CAN-18-2297. Epub 2018 Dec 18.
|
| 1290 |
Cloning of a human ortholog (RPH3AL) of (RNO)Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus.Genomics. 1999 Jul 1;59(1):97-101. doi: 10.1006/geno.1999.5864.
|
| 1291 |
Biological Function of Ribosomal Protein L10 on Cell Behavior in Human Epithelial Ovarian Cancer.J Cancer. 2018 Feb 6;9(4):745-756. doi: 10.7150/jca.21614. eCollection 2018.
|
| 1292 |
The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.Gynecol Oncol. 2017 Jan;144(1):140-145. doi: 10.1016/j.ygyno.2016.11.010. Epub 2016 Nov 9.
|
| 1293 |
Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition.PLoS One. 2015 Nov 30;10(11):e0143659. doi: 10.1371/journal.pone.0143659. eCollection 2015.
|
| 1294 |
Expression of RRBP1 in epithelial ovarian cancer and its clinical significance.Biosci Rep. 2019 Jul 23;39(7):BSR20190656. doi: 10.1042/BSR20190656. Print 2019 Jul 31.
|
| 1295 |
A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells.Virus Res. 2019 Apr 2;263:145-150. doi: 10.1016/j.virusres.2019.01.014. Epub 2019 Jan 23.
|
| 1296 |
Long non-coding RNA EPB41L4A-AS2 suppresses progression of ovarian cancer by sequestering microRNA-103a to upregulate transcription factor RUNX1T1.Exp Physiol. 2020 Jan;105(1):75-87. doi: 10.1113/EP087847. Epub 2019 Dec 9.
|
| 1297 |
Functional genetic variants of RUVBL1 predict overall survival of Chinese patients with epithelial ovarian cancer.Carcinogenesis. 2019 Oct 16;40(10):1209-1219. doi: 10.1093/carcin/bgz092.
|
| 1298 |
H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer.Mol Med. 1996 Mar;2(2):189-203.
|
| 1299 |
Prognostic values of S100 family mRNA expression in ovarian cancer.Cancer Biomark. 2019;25(1):67-78. doi: 10.3233/CBM-182276.
|
| 1300 |
S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin.J Ovarian Res. 2019 Nov 18;12(1):113. doi: 10.1186/s13048-019-0592-3.
|
| 1301 |
Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer.Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):110-116. doi: 10.1097/PAI.0000000000000275.
|
| 1302 |
S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.DNA Cell Biol. 2018 May;37(5):491-500. doi: 10.1089/dna.2017.3953. Epub 2018 Feb 27.
|
| 1303 |
Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.Gynecol Oncol. 2019 Feb;152(2):375-386. doi: 10.1016/j.ygyno.2018.11.016. Epub 2018 Nov 14.
|
| 1304 |
SALL2 represses cyclins D1 and E1 expression and restrains G1/S cell cycle transition and cancer-related phenotypes.Mol Oncol. 2018 Jun;12(7):1026-1046. doi: 10.1002/1878-0261.12308. Epub 2018 May 21.
|
| 1305 |
SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.Oncol Rep. 2016 Mar;35(3):1796-806. doi: 10.3892/or.2016.4545. Epub 2016 Jan 5.
|
| 1306 |
SR-A1, a member of the human pre-mRNA splicing factor family, and its expression in colon cancer progression.Biol Chem. 2004 Sep;385(9):785-90. doi: 10.1515/BC.2004.102.
|
| 1307 |
Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression.Mol Ther Nucleic Acids. 2019 Dec 6;18:24-33. doi: 10.1016/j.omtn.2019.07.012. Epub 2019 Jul 29.
|
| 1308 |
Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality.J Biomed Inform. 2019 Dec;100:103313. doi: 10.1016/j.jbi.2019.103313. Epub 2019 Oct 23.
|
| 1309 |
Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer.Gynecol Oncol. 2008 Apr;109(1):115-21. doi: 10.1016/j.ygyno.2007.12.030. Epub 2008 Feb 13.
|
| 1310 |
siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer.SLAS Technol. 2019 Apr;24(2):137-150. doi: 10.1177/2472630318816668. Epub 2019 Jan 7.
|
| 1311 |
Upregulation of SENP3/SMT3IP1 promotes epithelial ovarian cancer progression and forecasts poor prognosis.Tumour Biol. 2017 Mar;39(3):1010428317694543. doi: 10.1177/1010428317694543.
|
| 1312 |
Study on early diagnosis of epithelial ovarian cancer by analysis of plasma septin-9 and clusterin level.J Cancer Res Ther. 2018 Jun;14(Supplement):S444-S449. doi: 10.4103/0973-1482.181178.
|
| 1313 |
Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.Gynecol Obstet Invest. 2018;83(5):508-514. doi: 10.1159/000479027. Epub 2017 Jul 22.
|
| 1314 |
Treading the beaten path with old and new obstacles: a report from the Indian HIPEC registry.Int J Hyperthermia. 2018;35(1):361-369. doi: 10.1080/02656736.2018.1503345. Epub 2018 Oct 9.
|
| 1315 |
Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?.Eur J Surg Oncol. 2017 Feb;43(2):252-257. doi: 10.1016/j.ejso.2016.06.002. Epub 2016 Jun 20.
|
| 1316 |
SEI1 induces genomic instability by inhibiting DNA damage response in ovarian cancer.Cancer Lett. 2017 Jan 28;385:271-279. doi: 10.1016/j.canlet.2016.09.032. Epub 2016 Oct 3.
|
| 1317 |
AEG-1 Contributes to Metastasis in Hypoxia-Related Ovarian Cancer by Modulating the HIF-1alpha/NF-kappaB/VEGF Pathway.Biomed Res Int. 2018 Mar 25;2018:3145689. doi: 10.1155/2018/3145689. eCollection 2018.
|
| 1318 |
MicroRNA-125b Suppresses Ovarian Cancer Progression via Suppression of the Epithelial-Mesenchymal Transition Pathway by Targeting the SET Protein.Cell Physiol Biochem. 2016;39(2):501-10. doi: 10.1159/000445642. Epub 2016 Jul 7.
|
| 1319 |
Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer.Onco Targets Ther. 2019 Sep 11;12:7451-7457. doi: 10.2147/OTT.S220700. eCollection 2019.
|
| 1320 |
Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients.Ann Oncol. 2013 Nov;24(11):2813-8. doi: 10.1093/annonc/mdt370. Epub 2013 Oct 10.
|
| 1321 |
MiR-1180 from bone marrow-derived mesenchymal stem cells induces glycolysis and chemoresistance in ovarian cancer cells by upregulating the Wnt signaling pathway.J Zhejiang Univ Sci B. 2019 Mar.;20(3):219-237. doi: 10.1631/jzus.B1800190.
|
| 1322 |
Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.Prostate. 2017 May;77(7):718-728. doi: 10.1002/pros.23302. Epub 2017 Feb 23.
|
| 1323 |
Bioinformatics analysis to screen the key prognostic genes in ovarian cancer.J Ovarian Res. 2017 Apr 13;10(1):27. doi: 10.1186/s13048-017-0323-6.
|
| 1324 |
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells.Gynecol Oncol. 2011 Sep;122(3):656-62. doi: 10.1016/j.ygyno.2011.04.052. Epub 2011 Jun 14.
|
| 1325 |
(18)F-FDG-PET/CT-guided intensity-modulated radiotherapy for 42 FIGO III/IV ovarian cancer: A retrospective study.Oncol Lett. 2019 Jan;17(1):149-158. doi: 10.3892/ol.2018.9601. Epub 2018 Oct 19.
|
| 1326 |
Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop.J Cell Biochem. 2019 Jun;120(6):10643-10651. doi: 10.1002/jcb.28354. Epub 2019 Jan 22.
|
| 1327 |
SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition.Sci Rep. 2019 Jun 5;9(1):8295. doi: 10.1038/s41598-019-44826-8.
|
| 1328 |
SNAP23 promotes the malignant process of ovarian cancer.J Ovarian Res. 2016 Nov 17;9(1):80. doi: 10.1186/s13048-016-0289-9.
|
| 1329 |
Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer.Theranostics. 2018 Oct 6;8(19):5200-5212. doi: 10.7150/thno.27806. eCollection 2018.
|
| 1330 |
The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts.Genome Biol. 2018 Mar 16;19(1):35. doi: 10.1186/s13059-018-1412-6.
|
| 1331 |
SOX18 Affects Cell Viability, Migration, Invasiveness, and Apoptosis in Hepatocellular Carcinoma (HCC) Cells by Participating in Epithelial-to-Mesenchymal Transition (EMT) Progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin (mTOR).Med Sci Monit. 2019 Aug 20;25:6244-6254. doi: 10.12659/MSM.915729.
|
| 1332 |
Sex-determining region Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian cancer by targeting Src kinase.Tumour Biol. 2016 Sep;37(9):12263-12271. doi: 10.1007/s13277-016-5095-x. Epub 2016 Jun 1.
|
| 1333 |
LncRNA SNHG12 accelerates the progression of ovarian cancer via absorbing miRNA-129 to upregulate SOX4.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2345-2352. doi: 10.26355/eurrev_201903_17378.
|
| 1334 |
Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.Tumour Biol. 2018 May;40(5):1010428318773652. doi: 10.1177/1010428318773652.
|
| 1335 |
Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer.Cancer Sci. 2019 Mar;110(3):1117-1126. doi: 10.1111/cas.13955. Epub 2019 Feb 16.
|
| 1336 |
Spy1 participates in the proliferation and apoptosis of epithelial ovarian cancer.J Mol Histol. 2016 Feb;47(1):47-57. doi: 10.1007/s10735-015-9646-z. Epub 2015 Dec 7.
|
| 1337 |
Emerging Roles of SPINK1 in Cancer.Clin Chem. 2016 Mar;62(3):449-57. doi: 10.1373/clinchem.2015.241513. Epub 2015 Dec 11.
|
| 1338 |
Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells.Cell Physiol Biochem. 2018;45(3):1061-1071. doi: 10.1159/000487348. Epub 2018 Feb 7.
|
| 1339 |
Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer.Aging (Albany NY). 2019 Dec 3;11(23):11416-11439. doi: 10.18632/aging.102538. Epub 2019 Dec 3.
|
| 1340 |
SPOP Regulates The Biological Mechanism Of Ovarian Cancer Cells Through The Hh Signaling Pathway.Onco Targets Ther. 2019 Nov 6;12:9239-9248. doi: 10.2147/OTT.S215940. eCollection 2019.
|
| 1341 |
Knockdown of SPRY4 and SPRY4-IT1 inhibits cell growth and phosphorylation of Akt in human testicular germ cell tumours.Sci Rep. 2018 Feb 6;8(1):2462. doi: 10.1038/s41598-018-20846-8.
|
| 1342 |
SPSB1 enhances ovarian cancer cell survival by destabilizing p21.Biochem Biophys Res Commun. 2019 Mar 12;510(3):364-369. doi: 10.1016/j.bbrc.2019.01.088. Epub 2019 Jan 31.
|
| 1343 |
Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer.Biochem Biophys Res Commun. 2006 Jun 2;344(2):667-74. doi: 10.1016/j.bbrc.2006.03.184. Epub 2006 Apr 7.
|
| 1344 |
Serine/arginine-rich splicing factor 3 (SRSF3) regulates homologous recombination-mediated DNA repair.Mol Cancer. 2015 Aug 19;14:158. doi: 10.1186/s12943-015-0422-1.
|
| 1345 |
MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression.Int J Mol Sci. 2017 Jun 6;18(6):1208. doi: 10.3390/ijms18061208.
|
| 1346 |
Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.Gynecol Oncol. 2016 Sep;142(3):539-47. doi: 10.1016/j.ygyno.2016.06.017. Epub 2016 Jun 30.
|
| 1347 |
Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-1-induced EMT and confers paclitaxel resistance in ovarian cancer.Cell Death Dis. 2018 Oct 30;9(11):1102. doi: 10.1038/s41419-018-1101-0.
|
| 1348 |
Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer.Glycobiology. 2018 Nov 1;28(11):898-903. doi: 10.1093/glycob/cwy065.
|
| 1349 |
Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway.Cancer Cell Int. 2019 Apr 5;19:86. doi: 10.1186/s12935-019-0780-7. eCollection 2019.
|
| 1350 |
Sequencing of a 'mouse azoospermia' gene panel in azoospermic men: identification of RNF212 and STAG3 mutations as novel genetic causes of meiotic arrest.Hum Reprod. 2019 Jun 4;34(6):978-988. doi: 10.1093/humrep/dez042.
|
| 1351 |
Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.Oncotarget. 2017 Apr 18;8(16):27380-27392. doi: 10.18632/oncotarget.16068.
|
| 1352 |
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
|
| 1353 |
Identification of cell membrane protein stress-induced phosphoprotein 1 as a potential ovarian cancer biomarker using aptamers selected by cell systematic evolution of ligands by exponential enrichment.Anal Chem. 2014 May 6;86(9):4521-7. doi: 10.1021/ac500466x. Epub 2014 Apr 9.
|
| 1354 |
AMPK-Independent LKB1 Activity Is Required for Efficient Epithelial Ovarian Cancer Metastasis.Mol Cancer Res. 2020 Mar;18(3):488-500. doi: 10.1158/1541-7786.MCR-19-0530. Epub 2019 Nov 19.
|
| 1355 |
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Nat Genet. 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27.
|
| 1356 |
Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.PLoS One. 2019 Dec 11;14(12):e0225860. doi: 10.1371/journal.pone.0225860. eCollection 2019.
|
| 1357 |
Stonin 2 Overexpression is Correlated with Unfavorable Prognosis and Tumor Invasion in Epithelial Ovarian Cancer.Int J Mol Sci. 2017 Jul 29;18(8):1653. doi: 10.3390/ijms18081653.
|
| 1358 |
Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells.Platelets. 2018 Dec;29(8):834-837. doi: 10.1080/09537104.2018.1530345. Epub 2018 Oct 18.
|
| 1359 |
SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.Mol Cancer Res. 2012 Nov;10(11):1462-72. doi: 10.1158/1541-7786.MCR-12-0335. Epub 2012 Sep 10.
|
| 1360 |
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.
|
| 1361 |
SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation.Tumour Biol. 2015 Jun;36(6):4633-42. doi: 10.1007/s13277-015-3111-1. Epub 2015 Jan 28.
|
| 1362 |
Association of a common variant of SYNPO2 gene with increased risk of serous epithelial ovarian cancer.Tumour Biol. 2017 Feb;39(2):1010428317691185. doi: 10.1177/1010428317691185.
|
| 1363 |
Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-B pathway.Cell Prolif. 2016 Dec;49(6):657-668. doi: 10.1111/cpr.12293. Epub 2016 Sep 21.
|
| 1364 |
Expression of TBC1D16 Is Associated with Favorable Prognosis of Epithelial Ovarian Cancer.Tohoku J Exp Med. 2018 Jul;245(3):141-148. doi: 10.1620/tjem.245.141.
|
| 1365 |
TBC1D8 Amplification Drives Tumorigenesis through Metabolism Reprogramming in Ovarian Cancer.Theranostics. 2019 Jan 24;9(3):676-690. doi: 10.7150/thno.30224. eCollection 2019.
|
| 1366 |
Downregulation of TCEAL7 expression induces CCND1 expression in non-small cell lung cancer.Mol Biol Rep. 2019 Oct;46(5):5251-5256. doi: 10.1007/s11033-019-04982-6. Epub 2019 Jul 18.
|
| 1367 |
Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers.J Clin Med. 2019 Mar 8;8(3):330. doi: 10.3390/jcm8030330.
|
| 1368 |
Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.Int J Oncol. 2009 Nov;35(5):1069-79.
|
| 1369 |
Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.PLoS One. 2017 May 4;12(5):e0177244. doi: 10.1371/journal.pone.0177244. eCollection 2017.
|
| 1370 |
TET3 inhibits TGF-1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells.J Exp Clin Cancer Res. 2016 May 4;35:72. doi: 10.1186/s13046-016-0350-y.
|
| 1371 |
TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.Life Sci. 2020 Jan 15;241:117171. doi: 10.1016/j.lfs.2019.117171. Epub 2019 Dec 13.
|
| 1372 |
NEO212 induces mitochondrial apoptosis and impairs autophagy flux in ovarian cancer.J Exp Clin Cancer Res. 2019 Jun 7;38(1):239. doi: 10.1186/s13046-019-1249-1.
|
| 1373 |
Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGF1-independent manner.Oncotarget. 2017 Jul 31;8(47):82506-82530. doi: 10.18632/oncotarget.19714. eCollection 2017 Oct 10.
|
| 1374 |
ERRATUM.Oncol Res. 2017 Jan 2;25(1):155. doi: 10.3727/096504017X14811155525280.
|
| 1375 |
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.Jpn J Cancer Res. 2002 Oct;93(10):1114-22. doi: 10.1111/j.1349-7006.2002.tb01213.x.
|
| 1376 |
Icb-1 gene polymorphism rs1467465 is associated with susceptibility to ovarian cancer.J Ovarian Res. 2014 Apr 23;7:42. doi: 10.1186/1757-2215-7-42. eCollection 2014.
|
| 1377 |
Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):680-688. doi: 10.1158/1055-9965.EPI-17-1101. Epub 2018 Mar 12.
|
| 1378 |
TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.BMC Cancer. 2019 Mar 15;19(1):237. doi: 10.1186/s12885-019-5417-7.
|
| 1379 |
TMED2 promotes epithelial ovarian cancer growth.Oncotarget. 2017 Oct 6;8(55):94151-94165. doi: 10.18632/oncotarget.21593. eCollection 2017 Nov 7.
|
| 1380 |
TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer.Cancer Manag Res. 2019 Jan 17;11:839-855. doi: 10.2147/CMAR.S186080. eCollection 2019.
|
| 1381 |
Knockdown of TMEM14A expression by RNAi inhibits the proliferation and invasion of human ovarian cancer cells.Biosci Rep. 2016 Feb 19;36(1):e00298. doi: 10.1042/BSR20150258. Print 2016.
|
| 1382 |
Overexpression of TMEM158 contributes to ovarian carcinogenesis.J Exp Clin Cancer Res. 2015 Aug 4;34(1):75. doi: 10.1186/s13046-015-0193-y.
|
| 1383 |
Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.Oncol Rep. 2015 Jun;33(6):3124-30. doi: 10.3892/or.2015.3902. Epub 2015 Apr 7.
|
| 1384 |
A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation.Gynecol Oncol. 2012 Jun;125(3):720-6. doi: 10.1016/j.ygyno.2012.03.026. Epub 2012 Mar 21.
|
| 1385 |
Tumor necrosis factor -induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.Hum Pathol. 2018 Dec;82:239-248. doi: 10.1016/j.humpath.2018.02.031. Epub 2018 Aug 11.
|
| 1386 |
TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia.Gynecol Oncol. 2012 Aug;126(2):268-73. doi: 10.1016/j.ygyno.2012.04.038. Epub 2012 Apr 30.
|
| 1387 |
Overexpression of salusin- is associated with poor prognosis in ovarian cancer.Oncol Rep. 2017 Mar;37(3):1826-1832. doi: 10.3892/or.2017.5429. Epub 2017 Feb 7.
|
| 1388 |
Migration-inducing gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer.Oncotarget. 2016 May 10;7(19):27552-66. doi: 10.18632/oncotarget.8487.
|
| 1389 |
TPM4 promotes cell migration by modulating F-actin formation in lung cancer.Onco Targets Ther. 2019 May 31;12:4055-4063. doi: 10.2147/OTT.S198542. eCollection 2019.
|
| 1390 |
Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.Int J Cancer. 2017 Oct 15;141(8):1600-1614. doi: 10.1002/ijc.30860. Epub 2017 Jul 12.
|
| 1391 |
Tripartite Motif 16 Inhibits the Migration and Invasion in Ovarian Cancer Cells.Oncol Res. 2017 Apr 14;25(4):551-558. doi: 10.3727/096504016X14758370595285. Epub 2016 Oct 12.
|
| 1392 |
TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.J Neurooncol. 2019 Nov;145(2):211-222. doi: 10.1007/s11060-019-03301-0. Epub 2019 Oct 11.
|
| 1393 |
TRIM50 acts as a novel Src suppressor and inhibits ovarian cancer progression.Biochim Biophys Acta Mol Cell Res. 2019 Sep;1866(9):1412-1420. doi: 10.1016/j.bbamcr.2019.06.002. Epub 2019 Jun 6.
|
| 1394 |
Poly r(C) Binding Protein 1 Regulates Posttranscriptional Expression of the Ubiquitin Ligase TRIM56 in Ovarian Cancer.IUBMB Life. 2019 Feb;71(2):177-182. doi: 10.1002/iub.1948. Epub 2018 Oct 3.
|
| 1395 |
TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):522-529. doi: 10.26355/eurrev_201901_16864.
|
| 1396 |
Ovarian cancer proliferation and apoptosis are regulated by human transfer RNA methyltransferase 9-likevia LIN9.Oncol Lett. 2017 Oct;14(4):4461-4466. doi: 10.3892/ol.2017.6750. Epub 2017 Aug 14.
|
| 1397 |
TRRAP stimulates the tumorigenic potential of ovarian cancer stem cells.BMB Rep. 2018 Oct;51(10):514-519. doi: 10.5483/BMBRep.2018.51.10.042.
|
| 1398 |
TSPAN12 Precedes Tumor Proliferation by Cell Cycle Control in Ovarian Cancer.Mol Cells. 2019 Jul 31;42(7):557-567. doi: 10.14348/molcells.2019.0015.
|
| 1399 |
Knockdown of miR-629 Inhibits Ovarian Cancer Malignant Behaviors by Targeting Testis-Specific Y-Like Protein 5.DNA Cell Biol. 2017 Dec;36(12):1108-1116. doi: 10.1089/dna.2017.3904. Epub 2017 Oct 3.
|
| 1400 |
Annexin A4 fucosylation enhances its interaction with the NF-kB p50 and promotes tumor progression of ovarian clear cell carcinoma.Oncotarget. 2016 Jun 22;8(64):108093-108107. doi: 10.18632/oncotarget.10226. eCollection 2017 Dec 8.
|
| 1401 |
Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.J BUON. 2017 Sep-Oct;22(5):1314-1321.
|
| 1402 |
Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.Int J Cancer. 2010 Feb 15;126(4):885-95. doi: 10.1002/ijc.24787.
|
| 1403 |
Sox9 and Hif-2 regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.Gene. 2014 Jun 1;542(2):173-81. doi: 10.1016/j.gene.2014.03.037. Epub 2014 Mar 21.
|
| 1404 |
Macrophage capping protein CapG is a putative oncogene involved in migration and invasiveness in ovarian carcinoma.Biomed Res Int. 2014;2014:379847. doi: 10.1155/2014/379847. Epub 2014 Apr 2.
|
| 1405 |
Overexpression of WDFY2 inhibits prostate cancer cell growth and migration via inactivation of Akt pathway.Tumour Biol. 2017 Jun;39(6):1010428317704821. doi: 10.1177/1010428317704821.
|
| 1406 |
The prognostic of p27(kip1) in ovarian cancer: a meta-analysis.Arch Gynecol Obstet. 2016 Jan;293(1):169-176. doi: 10.1007/s00404-015-3817-8. Epub 2015 Jul 22.
|
| 1407 |
Identification of the Critical Site of Calponin 1 for Suppression of Ovarian Cancer Properties.Anticancer Res. 2015 Nov;35(11):5993-9.
|
| 1408 |
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.Gynecol Oncol. 2020 Feb;156(2):488-497. doi: 10.1016/j.ygyno.2019.09.021. Epub 2019 Oct 17.
|
| 1409 |
Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1698-1703. doi: 10.1073/pnas.1803999116. Epub 2019 Jan 15.
|
| 1410 |
Crk-like adapter protein is required for TGF--induced AKT and ERK-signaling pathway in epithelial ovarian carcinomas.Tumour Biol. 2015 Feb;36(2):915-9. doi: 10.1007/s13277-014-2724-0. Epub 2014 Oct 12.
|
| 1411 |
The homeoprotein DLX4 stimulates NF-B activation and CD44-mediated tumor-mesothelial cell interactions in ovarian cancer.Am J Pathol. 2015 Aug;185(8):2298-308. doi: 10.1016/j.ajpath.2015.04.004. Epub 2015 Jun 9.
|
| 1412 |
The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas.Int J Cancer. 2008 Oct 15;123(8):1761-9. doi: 10.1002/ijc.23708.
|
| 1413 |
RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.PLoS One. 2013 Aug 9;8(8):e72820. doi: 10.1371/journal.pone.0072820. eCollection 2013.
|
| 1414 |
Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.Mol Oncol. 2014 Oct;8(7):1326-38. doi: 10.1016/j.molonc.2014.04.009. Epub 2014 May 13.
|
| 1415 |
Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.Int J Oncol. 2000 Jul;17(1):103-6. doi: 10.3892/ijo.17.1.103.
|
| 1416 |
Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells.BMC Mol Biol. 2014 Oct 7;15:24. doi: 10.1186/1471-2199-15-24.
|
| 1417 |
GOLPH3 induces epithelial-mesenchymal transition via Wnt/-catenin signaling pathway in epithelial ovarian cancer.Cancer Med. 2017 Apr;6(4):834-844. doi: 10.1002/cam4.1040. Epub 2017 Mar 23.
|
| 1418 |
Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.Cancer Lett. 2001 Sep 28;171(1):37-45. doi: 10.1016/s0304-3835(01)00543-2.
|
| 1419 |
Downregulation of HOXC6 in Serous Ovarian Cancer.Cancer Invest. 2015;33(7):303-11. doi: 10.3109/07357907.2015.1041641. Epub 2015 Jun 5.
|
| 1420 |
Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer.Oncol Rep. 2014 May;31(5):2139-46. doi: 10.3892/or.2014.3110. Epub 2014 Mar 24.
|
| 1421 |
Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.Br J Cancer. 2015 Jul 28;113(3):414-24. doi: 10.1038/bjc.2015.254. Epub 2015 Jul 9.
|
| 1422 |
Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1383-93. doi: 10.1158/1055-9965.EPI-13-1361. Epub 2014 May 1.
|
| 1423 |
Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer.Clin Biochem. 2013 Oct;46(15):1453-61. doi: 10.1016/j.clinbiochem.2013.03.002. Epub 2013 Mar 13.
|
| 1424 |
Recombinant adenovirus-mediated overexpression of PTEN and KRT10 improves cisplatin resistance of ovarian cancer in vitro and in vivo.Genet Mol Res. 2015 Jun 18;14(2):6591-7. doi: 10.4238/2015.June.18.1.
|
| 1425 |
MKK4 acts as a potential tumor suppressor in ovarian cancer.Tumour Biol. 2011 Aug;32(4):661-70. doi: 10.1007/s13277-011-0166-5. Epub 2011 Apr 14.
|
| 1426 |
EVI1 splice variants modulate functional responses in ovarian cancer cells.Mol Oncol. 2013 Jun;7(3):647-68. doi: 10.1016/j.molonc.2013.02.008. Epub 2013 Mar 5.
|
| 1427 |
Downregulation of NEK11 is associated with drug resistance in ovarian cancer.Int J Oncol. 2014 Sep;45(3):1266-74. doi: 10.3892/ijo.2014.2503. Epub 2014 Jun 18.
|
| 1428 |
MicroRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer.Am J Transl Res. 2017 Feb 15;9(2):466-477. eCollection 2017.
|
| 1429 |
OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.Carcinogenesis. 2014 Jul;35(7):1573-81. doi: 10.1093/carcin/bgu070. Epub 2014 Mar 25.
|
| 1430 |
Nac1 interacts with the POZ-domain transcription factor, Miz1.Biosci Rep. 2014 Jun 5;34(3):e00110. doi: 10.1042/BSR20140049.
|
| 1431 |
Screening of HELQ in breast and ovarian cancer families.Fam Cancer. 2016 Jan;15(1):19-23. doi: 10.1007/s10689-015-9838-4.
|
| 1432 |
RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis.Oncotarget. 2014 Aug 30;5(16):6734-45. doi: 10.18632/oncotarget.2244.
|
| 1433 |
ShRNA-mediated silencing of the RFC3 gene suppress ovarian tumor cells proliferation.Int J Clin Exp Pathol. 2015 Aug 1;8(8):8968-75. eCollection 2015.
|
| 1434 |
The role of S100A14 in epithelial ovarian tumors.Oncotarget. 2014 Jun 15;5(11):3482-96. doi: 10.18632/oncotarget.1947.
|
| 1435 |
Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/-catenin signaling pathway.J Ovarian Res. 2014 Sep 5;7:87. doi: 10.1186/s13048-014-0087-1.
|
| 1436 |
MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.Gynecol Oncol. 2015 Dec;139(3):513-9. doi: 10.1016/j.ygyno.2015.10.008. Epub 2015 Oct 16.
|
|
|
|
|
|
|
